| 1 | N | Y | N | N | Aminoglutethimide
 | CYP21A2: cytochrome P450, family 21, subfamily A, polypeptide 2 (EC:1.14.99.10) | 0.29630 | Tolbutamide
 | 0.25504 | CYP17A1: cytochrome P450, family 17, subfamily A, polypeptide 1 (EC:1.14.99.9) |
| 2 | N | Y | Y | N | Halothane
 | CYP2E1: cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) | 0.66667 | Methoxyflurane
 | 0.60720 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 3 | N | Y | Y | N | Methoxsalen
 | CYP1A1: cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) | 0.31034 | Alprazolam
 | 0.73543 | CYP1A2: cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) |
| 4 | N | Y | N | N | Nifedipine
 | CYP11B2: cytochrome P450, family 11, subfamily B, polypeptide 2 (EC:1.14.15.4 1.14.15.5) | 0.23684 | Trimipramine
 | 0.93004 | CYP11B1: cytochrome P450, family 11, subfamily B, polypeptide 1 (EC:1.14.15.4) |
| 5 | N | Y | Y | N | Nifedipine
| CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.23684 | Trimipramine
| 0.92357 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 6 | N | Y | N | N | Caffeine
 | CYP2A7: cytochrome P450, family 2, subfamily A, polypeptide 7 (EC:1.14.14.1) | 0.25000 | Methoxsalen
| 0.94393 | CYP2A6: cytochrome P450, family 2, subfamily A, polypeptide 6 (EC:1.14.14.1) |
| 7 | N | N | N | N | Dyphylline
 | PDE9A: phosphodiesterase 9A (EC:3.1.4.35) | 0.68421 | Caffeine
| 0.17116 | PDE4B: phosphodiesterase 4B, cAMP-specific (EC:3.1.4.17) |
| 8 | N | Y | N | N | Metyrapone
 | CYP11A1: cytochrome P450, family 11, subfamily A, polypeptide 1 (EC:1.14.15.6) | 0.34483 | Alprazolam
| 0.33457 | CYP11B1: cytochrome P450, family 11, subfamily B, polypeptide 1 (EC:1.14.15.4) |
| 9 | N | N | N | N | Deferoxamine
 | CYP4A11: cytochrome P450, family 4, subfamily A, polypeptide 11 (EC:1.14.15.3) | 0.14000 | Tolbutamide
| 0.94681 | CYP4A22 |
| 10 | N | N | N | N | Dyphylline
| PDE5A: phosphodiesterase 5A, cGMP-specific (EC:3.1.4.35) | 0.68421 | Caffeine
| 0.21690 | PDE10A: phosphodiesterase 10A (EC:3.1.4.35 3.1.4.17) |
| 11 | N | Y | N | N | Ibuprofen
 | ALOX15B: arachidonate 15-lipoxygenase, type B (EC:1.13.11.33) | 0.52381 | Naproxen
 | 0.46753 | ALOX12B: arachidonate 12-lipoxygenase, 12R type (EC:1.13.11.-) |
| 12 | N | Y | N | N | Metyrapone
| CYP1A1: cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) | 0.34483 | Alprazolam
| 0.73543 | CYP1A2: cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) |
| 13 | N | N | N | N | Sulfinpyrazone
 | PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) | 0.67742 | Phenylbutazone
 | 0.63974 | PTGS2: prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) |
| 14 | N | N | Y | N | Phentermine
 | MAOA: monoamine oxidase A (EC:1.4.3.4) | 0.56250 | Selegiline
 | 0.74783 | MAOB |
| 15 | N | N | Y | N | Linezolid
 | MAOB | 0.50000 | Moclobemide
 | 0.74783 | MAOA: monoamine oxidase A (EC:1.4.3.4) |
| 16 | N | Y | Y | N | Metyrapone
| CYP11B2: cytochrome P450, family 11, subfamily B, polypeptide 2 (EC:1.14.15.4 1.14.15.5) | 0.34483 | Alprazolam
| 0.93004 | CYP11B1: cytochrome P450, family 11, subfamily B, polypeptide 1 (EC:1.14.15.4) |
| 17 | N | Y | N | N | Ibuprofen
| ALOX15: arachidonate 15-lipoxygenase (EC:1.13.11.33) | 0.52381 | Naproxen
| 0.66792 | ALOX12: arachidonate 12-lipoxygenase (EC:1.13.11.31) |
| 18 | N | N | Y | N | Dyphylline
| PDE7A: phosphodiesterase 7A (EC:3.1.4.17) | 0.63158 | Theophylline
 | 0.60024 | PDE7B: phosphodiesterase 7B (EC:3.1.4.17) |
| 19 | Y | N | N | N | Topiramate
 | CA1: carbonic anhydrase I (EC:4.2.1.1) | 0.26471 | Sezolamide hydrochloride
 | 0.60183 | CA2: carbonic anhydrase II (EC:4.2.1.1) |
| 20 | N | Y | Y | N | Salicylic acid
 | PTGS2: prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) | 0.75000 | Mesalamine
 | 0.63974 | PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) |
| 21 | N | N | N | N | Deferoxamine
| CYP7B1: cytochrome P450, family 7, subfamily B, polypeptide 1 (EC:1.14.13.100) | 0.14000 | Tolbutamide
| 0.36005 | CYP7A1: cytochrome P450, family 7, subfamily A, polypeptide 1 (EC:1.14.13.17) |
| 22 | N | N | N | N | Dyphylline
| PDE11A: phosphodiesterase 11A (EC:3.1.4.35 3.1.4.17) | 0.63158 | Theophylline
| 0.26533 | PDE10A: phosphodiesterase 10A (EC:3.1.4.35 3.1.4.17) |
| 23 | N | N | N | N | Ethinamate
 | CA4: carbonic anhydrase IV (EC:4.2.1.1) | 0.10000 | Sezolamide hydrochloride
| 0.23167 | CA2: carbonic anhydrase II (EC:4.2.1.1) |
| 24 | N | N | N | N | Deferoxamine
| CYP39A1 | 0.14000 | Tolbutamide
| 0.15698 | CYP8B1: cytochrome P450, family 8, subfamily B, polypeptide 1 (EC:1.14.13.95) |
| 25 | N | N | N | N | Methimazole
 | EPX: eosinophil peroxidase (EC:1.11.1.7) | 0.38461 | Propylthiouracil
 | 0.70056 | MPO |
| 26 | N | Y | N | N | Pentoxifylline
 | PDE11A: phosphodiesterase 11A (EC:3.1.4.35 3.1.4.17) | 0.60000 | Oxtriphylline
 | 0.32019 | PDE5A: phosphodiesterase 5A, cGMP-specific (EC:3.1.4.35) |
| 27 | N | N | N | N | Disulfiram
 | ALDH1A2: aldehyde dehydrogenase 1 family, member A2 (EC:1.2.1.36) | 0.15152 | Tretinoin
 | 0.74424 | ALDH1A1: aldehyde dehydrogenase 1 family, member A1 (EC:1.2.1.36) |
| 28 | N | Y | N | N | Deferoxamine
| MPO | 0.063830 | Acetaminophen
 | 0.70056 | EPX: eosinophil peroxidase (EC:1.11.1.7) |
| 29 | N | Y | N | Y | Caffeine
| PDE11A: phosphodiesterase 11A (EC:3.1.4.35 3.1.4.17) | 0.80000 | Theophylline
| 0.32019 | PDE5A: phosphodiesterase 5A, cGMP-specific (EC:3.1.4.35) |
| 30 | N | N | N | N | Methimazole
| LPO: lactoperoxidase (EC:1.11.1.7) | 0.38461 | Propylthiouracil
| 0.50955 | MPO |
| 31 | Y | N | Y | Y | Ethoxzolamide
 | CA2: carbonic anhydrase II (EC:4.2.1.1) | 0.50000 | Diazoxide
 | 0.60183 | CA1: carbonic anhydrase I (EC:4.2.1.1) |
| 32 | N | N | N | N | Pentoxifylline
| PDE7A: phosphodiesterase 7A (EC:3.1.4.17) | 0.60000 | Oxtriphylline
| 0.60024 | PDE7B: phosphodiesterase 7B (EC:3.1.4.17) |
| 33 | N | N | N | N | Voglibose
 | AMY2A: amylase, alpha 2A (pancreatic) (EC:3.2.1.1) | 0.45454 | Miglitol
 | 0.012625 | GANC |
| 34 | N | N | N | N | Naproxen
| LALBA | 0.56522 | Ketoprofen
 | 0.032575 | ALOX15B: arachidonate 15-lipoxygenase, type B (EC:1.13.11.33) |
| 35 | N | Y | N | N | Isoflurophate
 | CELA1: chymotrypsin-like elastase family, member 1 (EC:3.4.21.36) | 0 | Aminocaproic acid
 | 0.55155 | CELA2A: chymotrypsin-like elastase family, member 2A (EC:3.4.21.71) |
| 36 | N | N | N | Y | Caffeine
| PDE7A: phosphodiesterase 7A (EC:3.1.4.17) | 0.80000 | Theophylline
| 0.60024 | PDE7B: phosphodiesterase 7B (EC:3.1.4.17) |
| 37 | N | N | N | N | Cyclosporine
 | PPIL4: peptidylprolyl isomerase (cyclophilin)-like 4 (EC:5.2.1.8) | 0.22222 | Tacrolimus
 | 0.030219 | PPP1R1B: protein phosphatase 1, regulatory (inhibitor) subunit 1B (EC:3.1.3.16) |
| 38 | N | N | N | N | Indomethacin
 | LALBA | 0.51724 | Ketoprofen
| 0.032575 | ALOX15B: arachidonate 15-lipoxygenase, type B (EC:1.13.11.33) |
| 39 | N | N | N | N | Deferoxamine
| COQ6: coenzyme Q6 homolog, monooxygenase (S. cerevisiae) | 0.14000 | Tolbutamide
| 0.023550 | PRDX3: peroxiredoxin 3 (EC:1.11.1.15) |
| 40 | N | N | N | N | Cholecalciferol
 | CYP27B1: cytochrome P450, family 27, subfamily B, polypeptide 1 (EC:1.14.13.13) | 0.81250 | Calcitriol
 | 0.36424 | CYP27A1: cytochrome P450, family 27, subfamily A, polypeptide 1 (EC:1.14.13.15) |
| 41 | N | N | N | N | Threonine
 | BCKDK: branched chain ketoacid dehydrogenase kinase (EC:2.7.11.4) | 0.77778 | Valine
 | 0.021419 | PCCB |
| 42 | Y | N | Y | N | Nicotine
 | CYP2A6: cytochrome P450, family 2, subfamily A, polypeptide 6 (EC:1.14.14.1) | 0.36364 | Fadrozole hydrochloride
 | 0.94463 | CYP2A13: cytochrome P450, family 2, subfamily A, polypeptide 13 (EC:1.14.14.1) |
| 43 | N | N | N | N | Celgosivir hydrochloride
 | AMY2A: amylase, alpha 2A (pancreatic) (EC:3.2.1.1) | 0.43478 | Miglitol
| 0.012625 | GANC |
| 44 | N | N | N | N | Cyclosporine
| PPIL3: peptidylprolyl isomerase (cyclophilin)-like 3 (EC:5.2.1.8) | 0.22222 | Tacrolimus
| 0.063026 | DUSP15: dual specificity phosphatase 15 (EC:3.1.3.16 3.1.3.48) |
| 45 | N | N | N | N | Lopinavir
 | CYP17A1: cytochrome P450, family 17, subfamily A, polypeptide 1 (EC:1.14.99.9) | 0.33333 | Trimipramine
| 0.26626 | CYP1A1: cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) |
| 46 | N | N | N | N | Oxcarbazepine
 | CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.51852 | Trimipramine
| 0.92357 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 47 | N | N | N | N | Valine
| BCAT2: branched chain amino-acid transaminase 2, mitochondrial (EC:2.6.1.42) | 0.70000 | Isoleucine
 | 0.57560 | BCAT1: branched chain amino-acid transaminase 1, cytosolic (EC:2.6.1.42) |
| 48 | N | N | N | N | Glimepiride
 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.40541 | Tolbutamide
| 0.92357 | CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 49 | N | N | N | N | Profenamine hydrochloride
 | ACHE: acetylcholinesterase (EC:3.1.1.7) | 0.45238 | Ambenonium chloride
 | 0.53390 | BCHE: butyrylcholinesterase (EC:3.1.1.8) |
| 50 | N | N | Y | N | Olanzapine
 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.60714 | Clozapine
 | 0.13075 | CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) |
| 51 | Y | Y | Y | N | Tolrestat
 | AKR1B10: aldo-keto reductase family 1, member B10 (aldose reductase) (EC:1.1.1.2) | 0.21951 | Haloperidol
 | 0.73896 | AKR1B1: aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) |
| 52 | N | N | N | N | Threonine
| BCAT1: branched chain amino-acid transaminase 1, cytosolic (EC:2.6.1.42) | 0.77778 | Valine
| 0.020930 | PCCA: propionyl CoA carboxylase, alpha polypeptide (EC:6.4.1.3) |
| 53 | N | N | N | N | Cyclosporine
| PPID: peptidylprolyl isomerase D (EC:5.2.1.8) | 0.22222 | Tacrolimus
| 0.053636 | PPP5C: protein phosphatase 5, catalytic subunit (EC:3.1.3.16) |
| 54 | N | N | N | N | Fadrozole hydrochloride hydrate
 | CYP17A1: cytochrome P450, family 17, subfamily A, polypeptide 1 (EC:1.14.99.9) | 0.36364 | Liarozole hydrochloride
 | 0.26626 | CYP1A1: cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) |
| 55 | N | N | Y | N | Diazepam
 | CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.68000 | Alprazolam
| 0.92357 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 56 | N | N | N | N | Fadrozole hydrochloride
| CYP17A1: cytochrome P450, family 17, subfamily A, polypeptide 1 (EC:1.14.99.9) | 0.33333 | Alprazolam
| 0.26626 | CYP1A1: cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) |
| 57 | Y | N | Y | Y | Ethoxzolamide
| CA4: carbonic anhydrase IV (EC:4.2.1.1) | 0.50000 | Diazoxide
| 0.19740 | CA1: carbonic anhydrase I (EC:4.2.1.1) |
| 58 | N | N | N | N | Distigmine bromide
 | BCHE: butyrylcholinesterase (EC:3.1.1.8) | 0.64444 | Demecarium bromide
 | 0.53390 | ACHE: acetylcholinesterase (EC:3.1.1.7) |
| 59 | N | N | Y | N | Clozapine
| CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.45161 | Alprazolam
| 0.92357 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 60 | N | N | N | N | Levetiracetam
 | CA2: carbonic anhydrase II (EC:4.2.1.1) | 0.20000 | Ethinamate
| 0.60183 | CA1: carbonic anhydrase I (EC:4.2.1.1) |
| 61 | N | N | N | N | Letrozole
 | CYP17A1: cytochrome P450, family 17, subfamily A, polypeptide 1 (EC:1.14.99.9) | 0.45161 | Liarozole hydrochloride
| 0.26626 | CYP1A1: cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) |
| 62 | N | N | N | N | Anastrozole
 | CYP17A1: cytochrome P450, family 17, subfamily A, polypeptide 1 (EC:1.14.99.9) | 0.34483 | Metyrapone
| 0.26626 | CYP1A1: cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) |
| 63 | N | N | N | N | Cyclosporine
| PPIL1: peptidylprolyl isomerase (cyclophilin)-like 1 (EC:5.2.1.8) | 0.22222 | Tacrolimus
| 0.038764 | DUSP13: dual specificity phosphatase 13 (EC:3.1.3.16 3.1.3.48) |
| 64 | N | N | N | N | Tretinoin
| ALDH2: aldehyde dehydrogenase 2 family (mitochondrial) (EC:1.2.1.3) | 0.15152 | Disulfiram
| 0.69052 | ALDH1A1: aldehyde dehydrogenase 1 family, member A1 (EC:1.2.1.36) |
| 65 | N | N | N | N | Bendroflumethiazide
 | ATP1A1: ATPase, Na+/K+ transporting, alpha 1 polypeptide (EC:3.6.3.9) | 0.67857 | Hydroflumethiazide
 | 0.013918 | CA1: carbonic anhydrase I (EC:4.2.1.1) |
| 66 | N | N | N | N | Celecoxib
 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.41176 | Letrozole
| 0.92357 | CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 67 | N | N | Y | N | Flavin adenine dinucleotide
 | MAOA: monoamine oxidase A (EC:1.4.3.4) | 0.19355 | Chlorpromazine
 | 0.74783 | MAOB |
| 68 | N | N | N | N | Neostigmine bromide
 | BCHE: butyrylcholinesterase (EC:3.1.1.8) | 0.66667 | Rivastigmine
 | 0.53390 | ACHE: acetylcholinesterase (EC:3.1.1.7) |
| 69 | N | N | N | N | Cyclosporine
| : peptidyl-prolyl cis-trans isomerase A-like | 0.22222 | Tacrolimus
| 0.041770 | DUSP15: dual specificity phosphatase 15 (EC:3.1.3.16 3.1.3.48) |
| 70 | Y | N | N | N | Cyclosporine
| PPIB: peptidylprolyl isomerase B (cyclophilin B) (EC:5.2.1.8) | 0.22222 | Tacrolimus
| 0.036951 | DUSP21: dual specificity phosphatase 21 (EC:3.1.3.16 3.1.3.48) |
| 71 | N | N | N | N | Olanzapine
| CYP1A1: cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) | 0.37500 | Alprazolam
| 0.73543 | CYP1A2: cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) |
| 72 | N | N | N | N | Chlorzoxazone
 | CYP2A13: cytochrome P450, family 2, subfamily A, polypeptide 13 (EC:1.14.14.1) | 0.32000 | Alprazolam
| 0.91909 | CYP2A7: cytochrome P450, family 2, subfamily A, polypeptide 7 (EC:1.14.14.1) |
| 73 | N | N | Y | N | Ambenonium chloride
| BCHE: butyrylcholinesterase (EC:3.1.1.8) | 0.46512 | Dibucaine
 | 0.53390 | ACHE: acetylcholinesterase (EC:3.1.1.7) |
| 74 | N | N | N | N | Cyclothiazide
 | ATP1A1 | 0.62963 | Trichlormethiazide
 | 0.013918 | CA1: carbonic anhydrase I (EC:4.2.1.1) |
| 75 | N | N | N | N | Isoflurophate
| CTRB1: chymotrypsinogen B1 (EC:3.4.21.1) | 0.025000 | Bentiromide
 | 0.37782 | CELA3B: chymotrypsin-like elastase family, member 3B (EC:3.4.21.70) |
| 76 | N | N | N | N | Milrinone
 | ATM: ataxia telangiectasia mutated (EC:2.7.11.1) | 0.30435 | Caffeine
| 0.012516 | PDE6G: phosphodiesterase 6G, cGMP-specific, rod, gamma (EC:3.1.4.35) |
| 77 | N | N | N | N | Mesoridazine
 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.55882 | Perphenazine
 | 0.13075 | CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) |
| 78 | N | N | N | N | Idoxuridine
 | TYMS: thymidylate synthetase (EC:2.1.1.45) | 1 | Floxuridine
 | 0.021619 | ACAA1: acetyl-CoA acyltransferase 1 (EC:2.3.1.16) |
| 79 | N | N | N | N | Felbamate
 | CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.25926 | Aminoglutethimide
| 0.92357 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 80 | N | N | N | N | Dibucaine
| ACHE: acetylcholinesterase (EC:3.1.1.7) | 0.48571 | Itopride hydrochloride
 | 0.53390 | BCHE: butyrylcholinesterase (EC:3.1.1.8) |
| 81 | N | N | N | N | Pentoxifylline
| ATM: ataxia telangiectasia mutated (EC:2.7.11.1) | 0.61905 | Caffeine
| 0.012516 | PDE6G: phosphodiesterase 6G, cGMP-specific, rod, gamma (EC:3.1.4.35) |
| 82 | N | N | N | N | Tretinoin
| ALDH1B1: aldehyde dehydrogenase 1 family, member B1 (EC:1.2.1.3) | 0.15152 | Disulfiram
| 0.68300 | ALDH1A2: aldehyde dehydrogenase 1 family, member A2 (EC:1.2.1.36) |
| 83 | N | N | N | N | Valine
| ACADSB: acyl-CoA dehydrogenase, short/branched chain (EC:1.3.8.5) | 0.70000 | Isoleucine
| 0.26858 | ACAD8: acyl-CoA dehydrogenase family, member 8 |
| 84 | N | N | Y | N | Loratadine
 | CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) | 0.56250 | Clozapine
| 0.13075 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 85 | N | N | Y | N | Isoflurane
 | CYP2E1: cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) | 0.66667 | Enflurane
 | 0.021424 | ATP5D: ATP synthase, H+ transporting, mitochondrial F1 complex, delta subunit (EC:3.6.1.14) |
| 86 | N | N | N | N | Desflurane
 | CYP2E1: cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) | 0.66667 | Enflurane
| 0.021424 | ATP5D |
| 87 | N | Y | N | N | Acetaminophen
| TPO: thyroid peroxidase (EC:1.11.1.8) | 0.22222 | Propylthiouracil
| 0.36635 | MPO |
| 88 | N | N | N | N | Metformin
 | IGF1R: insulin-like growth factor 1 receptor (EC:2.7.10.1) | 0.083333 | Erlotinib hydrochloride
 | 0.56686 | INSR: insulin receptor (EC:2.7.10.1) |
| 89 | N | N | N | N | Physostigmine salicylate
 | BCHE: butyrylcholinesterase (EC:3.1.1.8) | 0.66667 | Physostigmine
 | 0.53390 | ACHE: acetylcholinesterase (EC:3.1.1.7) |
| 90 | N | N | N | N | Propylthiouracil
| FMO1: flavin containing monooxygenase 1 (EC:1.14.13.8) | 0.38461 | Methimazole
| 0.020430 | DIO2: deiodinase, iodothyronine, type II (EC:1.97.1.10) |
| 91 | N | N | Y | N | Edrophonium chloride
 | BCHE: butyrylcholinesterase (EC:3.1.1.8) | 0.47619 | Rivastigmine
| 0.53390 | ACHE: acetylcholinesterase (EC:3.1.1.7) |
| 92 | N | N | N | N | Ribavirin
 | IMPDH2: IMP (inosine 5'-monophosphate) dehydrogenase 2 (EC:1.1.1.205) | 0.29787 | Nadide
 | 0.80082 | IMPDH1: IMP (inosine 5'-monophosphate) dehydrogenase 1 (EC:1.1.1.205) |
| 93 | N | N | N | N | Aminocaproic acid
| PRCP: prolylcarboxypeptidase (angiotensinase C) (EC:3.4.16.2) | 0 | Isoflurophate
| 0.15192 | PRSS16: protease, serine, 16 (thymus) |
| 94 | N | N | Y | N | Phenacetin
 | CYP2E1: cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) | 0.71429 | Acetaminophen
| 0.24083 | CYP1A1: cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) |
| 95 | N | N | Y | N | Clozapine
| CYP1A1: cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) | 0.45161 | Alprazolam
| 0.73543 | CYP1A2: cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) |
| 96 | N | N | Y | N | Rivastigmine tartrate
 | BCHE: butyrylcholinesterase (EC:3.1.1.8) | 0.64286 | Rivastigmine
| 0.53390 | ACHE: acetylcholinesterase (EC:3.1.1.7) |
| 97 | N | N | N | N | Diethylstilbestrol
 | TPO: thyroid peroxidase (EC:1.11.1.8) | 0.19231 | Propylthiouracil
| 0.36635 | MPO |
| 98 | N | N | Y | N | Phenacetin
| CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) | 0.71429 | Acetaminophen
| 0.25328 | CYP1A1: cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) |
| 99 | N | Y | N | N | Isoflurophate
| CTRC: chymotrypsin C (caldecrin) (EC:3.4.21.2) | 0.025000 | Bentiromide
| 0.62815 | CELA2A: chymotrypsin-like elastase family, member 2A (EC:3.4.21.71) |
| 100 | N | N | N | N | Isoleucine
| VARS2: valyl-tRNA synthetase 2, mitochondrial (EC:6.1.1.9) | 0.70000 | Valine
| 0.057958 | IARS: isoleucyl-tRNA synthetase (EC:6.1.1.5) |
| 101 | N | N | Y | N | Aripiprazole
 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.54054 | Perphenazine
| 0.13075 | CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) |
| 102 | N | N | Y | Y | Pantoprazole
 | ATP4A: ATPase, H+/K+ exchanging, alpha polypeptide (EC:3.6.3.10) | 0.72414 | Omeprazole
 | 0.65015 | ATP1A1 |
| 103 | N | N | N | N | Quilostigmine
 | BCHE: butyrylcholinesterase (EC:3.1.1.8) | 0.60000 | Physostigmine
| 0.53390 | ACHE: acetylcholinesterase (EC:3.1.1.7) |
| 104 | N | N | Y | N | Carbamazepine
 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.76191 | Oxcarbazepine
| 0.81101 | CYP2C8: cytochrome P450, family 2, subfamily C, polypeptide 8 (EC:1.14.14.1) |
| 105 | Y | N | Y | N | Cyclosporine
| PPIA: peptidylprolyl isomerase A (cyclophilin A) (EC:5.2.1.8) | 0.22222 | Tacrolimus
| 0.040823 | DUSP13: dual specificity phosphatase 13 (EC:3.1.3.16 3.1.3.48) |
| 106 | N | N | Y | N | Eletriptan hydrobromide
 | CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) | 0.50000 | Mesoridazine
| 0.13075 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 107 | N | N | N | N | Ganciclovir
 | ABO: ABO blood group (transferase A, alpha 1-3-N-acetylgalactosaminyltransferase; transferase B, alpha 1-3-galactosyltransferase) (EC:2.4.1.37 2.4.1.40) | 0.78947 | Acyclovir
 | 0.015455 | ACAA1: acetyl-CoA acyltransferase 1 (EC:2.3.1.16) |
| 108 | N | N | N | N | Milrinone
| NT5C: 5', 3'-nucleotidase, cytosolic (EC:3.1.3.5) | 0.24138 | Pentoxifylline
| 0.037756 | PDE6H: phosphodiesterase 6H, cGMP-specific, cone, gamma (EC:3.1.4.35) |
| 109 | N | N | N | N | Milrinone
| IMPA1: inositol(myo)-1(or 4)-monophosphatase 1 (EC:3.1.3.25) | 0.24138 | Pentoxifylline
| 0.038864 | PDE6H: phosphodiesterase 6H, cGMP-specific, cone, gamma (EC:3.1.4.35) |
| 110 | N | N | N | N | Milrinone
| NT5C3: 5'-nucleotidase, cytosolic III (EC:3.1.3.5) | 0.24138 | Pentoxifylline
| 0.033948 | PDE6G: phosphodiesterase 6G, cGMP-specific, rod, gamma (EC:3.1.4.35) |
| 111 | N | N | N | N | Aminocaproic acid
| TPP1: tripeptidyl peptidase I (EC:3.4.14.9) | 0 | Isoflurophate
| 0.030918 | SPCS1: signal peptidase complex subunit 1 homolog (S. cerevisiae) (EC:3.4.-.-) |
| 112 | N | N | N | N | Milrinone
| RDH14: retinol dehydrogenase 14 (all-trans/9-cis/11-cis) (EC:1.1.1.-) | 0.24138 | Pentoxifylline
| 0.047768 | PDE6H: phosphodiesterase 6H, cGMP-specific, cone, gamma (EC:3.1.4.35) |
| 113 | N | N | N | N | Milrinone
| NT5C1A: 5'-nucleotidase, cytosolic IA (EC:3.1.3.5) | 0.24138 | Pentoxifylline
| 0.031796 | PDE6H: phosphodiesterase 6H, cGMP-specific, cone, gamma (EC:3.1.4.35) |
| 114 | N | N | N | N | Orlistat
 | LPL: lipoprotein lipase (EC:3.1.1.34) | 0.20000 | Capecitabine
 | 0.45390 | LIPG: lipase, endothelial (EC:3.1.1.3) |
| 115 | N | N | N | N | Aminocaproic acid
| CTSA: cathepsin A (EC:3.4.16.5) | 0 | Isoflurophate
| 0.027247 | PRTN3: proteinase 3 (EC:3.4.21.76) |
| 116 | N | N | N | N | Isoleucine
| ALDH6A1: aldehyde dehydrogenase 6 family, member A1 (EC:1.2.1.27 1.2.1.18) | 0.70000 | Valine
| 0.019573 | PCCA |
| 117 | N | N | N | N | Valine
| IARS: isoleucyl-tRNA synthetase (EC:6.1.1.5) | 0.70000 | Isoleucine
| 0.057958 | VARS2: valyl-tRNA synthetase 2, mitochondrial (EC:6.1.1.9) |
| 118 | N | N | N | N | Milrinone
| NT5E: 5'-nucleotidase, ecto (CD73) (EC:3.1.3.5) | 0.24138 | Pentoxifylline
| 0.023490 | PDE6G: phosphodiesterase 6G, cGMP-specific, rod, gamma (EC:3.1.4.35) |
| 119 | N | N | N | N | Floxuridine
| ACAA1: acetyl-CoA acyltransferase 1 (EC:2.3.1.16) | 1 | Idoxuridine
| 0.021619 | TYMS: thymidylate synthetase (EC:2.1.1.45) |
| 120 | N | N | N | N | Aminocaproic acid
| APEH: N-acylaminoacyl-peptide hydrolase (EC:3.4.19.1) | 0 | Isoflurophate
| 0.038792 | SPCS1: signal peptidase complex subunit 1 homolog (S. cerevisiae) (EC:3.4.-.-) |
| 121 | N | N | N | N | Isoleucine
| ACAD8: acyl-CoA dehydrogenase family, member 8 | 0.70000 | Valine
| 0.26858 | ACADSB: acyl-CoA dehydrogenase, short/branched chain (EC:1.3.8.5) |
| 122 | N | N | N | N | Metyrosine
 | PAH: phenylalanine hydroxylase (EC:1.14.16.1) | 0.62500 | Phenylalanine
 | 0.47966 | TH: tyrosine hydroxylase (EC:1.14.16.2) |
| 123 | N | N | N | N | Fluconazole
 | CYP2C18: cytochrome P450, family 2, subfamily C, polypeptide 18 (EC:1.14.14.1) | 0.40625 | Liarozole hydrochloride
| 0.85922 | CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 124 | N | N | N | N | Diphenhydramine
 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.51852 | Trimipramine
| 0.13075 | CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) |
| 125 | N | N | N | N | Aminocaproic acid
| PROC: protein C (inactivator of coagulation factors Va and VIIIa) (EC:3.4.21.69) | 0 | Menadione
 | 0.33733 | F7: coagulation factor VII (serum prothrombin conversion accelerator) (EC:3.4.21.21) |
| 126 | N | N | N | N | Miconazole
 | CYP2C18: cytochrome P450, family 2, subfamily C, polypeptide 18 (EC:1.14.14.1) | 0.54839 | Liarozole hydrochloride
| 0.85922 | CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 127 | N | N | N | N | Verapamil
 | CA2: carbonic anhydrase II (EC:4.2.1.1) | 0.22917 | Benzthiazide
 | 0.60183 | CA1: carbonic anhydrase I (EC:4.2.1.1) |
| 128 | N | N | N | N | Aminocaproic acid
| DPP4: dipeptidyl-peptidase 4 (EC:3.4.14.5) | 0 | Isoflurophate
| 0.025117 | KLK7: kallikrein-related peptidase 7 (EC:3.4.21.117) |
| 129 | N | N | N | N | Ciclopirox olamine
 | ALOX12: arachidonate 12-lipoxygenase (EC:1.13.11.31) | 0.22500 | Ketotifen fumarate
 | 0.66792 | ALOX15: arachidonate 15-lipoxygenase (EC:1.13.11.33) |
| 130 | N | N | N | N | Mirtazapine
 | CYP1A1: cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) | 0.44828 | Trimipramine
| 0.73543 | CYP1A2: cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) |
| 131 | N | N | N | N | Neostigmine methylsulfate
 | BCHE: butyrylcholinesterase (EC:3.1.1.8) | 0.60000 | Rivastigmine
| 0.53390 | ACHE: acetylcholinesterase (EC:3.1.1.7) |
| 132 | N | N | N | N | Physostigmine sulfate
 | BCHE: butyrylcholinesterase (EC:3.1.1.8) | 0.44444 | Physostigmine
| 0.53390 | ACHE: acetylcholinesterase (EC:3.1.1.7) |
| 133 | N | N | N | N | Tolrestat
| AKR1C1: aldo-keto reductase family 1, member C1 (EC:1.3.1.20 1.1.1.149 1.1.1.112) | 0.21951 | Haloperidol
| 0.49596 | AKR1B1: aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) |
| 134 | N | N | N | N | Calcitriol
| CYP27A1: cytochrome P450, family 27, subfamily A, polypeptide 1 (EC:1.14.13.15) | 0.81250 | Cholecalciferol
| 0.36424 | CYP27B1: cytochrome P450, family 27, subfamily B, polypeptide 1 (EC:1.14.13.13) |
| 135 | Y | N | Y | N | Pyridostigmine bromide
 | BCHE: butyrylcholinesterase (EC:3.1.1.8) | 0.52381 | Rivastigmine
| 0.53390 | ACHE: acetylcholinesterase (EC:3.1.1.7) |
| 136 | N | N | N | N | Caffeine
| NT5C: 5', 3'-nucleotidase, cytosolic (EC:3.1.3.5) | 0.61905 | Pentoxifylline
| 0.037756 | PDE6H: phosphodiesterase 6H, cGMP-specific, cone, gamma (EC:3.1.4.35) |
| 137 | N | N | Y | N | Phenytoin
 | CYP2C18: cytochrome P450, family 2, subfamily C, polypeptide 18 (EC:1.14.14.1) | 0.38461 | Metyrapone
| 0.85922 | CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 138 | N | N | N | N | Caffeine
| NT5C3: 5'-nucleotidase, cytosolic III (EC:3.1.3.5) | 0.61905 | Pentoxifylline
| 0.033948 | PDE6G: phosphodiesterase 6G, cGMP-specific, rod, gamma (EC:3.1.4.35) |
| 139 | N | N | N | N | Miconazole nitrate
 | CYP2C18: cytochrome P450, family 2, subfamily C, polypeptide 18 (EC:1.14.14.1) | 0.48571 | Liarozole hydrochloride
| 0.85922 | CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 140 | N | N | N | N | Caffeine
| IMPA1: inositol(myo)-1(or 4)-monophosphatase 1 (EC:3.1.3.25) | 0.61905 | Pentoxifylline
| 0.039334 | CYP19A1: cytochrome P450, family 19, subfamily A, polypeptide 1 (EC:1.14.14.1) |
| 141 | N | Y | N | N | Capecitabine
| LIPA: lipase A, lysosomal acid, cholesterol esterase (EC:3.1.1.13) | 0.20000 | Orlistat
| 0.59208 | LIPF: lipase, gastric (EC:3.1.1.3) |
| 142 | N | N | N | N | Uracil
 | ACACB: acetyl-CoA carboxylase beta (EC:6.4.1.2 6.3.4.14) | 0.043478 | Biotin
 | 0.73481 | ACACA: acetyl-CoA carboxylase alpha (EC:6.4.1.2 6.3.4.14) |
| 143 | N | N | N | N | Pantoprazole
| CYP2C8: cytochrome P450, family 2, subfamily C, polypeptide 8 (EC:1.14.14.1) | 0.37209 | Verapamil
| 0.81101 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 144 | N | N | N | N | Salicylic acid
| CHUK: conserved helix-loop-helix ubiquitous kinase (EC:2.7.11.10) | 0.31034 | Sulfasalazine
 | 0.49449 | IKBKB: inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta (EC:2.7.11.10) |
| 145 | N | N | N | N | Omeprazole
| ATP1A1 | 0.72414 | Pantoprazole
| 0.65015 | ATP4A: ATPase, H+/K+ exchanging, alpha polypeptide (EC:3.6.3.10) |
| 146 | N | N | N | N | Caffeine
| NT5C1A: 5'-nucleotidase, cytosolic IA (EC:3.1.3.5) | 0.61905 | Pentoxifylline
| 0.033034 | CYP2A13: cytochrome P450, family 2, subfamily A, polypeptide 13 (EC:1.14.14.1) |
| 147 | N | N | N | N | Caffeine
| RDH14: retinol dehydrogenase 14 (all-trans/9-cis/11-cis) (EC:1.1.1.-) | 0.61905 | Pentoxifylline
| 0.047768 | PDE6H: phosphodiesterase 6H, cGMP-specific, cone, gamma (EC:3.1.4.35) |
| 148 | N | N | N | N | Propylthiouracil
| FMO3: flavin containing monooxygenase 3 (EC:1.14.13.8 1.14.13.148) | 0.38461 | Methimazole
| 0.025611 | DIO1: deiodinase, iodothyronine, type I (EC:1.97.1.10) |
| 149 | N | N | N | N | Fludarabine phosphate
 | ADCY1: adenylate cyclase 1 (brain) (EC:4.6.1.1) | 0.88000 | Adenosine phosphate
 | 0.0097663 | RRM1: ribonucleotide reductase M1 (EC:1.17.4.1) |
| 150 | N | N | N | N | Profenamine hydrochloride
| F2: coagulation factor II (thrombin) (EC:3.4.21.5) | 0.72000 | Promethazine
 | 0.015532 | BCHE: butyrylcholinesterase (EC:3.1.1.8) |
| 151 | N | N | N | N | Adenosine
 | PNP: purine nucleoside phosphorylase (EC:2.4.2.1) | 0.80952 | Inosine
 | 0.012618 | ADCY1: adenylate cyclase 1 (brain) (EC:4.6.1.1) |
| 152 | N | N | N | N | Caffeine
| NT5E: 5'-nucleotidase, ecto (CD73) (EC:3.1.3.5) | 0.61905 | Pentoxifylline
| 0.023490 | PDE6G: phosphodiesterase 6G, cGMP-specific, rod, gamma (EC:3.1.4.35) |
| 153 | N | N | Y | N | Ergocalciferol
 | CYP27A1: cytochrome P450, family 27, subfamily A, polypeptide 1 (EC:1.14.13.15) | 0.78125 | Cholecalciferol
| 0.36424 | CYP27B1: cytochrome P450, family 27, subfamily B, polypeptide 1 (EC:1.14.13.13) |
| 154 | N | N | N | N | Mesalamine
| ALOX12B: arachidonate 12-lipoxygenase, 12R type (EC:1.13.11.-) | 0.75000 | Salicylic acid
| 0.38534 | ALOX5: arachidonate 5-lipoxygenase (EC:1.13.11.34) |
| 155 | N | N | N | N | Ketotifen fumarate
| PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) | 0.45714 | Zaltoprofen
 | 0.019709 | ALOX15B: arachidonate 15-lipoxygenase, type B (EC:1.13.11.33) |
| 156 | N | N | Y | N | Haloperidol
| CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) | 0.55882 | Perphenazine
| 0.13075 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 157 | N | N | Y | N | Chlorzoxazone
| CYP2A6: cytochrome P450, family 2, subfamily A, polypeptide 6 (EC:1.14.14.1) | 0.32000 | Alprazolam
| 0.94393 | CYP2A7: cytochrome P450, family 2, subfamily A, polypeptide 7 (EC:1.14.14.1) |
| 158 | Y | N | Y | N | Tacrine hydrochloride
 | BCHE: butyrylcholinesterase (EC:3.1.1.8) | 0.32353 | Donepezil hydrochloride
 | 0.53390 | ACHE: acetylcholinesterase (EC:3.1.1.7) |
| 159 | N | N | N | N | Valine
| TARS: threonyl-tRNA synthetase (EC:6.1.1.3) | 0.77778 | Threonine
| 0.019111 | BCAT1: branched chain amino-acid transaminase 1, cytosolic (EC:2.6.1.42) |
| 160 | N | N | N | N | Gulutamine
 | ACACB: acetyl-CoA carboxylase beta (EC:6.4.1.2 6.3.4.14) | 0.23810 | Biotin
| 0.73481 | ACACA: acetyl-CoA carboxylase alpha (EC:6.4.1.2 6.3.4.14) |
| 161 | N | N | N | N | Aminocaproic acid
| DPP8: dipeptidyl-peptidase 8 (EC:3.4.14.5) | 0 | Isoflurophate
| 0.028464 | KLK7: kallikrein-related peptidase 7 (EC:3.4.21.117) |
| 162 | N | N | N | N | Mesalamine
| ALOX12: arachidonate 12-lipoxygenase (EC:1.13.11.31) | 0.75000 | Salicylic acid
| 0.39384 | ALOX5: arachidonate 5-lipoxygenase (EC:1.13.11.34) |
| 163 | N | N | N | N | Valacyclovir hydrochloride
 | ABO: ABO blood group (transferase A, alpha 1-3-N-acetylgalactosaminyltransferase; transferase B, alpha 1-3-galactosyltransferase) (EC:2.4.1.37 2.4.1.40) | 0.60000 | Acyclovir
| 0.015455 | ACAA1: acetyl-CoA acyltransferase 1 (EC:2.3.1.16) |
| 164 | N | N | N | N | Salicylic acid
| TPO: thyroid peroxidase (EC:1.11.1.8) | 0.21429 | Methimazole
| 0.36635 | MPO |
| 165 | N | N | N | N | Aminocaproic acid
| DPP9: dipeptidyl-peptidase 9 (EC:3.4.14.5) | 0 | Isoflurophate
| 0.029891 | PREP: prolyl endopeptidase (EC:3.4.21.26) |
| 166 | N | N | N | N | Nicotine
| FMO1 | 0.26667 | Methimazole
| 0.57558 | FMO3: flavin containing monooxygenase 3 (EC:1.14.13.8 1.14.13.148) |
| 167 | N | N | N | N | Aminocaproic acid
| PON1: paraoxonase 1 (EC:3.1.1.2 3.1.8.1 3.1.1.81) | 0 | Isoflurophate
| 0.040345 | SPCS1: signal peptidase complex subunit 1 homolog (S. cerevisiae) (EC:3.4.-.-) |
| 168 | N | N | N | N | Aminocaproic acid
| PON2: paraoxonase 2 (EC:3.1.1.2 3.1.1.81) | 0 | Isoflurophate
| 0.033017 | TPSD1: tryptase delta 1 (EC:3.4.21.59) |
| 169 | N | N | N | N | Benzthiazide
| ATP1A1 | 0.48387 | Methyclothiazide
 | 0.013918 | CA1: carbonic anhydrase I (EC:4.2.1.1) |
| 170 | N | N | N | N | Mitomycin
 | NQO2: NAD(P)H dehydrogenase, quinone 2 (EC:1.10.99.2) | 0.13235 | Flavin adenine dinucleotide
| 0.43344 | NQO1: NAD(P)H dehydrogenase, quinone 1 (EC:1.6.5.2) |
| 171 | N | N | N | N | Caffeine
| NT5C2: 5'-nucleotidase, cytosolic II (EC:3.1.3.5) | 0.61905 | Pentoxifylline
| 0.036376 | PDE6H: phosphodiesterase 6H, cGMP-specific, cone, gamma (EC:3.1.4.35) |
| 172 | N | N | N | N | Milrinone
| NT5C2: 5'-nucleotidase, cytosolic II (EC:3.1.3.5) | 0.24138 | Pentoxifylline
| 0.036376 | PDE6H: phosphodiesterase 6H, cGMP-specific, cone, gamma (EC:3.1.4.35) |
| 173 | N | N | N | N | Icopezil maleate
 | BCHE: butyrylcholinesterase (EC:3.1.1.8) | 0.51163 | Donepezil hydrochloride
| 0.53390 | ACHE: acetylcholinesterase (EC:3.1.1.7) |
| 174 | N | N | Y | N | Oxiconazole nitrate
 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.90323 | Miconazole nitrate
| 0.020169 | ABO: ABO blood group (transferase A, alpha 1-3-N-acetylgalactosaminyltransferase; transferase B, alpha 1-3-galactosyltransferase) (EC:2.4.1.37 2.4.1.40) |
| 175 | N | N | N | N | Maprotiline
 | RRM2: ribonucleotide reductase M2 (EC:1.17.4.1) | 0.071429 | Deferoxamine
| 0.75877 | RRM2B: ribonucleotide reductase M2 B (TP53 inducible) (EC:1.17.4.1) |
| 176 | N | N | N | N | Valine
| ACAT1: acetyl-CoA acetyltransferase 1 (EC:2.3.1.9) | 0.70000 | Isoleucine
| 0.024734 | ACAD8: acyl-CoA dehydrogenase family, member 8 |
| 177 | N | Y | N | N | Isoflurophate
| ELANE: elastase, neutrophil expressed (EC:3.4.21.37) | 0.078947 | Sivelestat
 | 0.50758 | PRTN3: proteinase 3 (EC:3.4.21.76) |
| 178 | N | N | N | N | Ciclopirox olamine
| ALOX15B: arachidonate 15-lipoxygenase, type B (EC:1.13.11.33) | 0.22500 | Ketotifen fumarate
| 0.32420 | ALOX15: arachidonate 15-lipoxygenase (EC:1.13.11.33) |
| 179 | N | N | N | N | Orlistat
| PLA1A: phospholipase A1 member A (EC:3.1.1.-) | 0.20000 | Capecitabine
| 0.20191 | LIPC: lipase, hepatic (EC:3.1.1.3) |
| 180 | N | N | N | N | Penicillamine
 | PCCB | 0.70000 | Valine
| 0.022277 | CASP1: caspase 1, apoptosis-related cysteine peptidase (EC:3.4.22.36) |
| 181 | N | N | Y | N | Galantamine hydrobromide
 | BCHE: butyrylcholinesterase (EC:3.1.1.8) | 0.35484 | Physostigmine
| 0.53390 | ACHE: acetylcholinesterase (EC:3.1.1.7) |
| 182 | N | N | N | N | Folic acid
 | DHFR: dihydrofolate reductase (EC:1.5.1.3) | 0.80556 | Methotrexate
 | 0.039110 | GGH: gamma-glutamyl hydrolase (conjugase, folylpolygammaglutamyl hydrolase) (EC:3.4.19.9) |
| 183 | N | N | N | N | Threonine
| ALDH6A1: aldehyde dehydrogenase 6 family, member A1 (EC:1.2.1.27 1.2.1.18) | 0.77778 | Valine
| 0.019573 | PCCA |
| 184 | N | N | Y | N | Sulfasalazine
| PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) | 0.52941 | Etoricoxib
 | 0.019709 | ALOX15B: arachidonate 15-lipoxygenase, type B (EC:1.13.11.33) |
| 185 | N | N | N | N | Threonine
| VARS2: valyl-tRNA synthetase 2, mitochondrial (EC:6.1.1.9) | 0.77778 | Valine
| 0.012856 | PCCA |
| 186 | N | N | N | N | Penicillamine
| PCCA | 0.70000 | Valine
| 0.017548 | CASP1: caspase 1, apoptosis-related cysteine peptidase (EC:3.4.22.36) |
| 187 | N | N | N | N | Oxiconazole nitrate
| CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.90323 | Miconazole nitrate
| 0.018411 | ABO: ABO blood group (transferase A, alpha 1-3-N-acetylgalactosaminyltransferase; transferase B, alpha 1-3-galactosyltransferase) (EC:2.4.1.37 2.4.1.40) |
| 188 | N | N | N | N | Aminocaproic acid
| ESD: esterase D (EC:3.1.2.12 3.1.1.56) | 0.13333 | Capecitabine
| 0.043535 | SERHL: serine hydrolase-like |
| 189 | N | N | N | N | Folic acid
| TYMS: thymidylate synthetase (EC:2.1.1.45) | 0.68421 | Raltitrexed
 | 0.030670 | GGH: gamma-glutamyl hydrolase (conjugase, folylpolygammaglutamyl hydrolase) (EC:3.4.19.9) |
| 190 | N | N | N | N | Ketotifen fumarate
| LALBA | 0.32432 | Ketoprofen
| 0.035630 | PDE7B: phosphodiesterase 7B (EC:3.1.4.17) |
| 191 | Y | N | Y | N | Adenosine
| ADK: adenosine kinase (EC:2.7.1.20) | 0.75000 | Adenosine phosphate
| 0.013397 | ADCY1: adenylate cyclase 1 (brain) (EC:4.6.1.1) |
| 192 | N | N | Y | N | Ibuprofen
| CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.32000 | Tolbutamide
| 0.92357 | CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 193 | N | N | N | N | Pantoprazole
| CYP2C18: cytochrome P450, family 2, subfamily C, polypeptide 18 (EC:1.14.14.1) | 0.35484 | Methoxsalen
| 0.85922 | CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 194 | N | N | Y | N | Chlorzoxazone
| CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) | 0.32000 | Alprazolam
| 0.35638 | CYP2E1: cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) |
| 195 | N | N | N | N | Uracil
| TK1: thymidine kinase 1, soluble (EC:2.7.1.21) | 0.70000 | Fluorouracil
 | 0.020944 | DPYD: dihydropyrimidine dehydrogenase (EC:1.3.1.2) |
| 196 | N | N | Y | N | Perphenazine
| CYP1A2: cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) | 0.61290 | Clozapine
| 0.24342 | CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) |
| 197 | N | N | N | N | Uracil
| UMPS: uridine monophosphate synthetase (EC:2.4.2.10 4.1.1.23) | 0.70000 | Fluorouracil
| 0.013264 | DPYD: dihydropyrimidine dehydrogenase (EC:1.3.1.2) |
| 198 | N | N | N | N | Uracil
| UPP2: uridine phosphorylase 2 (EC:2.4.2.3) | 0.70000 | Fluorouracil
| 0.014338 | DPYD: dihydropyrimidine dehydrogenase (EC:1.3.1.2) |
| 199 | N | N | N | N | Mirtazapine
| CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.53571 | Clozapine
| 0.35919 | CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) |
| 200 | N | N | N | N | Uracil
| UPP1: uridine phosphorylase 1 (EC:2.4.2.3) | 0.70000 | Fluorouracil
| 0.014404 | DPYD: dihydropyrimidine dehydrogenase (EC:1.3.1.2) |
| 201 | N | N | N | N | Minalrestat
 | AKR1B10: aldo-keto reductase family 1, member B10 (aldose reductase) (EC:1.1.1.2) | 0.38461 | Haloperidol
| 0.73896 | AKR1B1: aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) |
| 202 | N | N | N | N | Uracil
| TK2: thymidine kinase 2, mitochondrial (EC:2.7.1.21) | 0.70000 | Fluorouracil
| 0.012301 | DPYD: dihydropyrimidine dehydrogenase (EC:1.3.1.2) |
| 203 | N | N | N | N | Bentiromide
| PNLIPRP1: pancreatic lipase-related protein 1 (EC:3.1.1.3) | 0.12245 | Capecitabine
| 0.70561 | PNLIP: pancreatic lipase (EC:3.1.1.3) |
| 204 | N | N | Y | N | Oxcarbazepine
| CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.76191 | Carbamazepine
| 0.14153 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 205 | N | N | Y | N | Miconazole
| CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.54839 | Liarozole hydrochloride
| 0.14915 | CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 206 | Y | N | Y | N | Galantamine
 | BCHE: butyrylcholinesterase (EC:3.1.1.8) | 0.36667 | Physostigmine
| 0.53390 | ACHE: acetylcholinesterase (EC:3.1.1.7) |
| 207 | N | N | N | N | Midazolam
 | CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) | 0.80000 | Alprazolam
| 0.13075 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 208 | N | N | N | N | Metrifonate
 | ATP5D | 0.35714 | Halothane
| 0.027573 | ACHE: acetylcholinesterase (EC:3.1.1.7) |
| 209 | N | N | N | N | Pantoprazole
| CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) | 0.36842 | Mesoridazine
| 0.35919 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 210 | N | N | N | N | Hydroxocobalamin
 | MAT1A: methionine adenosyltransferase I, alpha (EC:2.5.1.6) | 0.041237 | Racemethionine
 | 0.020944 | MMAB: methylmalonic aciduria (cobalamin deficiency) cblB type (EC:2.5.1.17) |
| 211 | Y | N | Y | N | Pimozide
 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.65854 | Astemizole
 | 0.012581 | F2: coagulation factor II (thrombin) (EC:3.4.21.5) |
| 212 | N | N | N | N | Cytarabine
 | TYMS: thymidylate synthetase (EC:2.1.1.45) | 0.75000 | Gemcitabine
 | 0.023352 | POLB: polymerase (DNA directed), beta (EC:2.7.7.7) |
| 213 | N | N | N | N | Propylthiouracil
| PRDX1: peroxiredoxin 1 (EC:1.11.1.15) | 0.22222 | Acetaminophen
| 0.044594 | DIO3: deiodinase, iodothyronine, type III (EC:1.97.1.11) |
| 214 | N | N | N | N | Hydroxocobalamin
| MSRA: methionine sulfoxide reductase A (EC:1.8.4.11) | 0.041237 | Racemethionine
| 0.024392 | MMAB: methylmalonic aciduria (cobalamin deficiency) cblB type (EC:2.5.1.17) |
| 215 | N | N | N | N | Carbamazepine
| CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) | 0.48148 | Trimipramine
| 0.37298 | CYP2C8: cytochrome P450, family 2, subfamily C, polypeptide 8 (EC:1.14.14.1) |
| 216 | N | N | Y | N | Fluconazole
| CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.40625 | Liarozole hydrochloride
| 0.14915 | CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 217 | N | N | Y | N | Nadide
| ALDH1A2: aldehyde dehydrogenase 1 family, member A2 (EC:1.2.1.36) | 0 | Tretinoin
| 0.74424 | ALDH1A1: aldehyde dehydrogenase 1 family, member A1 (EC:1.2.1.36) |
| 218 | N | N | N | N | Ketoprofen
| PTGIS: prostaglandin I2 (prostacyclin) synthase (EC:5.3.99.4) | 0.56522 | Metyrapone
| 0.018788 | LALBA |
| 219 | N | N | N | N | Isoleucine
| TARS: threonyl-tRNA synthetase (EC:6.1.1.3) | 0.70000 | Threonine
| 0.019111 | BCAT1: branched chain amino-acid transaminase 1, cytosolic (EC:2.6.1.42) |
| 220 | N | N | N | N | Propylthiouracil
| PRDX3: peroxiredoxin 3 (EC:1.11.1.15) | 0.22222 | Acetaminophen
| 0.035109 | DIO1: deiodinase, iodothyronine, type I (EC:1.97.1.10) |
| 221 | N | N | N | N | Triazolam
 | CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) | 0.87500 | Alprazolam
| 0.13075 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 222 | N | N | Y | N | Pimozide
| CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) | 0.65854 | Astemizole
| 0.014876 | F2: coagulation factor II (thrombin) (EC:3.4.21.5) |
| 223 | N | N | N | N | Propylthiouracil
| PRDX4: peroxiredoxin 4 (EC:1.11.1.15) | 0.22222 | Acetaminophen
| 0.031414 | DIO3: deiodinase, iodothyronine, type III (EC:1.97.1.11) |
| 224 | N | N | Y | N | Phenytoin
| CYP2C8: cytochrome P450, family 2, subfamily C, polypeptide 8 (EC:1.14.14.1) | 0.38461 | Metyrapone
| 0.81101 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 225 | N | Y | Y | N | Phenytoin
| CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.44444 | Diazepam
| 0.14915 | CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 226 | N | N | N | N | Metrifonate
| ATP2C1: ATPase, Ca++ transporting, type 2C, member 1 (EC:3.6.3.8) | 0.35714 | Halothane
| 0.011472 | BCHE: butyrylcholinesterase (EC:3.1.1.8) |
| 227 | N | N | N | N | Penciclovir
 | ABO: ABO blood group (transferase A, alpha 1-3-N-acetylgalactosaminyltransferase; transferase B, alpha 1-3-galactosyltransferase) (EC:2.4.1.37 2.4.1.40) | 0.54546 | Acyclovir
| 0.015455 | ACAA1: acetyl-CoA acyltransferase 1 (EC:2.3.1.16) |
| 228 | N | N | N | N | Bentiromide
| PNLIPRP2: pancreatic lipase-related protein 2 (EC:3.1.1.3 3.1.1.26) | 0.12245 | Capecitabine
| 0.67708 | PNLIP: pancreatic lipase (EC:3.1.1.3) |
| 229 | N | N | N | N | Racemethionine
| MUT: methylmalonyl CoA mutase (EC:5.4.99.2) | 0.041237 | Hydroxocobalamin
| 0.017685 | MSRA: methionine sulfoxide reductase A (EC:1.8.4.11) |
| 230 | N | N | N | N | Exemestane
 | PLA2G4A: phospholipase A2, group IVA (cytosolic, calcium-dependent) (EC:3.1.1.5 3.1.1.4) | 0.48485 | Fluorometholone
 | 0.014633 | CYP19A1: cytochrome P450, family 19, subfamily A, polypeptide 1 (EC:1.14.14.1) |
| 231 | N | N | N | N | Diazepam
| CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) | 0.68000 | Alprazolam
| 0.35919 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 232 | N | N | N | N | Orotic acid
 | DPYD: dihydropyrimidine dehydrogenase (EC:1.3.1.2) | 0.58333 | Uracil
| 0.054290 | DHODH: dihydroorotate dehydrogenase (quinone) (EC:1.3.5.2) |
| 233 | N | N | N | N | Hydrochlorothiazide
 | ATP1A1 | 0.76191 | Hydroflumethiazide
| 0.020226 | CA6: carbonic anhydrase VI (EC:4.2.1.1) |
| 234 | N | N | N | N | Racemethionine
| MMAB: methylmalonic aciduria (cobalamin deficiency) cblB type (EC:2.5.1.17) | 0.041237 | Hydroxocobalamin
| 0.024392 | MSRA: methionine sulfoxide reductase A (EC:1.8.4.11) |
| 235 | N | N | N | N | Inosine
| ADCY1: adenylate cyclase 1 (brain) (EC:4.6.1.1) | 0.80952 | Adenosine
| 0.012618 | PNP: purine nucleoside phosphorylase (EC:2.4.2.1) |
| 236 | N | N | N | N | Salicylic acid
| LALBA | 0.38889 | Ibuprofen
| 0.034331 | LPO: lactoperoxidase (EC:1.11.1.7) |
| 237 | N | N | N | N | Threonine
| ACAD8: acyl-CoA dehydrogenase family, member 8 | 0.77778 | Valine
| 0.017488 | PCCB |
| 238 | N | N | N | N | Indomethacin
| IKBKB: inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta (EC:2.7.11.10) | 0.56250 | Sulindac
 | 0.014552 | ALOX15B: arachidonate 15-lipoxygenase, type B (EC:1.13.11.33) |
| 239 | N | N | N | N | Diethylstilbestrol
| SULT1A2: sulfotransferase family, cytosolic, 1A, phenol-preferring, member 2 (EC:2.8.2.1) | 0.34783 | Acetaminophen
| 0.034942 | GPX5: glutathione peroxidase 5 (epididymal androgen-related protein) (EC:1.11.1.9) |
| 240 | N | N | N | N | Maprotiline
| CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.53571 | Trimipramine
| 0.017206 | RRM2B: ribonucleotide reductase M2 B (TP53 inducible) (EC:1.17.4.1) |
| 241 | N | N | N | N | Sulindac
| FMO1 | 0.14706 | Flavin adenine dinucleotide
| 0.57558 | FMO3: flavin containing monooxygenase 3 (EC:1.14.13.8 1.14.13.148) |
| 242 | N | N | N | N | Midazolam
| CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.80000 | Alprazolam
| 0.14153 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 243 | N | N | N | N | Nadide
| ALDH1B1: aldehyde dehydrogenase 1 family, member B1 (EC:1.2.1.3) | 0.034483 | Disulfiram
| 0.74238 | ALDH2: aldehyde dehydrogenase 2 family (mitochondrial) (EC:1.2.1.3) |
| 244 | N | N | Y | N | Verapamil
| CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) | 0.37500 | Trimipramine
| 0.37298 | CYP2C8: cytochrome P450, family 2, subfamily C, polypeptide 8 (EC:1.14.14.1) |
| 245 | N | N | N | N | Uracil
| TYMS: thymidylate synthetase (EC:2.1.1.45) | 0.70000 | Fluorouracil
| 0.015267 | DPYD: dihydropyrimidine dehydrogenase (EC:1.3.1.2) |
| 246 | N | N | N | N | Astemizole
| CYP1A2: cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) | 0.46154 | Clozapine
| 0.24342 | CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) |
| 247 | N | N | N | N | Esomeprazole magnesium
 | ATP1A1 | 0.34483 | Pantoprazole
| 0.65015 | ATP4A: ATPase, H+/K+ exchanging, alpha polypeptide (EC:3.6.3.10) |
| 248 | N | N | N | N | Zileuton
 | ALOX12: arachidonate 12-lipoxygenase (EC:1.13.11.31) | 0.40000 | Ketoprofen
| 0.39384 | ALOX5: arachidonate 5-lipoxygenase (EC:1.13.11.34) |
| 249 | N | N | N | N | Oleic acid
 | PPT1: palmitoyl-protein thioesterase 1 (EC:3.1.2.22) | 0.80952 | Palmitic acid
 | 0.027445 | GC: group-specific component (vitamin D binding protein) (EC:6.4.-.-) |
| 250 | N | N | N | N | Zileuton
| ALOX12B: arachidonate 12-lipoxygenase, 12R type (EC:1.13.11.-) | 0.40000 | Ketoprofen
| 0.38534 | ALOX5: arachidonate 5-lipoxygenase (EC:1.13.11.34) |
| 251 | N | N | N | N | Palmitic acid
| GC: group-specific component (vitamin D binding protein) (EC:6.4.-.-) | 0.80952 | Oleic acid
| 0.027445 | PPT1: palmitoyl-protein thioesterase 1 (EC:3.1.2.22) |
| 252 | N | N | N | N | Cladribine
 | ACAA1: acetyl-CoA acyltransferase 1 (EC:2.3.1.16) | 0.56522 | Idoxuridine
| 0.021956 | PNP: purine nucleoside phosphorylase (EC:2.4.2.1) |
| 253 | N | N | N | N | Testolactone
 | PLA2G4A: phospholipase A2, group IVA (cytosolic, calcium-dependent) (EC:3.1.1.5 3.1.1.4) | 0.48485 | Fluorometholone
| 0.014633 | CYP19A1: cytochrome P450, family 19, subfamily A, polypeptide 1 (EC:1.14.14.1) |
| 254 | N | N | N | N | Alrestatin sodium
 | AKR1B10: aldo-keto reductase family 1, member B10 (aldose reductase) (EC:1.1.1.2) | 0.24324 | Haloperidol
| 0.73896 | AKR1B1: aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) |
| 255 | N | Y | N | N | Mesalamine
| LTA4H: leukotriene A4 hydrolase (EC:3.3.2.6) | 0.75000 | Salicylic acid
| 0.019303 | PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) |
| 256 | N | N | N | N | Citric acid, anhydrous
 | AKR1B10: aldo-keto reductase family 1, member B10 (aldose reductase) (EC:1.1.1.2) | 0.083333 | Haloperidol
| 0.73896 | AKR1B1: aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) |
| 257 | N | N | N | N | Ketotifen fumarate
| PTGS2: prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) | 0.45714 | Zaltoprofen
| 0.016976 | LTA4H |
| 258 | N | Y | N | N | Acetaminophen
| GPX4: glutathione peroxidase 4 (EC:1.11.1.12) | 0.34783 | Diethylstilbestrol
| 0.046704 | PRDX5: peroxiredoxin 5 (EC:1.11.1.15) |
| 259 | N | N | Y | N | Diazoxide
| ATP1A1 | 0.36000 | Methyclothiazide
| 0.013918 | CA1: carbonic anhydrase I (EC:4.2.1.1) |
| 260 | N | N | N | N | Sulindac
| CHUK: conserved helix-loop-helix ubiquitous kinase (EC:2.7.11.10) | 0.43243 | Sulfasalazine
| 0.49449 | IKBKB: inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta (EC:2.7.11.10) |
| 261 | N | N | N | N | Fidarestat
 | AKR1B10: aldo-keto reductase family 1, member B10 (aldose reductase) (EC:1.1.1.2) | 0.24324 | Haloperidol
| 0.73896 | AKR1B1: aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) |
| 262 | N | N | N | N | Miconazole
| CYP2C8: cytochrome P450, family 2, subfamily C, polypeptide 8 (EC:1.14.14.1) | 0.54839 | Liarozole hydrochloride
| 0.81101 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 263 | N | N | N | N | Chlorzoxazone
| CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.34783 | Diazepam
| 0.60720 | CYP2E1: cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) |
| 264 | N | N | N | N | Salicylic acid
| PRDX5: peroxiredoxin 5 (EC:1.11.1.15) | 0.72727 | Benzoic acid
 | 0.022567 | ALOX15: arachidonate 15-lipoxygenase (EC:1.13.11.33) |
| 265 | N | N | N | N | Isoflurophate
| PROC: protein C (inactivator of coagulation factors Va and VIIIa) (EC:3.4.21.69) | 0.043478 | Menadione
| 0.33733 | F7: coagulation factor VII (serum prothrombin conversion accelerator) (EC:3.4.21.21) |
| 266 | N | N | N | N | Deslanoside
 | ATP4A: ATPase, H+/K+ exchanging, alpha polypeptide (EC:3.6.3.10) | 0.082569 | Esomeprazole magnesium
| 0.65015 | ATP1A1 |
| 267 | N | N | N | N | Propylthiouracil
| PRDX5: peroxiredoxin 5 (EC:1.11.1.15) | 0.22222 | Acetaminophen
| 0.036495 | DIO2: deiodinase, iodothyronine, type II (EC:1.97.1.10) |
| 268 | N | N | N | N | Fludarabine phosphate
| ADK: adenosine kinase (EC:2.7.1.20) | 0.88000 | Adenosine phosphate
| 0.018523 | RRM1: ribonucleotide reductase M1 (EC:1.17.4.1) |
| 269 | N | N | N | N | Flavin adenine dinucleotide
| ACADSB: acyl-CoA dehydrogenase, short/branched chain (EC:1.3.8.5) | 0.050847 | Isoleucine
| 0.34876 | ACADS: acyl-CoA dehydrogenase, C-2 to C-3 short chain (EC:1.3.8.1) |
| 270 | N | N | N | N | Triazolam
| CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.87500 | Alprazolam
| 0.14153 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 271 | N | N | N | N | Acetaminophen
| CYP2A7: cytochrome P450, family 2, subfamily A, polypeptide 7 (EC:1.14.14.1) | 0.38095 | Tolbutamide
| 0.46889 | CYP2E1: cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) |
| 272 | N | N | N | N | Oxcarbazepine
| CYP2C8: cytochrome P450, family 2, subfamily C, polypeptide 8 (EC:1.14.14.1) | 0.76191 | Carbamazepine
| 0.81101 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 273 | N | Y | N | N | Acetaminophen
| GPX7: glutathione peroxidase 7 (EC:1.11.1.9) | 0.34783 | Diethylstilbestrol
| 0.036838 | CYP1A2: cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) |
| 274 | N | N | N | N | Epalrestat
 | AKR1B10: aldo-keto reductase family 1, member B10 (aldose reductase) (EC:1.1.1.2) | 0.17500 | Haloperidol
| 0.73896 | AKR1B1: aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) |
| 275 | N | N | N | N | Docebenone
 | ALOX12B: arachidonate 12-lipoxygenase, 12R type (EC:1.13.11.-) | 0.17500 | Phenylbutazone
| 0.38534 | ALOX5: arachidonate 5-lipoxygenase (EC:1.13.11.34) |
| 276 | N | N | Y | N | Sulfasalazine
| PTGS2: prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) | 0.52941 | Etoricoxib
| 0.017622 | NAT2: N-acetyltransferase 2 (arylamine N-acetyltransferase) (EC:2.3.1.5) |
| 277 | N | N | N | N | Lidorestat
 | AKR1B10: aldo-keto reductase family 1, member B10 (aldose reductase) (EC:1.1.1.2) | 0.26190 | Haloperidol
| 0.73896 | AKR1B1: aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) |
| 278 | N | N | N | N | Terfenadine
 | CYP1A2: cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) | 0.42500 | Trimipramine
| 0.24342 | CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) |
| 279 | Y | N | Y | N | Nicotine
| CYP1A2: cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) | 0.39130 | Mirtazapine
| 0.24056 | CYP2A13: cytochrome P450, family 2, subfamily A, polypeptide 13 (EC:1.14.14.1) |
| 280 | N | N | Y | N | Trifluridine
 | TYMS: thymidylate synthetase (EC:2.1.1.45) | 0.76191 | Floxuridine
| 0.021619 | ACAA1: acetyl-CoA acyltransferase 1 (EC:2.3.1.16) |
| 281 | N | N | N | N | Docebenone
| ALOX12: arachidonate 12-lipoxygenase (EC:1.13.11.31) | 0.17500 | Phenylbutazone
| 0.39384 | ALOX5: arachidonate 5-lipoxygenase (EC:1.13.11.34) |
| 282 | N | N | N | N | Ximelagatran
 | ACE: angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 (EC:3.4.15.1) | 0.51163 | Trandolapril
 | 0.010996 | F2: coagulation factor II (thrombin) (EC:3.4.21.5) |
| 283 | N | N | N | N | Threonine
| IARS: isoleucyl-tRNA synthetase (EC:6.1.1.5) | 0.70000 | Isoleucine
| 0.013140 | PCCA |
| 284 | N | N | N | N | Nilutamide
 | AKR1B1: aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) | 0.37500 | Risarestat
 | 0.014469 | POR: P450 (cytochrome) oxidoreductase (EC:1.6.2.4) |
| 285 | N | N | Y | N | Cisapride
 | CYP1A2: cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) | 0.37500 | Clozapine
| 0.24342 | CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) |
| 286 | N | N | N | N | Digoxin
 | ATP4A: ATPase, H+/K+ exchanging, alpha polypeptide (EC:3.6.3.10) | 0.080808 | Esomeprazole magnesium
| 0.65015 | ATP1A1 |
| 287 | N | N | N | N | Ketotifen fumarate
| PDE11A: phosphodiesterase 11A (EC:3.1.4.35 3.1.4.17) | 0.37209 | Vesnarinone
 | 0.14623 | PDE7A: phosphodiesterase 7A (EC:3.1.4.17) |
| 288 | N | N | N | N | Aripiprazole
| CYP1A2: cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) | 0.47222 | Clozapine
| 0.24342 | CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) |
| 289 | N | N | N | N | Mesalamine
| ALOX15B: arachidonate 15-lipoxygenase, type B (EC:1.13.11.33) | 0.75000 | Salicylic acid
| 0.38637 | ALOX5: arachidonate 5-lipoxygenase (EC:1.13.11.34) |
| 290 | N | N | N | N | Adenosine phosphate
| POLA1: polymerase (DNA directed), alpha 1, catalytic subunit (EC:2.7.7.7) | 0.88000 | Fludarabine phosphate
| 0.012396 | APRT: adenine phosphoribosyltransferase (EC:2.4.2.7) |
| 291 | N | N | Y | N | Nicotine
| CYP2E1: cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) | 0.36364 | Fadrozole hydrochloride
| 0.48556 | CYP2A13: cytochrome P450, family 2, subfamily A, polypeptide 13 (EC:1.14.14.1) |
| 292 | N | N | N | N | Fluconazole
| CYP2C8: cytochrome P450, family 2, subfamily C, polypeptide 8 (EC:1.14.14.1) | 0.40625 | Liarozole hydrochloride
| 0.81101 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 293 | N | N | Y | N | Miconazole nitrate
| CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.48571 | Liarozole hydrochloride
| 0.14915 | CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 294 | N | N | N | N | Inosine
| ACAA1: acetyl-CoA acyltransferase 1 (EC:2.3.1.16) | 0.50000 | Idoxuridine
| 0.021956 | PNP: purine nucleoside phosphorylase (EC:2.4.2.1) |
| 295 | N | N | N | N | Zenarestat
 | AKR1B10: aldo-keto reductase family 1, member B10 (aldose reductase) (EC:1.1.1.2) | 0.33333 | Haloperidol
| 0.73896 | AKR1B1: aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) |
| 296 | N | N | N | N | Threonine
| ACADSB: acyl-CoA dehydrogenase, short/branched chain (EC:1.3.8.5) | 0.70000 | Isoleucine
| 0.019336 | PCCB |
| 297 | N | N | N | N | Metyrosine
| PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) | 0.61111 | Ibuprofen
| 0.014274 | TH: tyrosine hydroxylase (EC:1.14.16.2) |
| 298 | N | N | Y | N | Diphenhydramine
| CYP1A2: cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) | 0.51852 | Trimipramine
| 0.24342 | CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) |
| 299 | N | N | N | N | Ponalrestat
 | AKR1B10: aldo-keto reductase family 1, member B10 (aldose reductase) (EC:1.1.1.2) | 0.31579 | Haloperidol
| 0.73896 | AKR1B1: aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) |
| 300 | N | N | N | N | Cytarabine
| RRM1: ribonucleotide reductase M1 (EC:1.17.4.1) | 0.75000 | Gemcitabine
| 0.017953 | POLB |
| 301 | N | N | N | N | Penicillamine
| BCKDK: branched chain ketoacid dehydrogenase kinase (EC:2.7.11.4) | 0.70000 | Valine
| 0.015484 | CASP1: caspase 1, apoptosis-related cysteine peptidase (EC:3.4.22.36) |
| 302 | N | N | N | N | Salicylic acid
| DIO3: deiodinase, iodothyronine, type III (EC:1.97.1.11) | 0.31250 | Acetaminophen
| 0.025577 | ALOX12: arachidonate 12-lipoxygenase (EC:1.13.11.31) |
| 303 | N | N | N | N | Fluorouracil
| ACACA: acetyl-CoA carboxylase alpha (EC:6.4.1.2 6.3.4.14) | 0.70000 | Uracil
| 0.011848 | UPP2: uridine phosphorylase 2 (EC:2.4.2.3) |
| 304 | N | N | N | N | Mesalamine
| ALOX15: arachidonate 15-lipoxygenase (EC:1.13.11.33) | 0.75000 | Salicylic acid
| 0.38087 | ALOX5: arachidonate 5-lipoxygenase (EC:1.13.11.34) |
| 305 | N | N | N | N | Ketotifen fumarate
| IKBKB: inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta (EC:2.7.11.10) | 0.34146 | Sulindac
| 0.016539 | PDE7A: phosphodiesterase 7A (EC:3.1.4.17) |
| 306 | N | N | N | N | Miconazole nitrate
| CYP2C8: cytochrome P450, family 2, subfamily C, polypeptide 8 (EC:1.14.14.1) | 0.48571 | Liarozole hydrochloride
| 0.81101 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 307 | N | N | Y | N | Clozapine
| CYP2E1: cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) | 0.45161 | Alprazolam
| 0.60720 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 308 | N | N | N | N | Bentiromide
| CELA1: chymotrypsin-like elastase family, member 1 (EC:3.4.21.36) | 0.11429 | Aminocaproic acid
| 0.47007 | CTRC: chymotrypsin C (caldecrin) (EC:3.4.21.2) |
| 309 | N | N | N | N | Salicylic acid
| DIO1: deiodinase, iodothyronine, type I (EC:1.97.1.10) | 0.31250 | Acetaminophen
| 0.022411 | IKBKB: inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta (EC:2.7.11.10) |
| 310 | N | N | N | N | Risarestat
| AKR1B10: aldo-keto reductase family 1, member B10 (aldose reductase) (EC:1.1.1.2) | 0.20000 | Haloperidol
| 0.73896 | AKR1B1: aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) |
| 311 | N | N | N | N | Salicylic acid
| DIO2: deiodinase, iodothyronine, type II (EC:1.97.1.10) | 0.31250 | Acetaminophen
| 0.022216 | ALOX12: arachidonate 12-lipoxygenase (EC:1.13.11.31) |
| 312 | N | N | N | N | Adenosine phosphate
| RRM1: ribonucleotide reductase M1 (EC:1.17.4.1) | 0.88000 | Fludarabine phosphate
| 0.018523 | ADK: adenosine kinase (EC:2.7.1.20) |
| 313 | N | N | Y | N | Verapamil
| CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.37500 | Trimipramine
| 0.81101 | CYP2C8: cytochrome P450, family 2, subfamily C, polypeptide 8 (EC:1.14.14.1) |
| 314 | N | N | Y | N | Methotrexate sodium
 | TYMS: thymidylate synthetase (EC:2.1.1.45) | 0.63415 | Pemetrexed disodium
 | 0.028456 | DHFR: dihydrofolate reductase (EC:1.5.1.3) |
| 315 | N | N | N | N | Doramapimod
 | CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) | 0.52083 | Astemizole
| 0.022027 | MAPK13: mitogen-activated protein kinase 13 (EC:2.7.11.24) |
| 316 | N | N | Y | N | Verapamil
| CYP3A7: cytochrome P450, family 3, subfamily A, polypeptide 7 (EC:1.14.14.1) | 0.37500 | Trimipramine
| 0.89469 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 317 | N | N | Y | N | Maprotiline
| CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) | 0.53571 | Trimipramine
| 0.016775 | RRM2B: ribonucleotide reductase M2 B (TP53 inducible) (EC:1.17.4.1) |
| 318 | N | N | N | N | Zopolrestat
 | AKR1B10: aldo-keto reductase family 1, member B10 (aldose reductase) (EC:1.1.1.2) | 0.27907 | Haloperidol
| 0.73896 | AKR1B1: aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) |
| 319 | N | N | N | N | Efegatran sulfate
 | ACE: angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 (EC:3.4.15.1) | 0.46512 | Alacepril
 | 0.010996 | F2: coagulation factor II (thrombin) (EC:3.4.21.5) |
| 320 | N | N | N | N | Naproxen
| IKBKB: inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta (EC:2.7.11.10) | 0.44828 | Sulindac
| 0.014552 | ALOX15B: arachidonate 15-lipoxygenase, type B (EC:1.13.11.33) |
| 321 | N | N | N | N | Penicillamine
| BCAT1: branched chain amino-acid transaminase 1, cytosolic (EC:2.6.1.42) | 0.70000 | Valine
| 0.019308 | CASP1: caspase 1, apoptosis-related cysteine peptidase (EC:3.4.22.36) |
| 322 | N | N | N | N | Zileuton
| ALOX15B: arachidonate 15-lipoxygenase, type B (EC:1.13.11.33) | 0.40000 | Ketoprofen
| 0.38637 | ALOX5: arachidonate 5-lipoxygenase (EC:1.13.11.34) |
| 323 | N | N | N | N | Diethylstilbestrol
| WARS: tryptophanyl-tRNA synthetase (EC:6.1.1.2) | 0.19231 | Propylthiouracil
| 0.027023 | PRDX1: peroxiredoxin 1 (EC:1.11.1.15) |
| 324 | N | N | Y | N | Chlorpromazine
| CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.60000 | Perphenazine
| 0.015930 | MAOA: monoamine oxidase A (EC:1.4.3.4) |
| 325 | N | N | Y | N | Clozapine
| CYP2C8: cytochrome P450, family 2, subfamily C, polypeptide 8 (EC:1.14.14.1) | 0.45161 | Alprazolam
| 0.81101 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 326 | N | N | N | N | Threonine
| ACAT1: acetyl-CoA acetyltransferase 1 (EC:2.3.1.9) | 0.70000 | Isoleucine
| 0.018674 | PCCB |
| 327 | N | N | N | N | Acetaminophen
| WARS: tryptophanyl-tRNA synthetase (EC:6.1.1.2) | 0.22222 | Propylthiouracil
| 0.027023 | PRDX1: peroxiredoxin 1 (EC:1.11.1.15) |
| 328 | N | N | N | N | Propofol
 | ACHE: acetylcholinesterase (EC:3.1.1.7) | 0.44444 | Edrophonium chloride
| 0.012915 | ACOX1: acyl-CoA oxidase 1, palmitoyl (EC:1.3.3.6) |
| 329 | N | N | N | N | Mesoridazine
| CYP1A2: cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) | 0.53125 | Clozapine
| 0.24342 | CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) |
| 330 | N | N | N | N | Nadide
| IMPDH1: IMP (inosine 5'-monophosphate) dehydrogenase 1 (EC:1.1.1.205) | 0.29787 | Ribavirin
| 0.80082 | IMPDH2: IMP (inosine 5'-monophosphate) dehydrogenase 2 (EC:1.1.1.205) |
| 331 | N | N | Y | N | Diazepam
| CYP2C8: cytochrome P450, family 2, subfamily C, polypeptide 8 (EC:1.14.14.1) | 0.68000 | Alprazolam
| 0.81101 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 332 | N | N | N | N | Disulfiram
| ALDH6A1: aldehyde dehydrogenase 6 family, member A1 (EC:1.2.1.27 1.2.1.18) | 0.090909 | Valine
| 0.22923 | ALDH9A1: aldehyde dehydrogenase 9 family, member A1 (EC:1.2.1.3 1.2.1.19 1.2.1.47) |
| 333 | N | N | Y | N | Midazolam
| CYP3A7: cytochrome P450, family 3, subfamily A, polypeptide 7 (EC:1.14.14.1) | 0.80000 | Alprazolam
| 0.89469 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 334 | N | Y | N | N | Acetaminophen
| GPX2: glutathione peroxidase 2 (gastrointestinal) (EC:1.11.1.9) | 0.34783 | Diethylstilbestrol
| 0.035543 | DIO1: deiodinase, iodothyronine, type I (EC:1.97.1.10) |
| 335 | N | Y | N | N | Acetaminophen
| GPX3: glutathione peroxidase 3 (plasma) (EC:1.11.1.9) | 0.34783 | Diethylstilbestrol
| 0.038088 | PRDX1: peroxiredoxin 1 (EC:1.11.1.15) |
| 336 | N | N | N | N | Metyrosine
| FARSB: phenylalanyl-tRNA synthetase, beta subunit (EC:6.1.1.20) | 0.62500 | Phenylalanine
| 0.015447 | TH: tyrosine hydroxylase (EC:1.14.16.2) |
| 337 | N | N | N | N | Metyrosine
| FARS2: phenylalanyl-tRNA synthetase 2, mitochondrial (EC:6.1.1.20) | 0.62500 | Phenylalanine
| 0.015325 | TH: tyrosine hydroxylase (EC:1.14.16.2) |
| 338 | N | N | N | N | Levetiracetam
| CA4: carbonic anhydrase IV (EC:4.2.1.1) | 0.17857 | Sezolamide hydrochloride
| 0.19740 | CA1: carbonic anhydrase I (EC:4.2.1.1) |
| 339 | N | N | N | N | Metyrosine
| FARSA: phenylalanyl-tRNA synthetase, alpha subunit (EC:6.1.1.20) | 0.62500 | Phenylalanine
| 0.014973 | TH: tyrosine hydroxylase (EC:1.14.16.2) |
| 340 | N | N | N | N | Racemethionine
| PCCB | 0.63636 | Isoleucine
| 0.019162 | MSRA: methionine sulfoxide reductase A (EC:1.8.4.11) |
| 341 | N | N | N | N | Ciclopirox olamine
| ALOX5: arachidonate 5-lipoxygenase (EC:1.13.11.34) | 0.25000 | Zileuton
| 0.38087 | ALOX15: arachidonate 15-lipoxygenase (EC:1.13.11.33) |
| 342 | N | N | Y | N | Acetaminophen
| CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.38095 | Tolbutamide
| 0.59436 | CYP2E1: cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) |
| 343 | N | N | N | N | Alrestatin sodium
| AKR1A1: aldo-keto reductase family 1, member A1 (aldehyde reductase) (EC:1.1.1.2) | 0.33333 | Tolrestat
| 0.49917 | AKR1B1: aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) |
| 344 | N | N | Y | N | Miconazole
| CYP2E1: cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) | 0.54839 | Liarozole hydrochloride
| 0.60720 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 345 | N | N | N | N | Threonine
| BCAT2: branched chain amino-acid transaminase 2, mitochondrial (EC:2.6.1.42) | 0.70000 | Isoleucine
| 0.015800 | PCCB |
| 346 | N | N | Y | N | Nicotine
| CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) | 0.39130 | Mirtazapine
| 0.34239 | CYP2A13: cytochrome P450, family 2, subfamily A, polypeptide 13 (EC:1.14.14.1) |
| 347 | N | N | N | N | Zileuton
| ALOX15: arachidonate 15-lipoxygenase (EC:1.13.11.33) | 0.40000 | Ketoprofen
| 0.38087 | ALOX5: arachidonate 5-lipoxygenase (EC:1.13.11.34) |
| 348 | N | N | N | N | Lidorestat
| AKR1A1: aldo-keto reductase family 1, member A1 (aldehyde reductase) (EC:1.1.1.2) | 0.41667 | Tolrestat
| 0.49917 | AKR1B1: aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) |
| 349 | N | N | Y | N | Bisoprolol
 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.34959 | Verapamil
| 0.13075 | CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) |
| 350 | N | Y | N | N | Acetaminophen
| GPX5 | 0.34783 | Diethylstilbestrol
| 0.035631 | PRDX5: peroxiredoxin 5 (EC:1.11.1.15) |
| 351 | N | N | N | N | Minalrestat
| AKR1A1: aldo-keto reductase family 1, member A1 (aldehyde reductase) (EC:1.1.1.2) | 0.38461 | Haloperidol
| 0.49917 | AKR1B1: aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) |
| 352 | N | N | N | N | Racemethionine
| PCCA | 0.63636 | Isoleucine
| 0.020538 | MAT1A: methionine adenosyltransferase I, alpha (EC:2.5.1.6) |
| 353 | N | N | N | N | Oleic acid
| CYP2C8: cytochrome P450, family 2, subfamily C, polypeptide 8 (EC:1.14.14.1) | 0.80952 | Palmitic acid
| 0.015075 | GC: group-specific component (vitamin D binding protein) (EC:6.4.-.-) |
| 354 | N | N | Y | N | Lovastatin
 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.90323 | Simvastatin
 | 0.014302 | HMGCR: 3-hydroxy-3-methylglutaryl-CoA reductase (EC:1.1.1.34) |
| 355 | N | N | N | N | Salicylic acid
| IKBKE: inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilon (EC:2.7.11.10) | 0.31034 | Sulfasalazine
| 0.10355 | IKBKB: inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta (EC:2.7.11.10) |
| 356 | N | N | Y | N | Nicotine
| CYP2B6: cytochrome P450, family 2, subfamily B, polypeptide 6 (EC:1.14.14.1) | 0.36364 | Fadrozole hydrochloride
| 0.56696 | CYP2A13: cytochrome P450, family 2, subfamily A, polypeptide 13 (EC:1.14.14.1) |
| 357 | N | N | N | N | Acetaminophen
| CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.38095 | Tolbutamide
| 0.60720 | CYP2E1: cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) |
| 358 | N | N | N | N | Glutathione
 | ACE: angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 (EC:3.4.15.1) | 0.39474 | Zofenoprilat arginine
 | 0.013195 | GSTP1: glutathione S-transferase pi 1 (EC:2.5.1.18) |
| 359 | N | N | N | N | Palmitic acid
| CYP2C18: cytochrome P450, family 2, subfamily C, polypeptide 18 (EC:1.14.14.1) | 0.26667 | Deferoxamine
| 0.79843 | CYP2C8: cytochrome P450, family 2, subfamily C, polypeptide 8 (EC:1.14.14.1) |
| 360 | N | N | Y | N | Simvastatin
| CYP3A7: cytochrome P450, family 3, subfamily A, polypeptide 7 (EC:1.14.14.1) | 0.17021 | Nifedipine
| 0.89469 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 361 | N | N | N | N | Ciclopirox olamine
| ALOX12B: arachidonate 12-lipoxygenase, 12R type (EC:1.13.11.-) | 0.22500 | Ketotifen fumarate
| 0.31132 | ALOX15: arachidonate 15-lipoxygenase (EC:1.13.11.33) |
| 362 | N | N | N | N | Fondaparinux sodium
 | F9: coagulation factor IX (EC:3.4.21.22) | 0.047619 | Aminocaproic acid
| 0.41683 | F10: coagulation factor X (EC:3.4.21.6) |
| 363 | N | N | N | N | Loratadine
| CYP3A7: cytochrome P450, family 3, subfamily A, polypeptide 7 (EC:1.14.14.1) | 0.36111 | Alprazolam
| 0.89469 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 364 | N | N | N | N | Promethazine
| BCHE: butyrylcholinesterase (EC:3.1.1.8) | 0.72000 | Profenamine hydrochloride
| 0.015532 | F2: coagulation factor II (thrombin) (EC:3.4.21.5) |
| 365 | N | N | Y | N | Imatinib mesylate
 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.38750 | Terfenadine
| 0.025570 | ERBB3: v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) (EC:2.7.10.1) |
| 366 | N | N | N | N | Razaxaban hydrochloride
 | F9: coagulation factor IX (EC:3.4.21.22) | 0.13043 | Menadione
| 0.41683 | F10: coagulation factor X (EC:3.4.21.6) |
| 367 | N | N | N | N | Doramapimod
| CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.52083 | Astemizole
| 0.027294 | MAPK12: mitogen-activated protein kinase 12 (EC:2.7.11.24) |
| 368 | N | N | N | N | Diethylstilbestrol
| CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) | 0.44444 | Diphenhydramine
| 0.029507 | DIO1: deiodinase, iodothyronine, type I (EC:1.97.1.10) |
| 369 | N | N | N | N | Glimepiride
| ACE: angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 (EC:3.4.15.1) | 0.39130 | Ramipril
 | 0.011541 | CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 370 | N | N | Y | N | Haloperidol
| CYP3A7: cytochrome P450, family 3, subfamily A, polypeptide 7 (EC:1.14.14.1) | 0.37500 | Fadrozole hydrochloride
| 0.89469 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 371 | N | N | Y | N | Cladribine
| RRM1: ribonucleotide reductase M1 (EC:1.17.4.1) | 0.65385 | Fludarabine phosphate
| 0.024986 | PNP: purine nucleoside phosphorylase (EC:2.4.2.1) |
| 372 | N | N | N | N | Benzoic acid
| QPRT: quinolinate phosphoribosyltransferase (EC:2.4.2.19) | 0.80000 | Niacin
 | 0.029637 | PRDX5: peroxiredoxin 5 (EC:1.11.1.15) |
| 373 | N | N | Y | N | Verapamil
| CYP3A5: cytochrome P450, family 3, subfamily A, polypeptide 5 (EC:1.14.14.1) | 0.37500 | Trimipramine
| 0.86492 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 374 | Y | N | Y | N | Chlorpromazine
| CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) | 0.60000 | Perphenazine
| 0.016264 | MAOB |
| 375 | N | N | N | N | Tolbutamide
| DCXR: dicarbonyl/L-xylulose reductase (EC:1.1.1.10) | 0.53846 | Acetohexamide
 | 0.026698 | COQ6: coenzyme Q6 homolog, monooxygenase (S. cerevisiae) |
| 376 | N | N | Y | N | Triazolam
| CYP3A7: cytochrome P450, family 3, subfamily A, polypeptide 7 (EC:1.14.14.1) | 0.87500 | Alprazolam
| 0.89469 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 377 | N | N | N | N | Sulfasalazine
| LALBA | 0.34286 | Ketoprofen
| 0.032575 | ALOX15B: arachidonate 15-lipoxygenase, type B (EC:1.13.11.33) |
| 378 | N | N | N | N | Deferoxamine
| SULT1A2: sulfotransferase family, cytosolic, 1A, phenol-preferring, member 2 (EC:2.8.2.1) | 0.063830 | Acetaminophen
| 0.028580 | PRDX5: peroxiredoxin 5 (EC:1.11.1.15) |
| 379 | N | N | N | N | Ribavirin
| ENPP3: ectonucleotide pyrophosphatase/phosphodiesterase 3 (EC:3.1.4.1 3.6.1.9) | 0.19355 | Pentoxifylline
| 0.53259 | ENPP1: ectonucleotide pyrophosphatase/phosphodiesterase 1 (EC:3.1.4.1 3.6.1.9) |
| 380 | N | N | N | N | Benzoic acid
| NNMT: nicotinamide N-methyltransferase (EC:2.1.1.1) | 0.80000 | Niacin
| 0.029271 | PRDX5: peroxiredoxin 5 (EC:1.11.1.15) |
| 381 | N | N | Y | N | Carbamazepine
| CYP3A7: cytochrome P450, family 3, subfamily A, polypeptide 7 (EC:1.14.14.1) | 0.48148 | Trimipramine
| 0.89469 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 382 | N | Y | N | N | Acetaminophen
| GPX1: glutathione peroxidase 1 (EC:1.11.1.9) | 0.34783 | Diethylstilbestrol
| 0.037431 | PRDX1: peroxiredoxin 1 (EC:1.11.1.15) |
| 383 | N | N | N | N | Cytarabine
| ACAA1: acetyl-CoA acyltransferase 1 (EC:2.3.1.16) | 0.54546 | Idoxuridine
| 0.022718 | POLB |
| 384 | N | N | N | N | Miconazole nitrate
| ABO: ABO blood group (transferase A, alpha 1-3-N-acetylgalactosaminyltransferase; transferase B, alpha 1-3-galactosyltransferase) (EC:2.4.1.37 2.4.1.40) | 0.90323 | Oxiconazole nitrate
| 0.020169 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 385 | N | N | N | N | Ribavirin
| ADCY1: adenylate cyclase 1 (brain) (EC:4.6.1.1) | 0.63636 | Adenosine
| 0.013397 | ADK: adenosine kinase (EC:2.7.1.20) |
| 386 | N | N | N | N | Clofibrate
 | ACHE: acetylcholinesterase (EC:3.1.1.7) | 0.50000 | Pyridostigmine bromide
| 0.015513 | ZMPSTE24: zinc metallopeptidase STE24 (EC:3.4.24.84) |
| 387 | N | N | Y | N | Verapamil
| CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.37500 | Trimipramine
| 0.79849 | CYP2C8: cytochrome P450, family 2, subfamily C, polypeptide 8 (EC:1.14.14.1) |
| 388 | N | N | N | N | Acetaminophen
| CYP1B1: cytochrome P450, family 1, subfamily B, polypeptide 1 (EC:1.14.14.1) | 0.38095 | Tolbutamide
| 0.35910 | CYP1A1: cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) |
| 389 | N | N | N | N | Uracil
| DHODH: dihydroorotate dehydrogenase (quinone) (EC:1.3.5.2) | 0.58333 | Orotic acid
| 0.054290 | DPYD: dihydropyrimidine dehydrogenase (EC:1.3.1.2) |
| 390 | N | N | N | N | Niacin
| DAO: D-amino-acid oxidase (EC:1.4.3.3) | 0.80000 | Benzoic acid
| 0.025825 | QPRT: quinolinate phosphoribosyltransferase (EC:2.4.2.19) |
| 391 | N | N | Y | N | Cisapride
| CYP3A7: cytochrome P450, family 3, subfamily A, polypeptide 7 (EC:1.14.14.1) | 0.35000 | Trimipramine
| 0.89469 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 392 | N | N | N | N | Benzoic acid
| PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) | 0.72727 | Salicylic acid
| 0.019816 | PRDX5: peroxiredoxin 5 (EC:1.11.1.15) |
| 393 | N | N | N | N | Fludarabine phosphate
| PNP: purine nucleoside phosphorylase (EC:2.4.2.1) | 0.65385 | Cladribine
| 0.024986 | RRM1: ribonucleotide reductase M1 (EC:1.17.4.1) |
| 394 | N | N | Y | N | Loratadine
| CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.56250 | Clozapine
| 0.14153 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 395 | N | N | N | N | Riboflavin
 | ACAA1: acetyl-CoA acyltransferase 1 (EC:2.3.1.16) | 0.45161 | Ganciclovir
| 0.028932 | BLVRB: biliverdin reductase B (flavin reductase (NADPH)) (EC:1.3.1.24 1.5.1.30) |
| 396 | N | N | N | N | Alvocidib hydrochloride
 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.44444 | Clozapine
| 0.021886 | CDK3: cyclin-dependent kinase 3 (EC:2.7.11.22) |
| 397 | N | N | N | N | Epalrestat
| AKR1A1: aldo-keto reductase family 1, member A1 (aldehyde reductase) (EC:1.1.1.2) | 0.28571 | Tolrestat
| 0.49917 | AKR1B1: aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) |
| 398 | N | N | N | N | Phenacetin
| CYP2A7: cytochrome P450, family 2, subfamily A, polypeptide 7 (EC:1.14.14.1) | 0.47619 | Tolbutamide
| 0.26007 | CYP1A1: cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) |
| 399 | N | N | Y | N | Terfenadine
| CYP3A7: cytochrome P450, family 3, subfamily A, polypeptide 7 (EC:1.14.14.1) | 0.42500 | Trimipramine
| 0.89469 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 400 | N | N | Y | N | Imatinib mesylate
| CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) | 0.38776 | Mesoridazine
| 0.024668 | MAP2K3: mitogen-activated protein kinase kinase 3 (EC:2.7.12.2) |
| 401 | N | N | N | N | Mirtazapine
| CYP3A7: cytochrome P450, family 3, subfamily A, polypeptide 7 (EC:1.14.14.1) | 0.44828 | Trimipramine
| 0.89469 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 402 | N | N | N | N | Bentiromide
| CELA2A: chymotrypsin-like elastase family, member 2A (EC:3.4.21.71) | 0.11429 | Aminocaproic acid
| 0.62815 | CTRC: chymotrypsin C (caldecrin) (EC:3.4.21.2) |
| 403 | N | N | N | N | Fludarabine phosphate
| PRKAA1: protein kinase, AMP-activated, alpha 1 catalytic subunit (EC:2.7.11.1 2.7.11.26 2.7.11.27 2.7.11.31) | 0.88000 | Adenosine phosphate
| 0.013717 | RRM1: ribonucleotide reductase M1 (EC:1.17.4.1) |
| 404 | N | N | N | N | Tretinoin
| ALDH9A1: aldehyde dehydrogenase 9 family, member A1 (EC:1.2.1.3 1.2.1.19 1.2.1.47) | 0.15152 | Disulfiram
| 0.34856 | ALDH1A2: aldehyde dehydrogenase 1 family, member A2 (EC:1.2.1.36) |
| 405 | N | N | N | N | Fludarabine phosphate
| ACSL1: acyl-CoA synthetase long-chain family member 1 (EC:6.2.1.3) | 0.88000 | Adenosine phosphate
| 0.011652 | RRM1: ribonucleotide reductase M1 (EC:1.17.4.1) |
| 406 | N | N | N | N | Fludarabine phosphate
| AMPD1: adenosine monophosphate deaminase 1 (EC:3.5.4.6) | 0.88000 | Adenosine phosphate
| 0.011262 | RRM1: ribonucleotide reductase M1 (EC:1.17.4.1) |
| 407 | N | Y | N | N | Deferoxamine
| TPO: thyroid peroxidase (EC:1.11.1.8) | 0.041667 | Propylthiouracil
| 0.36582 | EPX: eosinophil peroxidase (EC:1.11.1.7) |
| 408 | N | N | N | N | Liarozole fumarate
 | CYP21A2: cytochrome P450, family 21, subfamily A, polypeptide 2 (EC:1.14.99.10) | 0.18421 | Alprazolam
| 0.25504 | CYP17A1: cytochrome P450, family 17, subfamily A, polypeptide 1 (EC:1.14.99.9) |
| 409 | N | N | N | N | Eletriptan hydrobromide
| CYP3A7: cytochrome P450, family 3, subfamily A, polypeptide 7 (EC:1.14.14.1) | 0.38889 | Alprazolam
| 0.89469 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 410 | N | N | N | N | Fludarabine phosphate
| ACSS1: acyl-CoA synthetase short-chain family member 1 (EC:6.2.1.1) | 0.88000 | Adenosine phosphate
| 0.012328 | RRM1: ribonucleotide reductase M1 (EC:1.17.4.1) |
| 411 | N | N | N | N | Fludarabine phosphate
| ACSS2: acyl-CoA synthetase short-chain family member 2 (EC:6.2.1.1) | 0.88000 | Adenosine phosphate
| 0.011867 | RRM1: ribonucleotide reductase M1 (EC:1.17.4.1) |
| 412 | N | N | N | N | Phenacetin
| PTGS2: prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) | 0.71429 | Acetaminophen
| 0.013746 | CYP1A1: cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) |
| 413 | N | N | N | N | Metyrosine
| PTGS2: prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) | 0.61111 | Ibuprofen
| 0.018407 | TH: tyrosine hydroxylase (EC:1.14.16.2) |
| 414 | N | N | N | N | Acetaminophen
| CYC1: cytochrome c-1 | 0.063830 | Deferoxamine
| 0.034093 | PRDX5: peroxiredoxin 5 (EC:1.11.1.15) |
| 415 | N | N | N | N | Diethylstilbestrol
| PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) | 0.45161 | Mofezolac
 | 0.046083 | LPO: lactoperoxidase (EC:1.11.1.7) |
| 416 | N | N | N | N | Cladribine
| ADCY1: adenylate cyclase 1 (brain) (EC:4.6.1.1) | 0.72727 | Adenosine
| 0.012618 | PNP: purine nucleoside phosphorylase (EC:2.4.2.1) |
| 417 | N | N | Y | N | Phenacetin
| PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) | 0.71429 | Acetaminophen
| 0.013912 | CYP1A2: cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) |
| 418 | N | N | N | N | Nicotine
| CYP2F1: cytochrome P450, family 2, subfamily F, polypeptide 1 (EC:1.14.14.1) | 0.36364 | Fadrozole hydrochloride
| 0.54347 | CYP2A13: cytochrome P450, family 2, subfamily A, polypeptide 13 (EC:1.14.14.1) |
| 419 | N | N | N | N | Phytonadione
 | DHRS4: dehydrogenase/reductase (SDR family) member 4 (EC:1.1.1.184) | 0.35294 | Menadione
| 0.015477 | GGCX: gamma-glutamyl carboxylase (EC:4.1.1.90) |
| 420 | Y | N | Y | N | Methotrexate
| TYMS: thymidylate synthetase (EC:2.1.1.45) | 0.66667 | Raltitrexed
| 0.028456 | DHFR: dihydrofolate reductase (EC:1.5.1.3) |
| 421 | N | N | N | N | Adenosine
| PRKAA1: protein kinase, AMP-activated, alpha 1 catalytic subunit (EC:2.7.11.1 2.7.11.26 2.7.11.27 2.7.11.31) | 0.75000 | Adenosine phosphate
| 0.0096523 | ADCY1: adenylate cyclase 1 (brain) (EC:4.6.1.1) |
| 422 | N | N | N | N | Floxuridine
| RRM1: ribonucleotide reductase M1 (EC:1.17.4.1) | 0.59091 | Gemcitabine
| 0.013909 | TYMS: thymidylate synthetase (EC:2.1.1.45) |
| 423 | N | N | N | N | Adenosine
| ACSL1: acyl-CoA synthetase long-chain family member 1 (EC:6.2.1.3) | 0.75000 | Adenosine phosphate
| 0.014542 | ADCY1: adenylate cyclase 1 (brain) (EC:4.6.1.1) |
| 424 | N | N | N | N | Glimepiride
| CYP2C18: cytochrome P450, family 2, subfamily C, polypeptide 18 (EC:1.14.14.1) | 0.40541 | Tolbutamide
| 0.85922 | CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 425 | N | N | N | N | Pantoprazole
| CYP2E1: cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) | 0.35484 | Methoxsalen
| 0.60720 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 426 | N | N | Y | N | Midazolam
| CYP3A5: cytochrome P450, family 3, subfamily A, polypeptide 5 (EC:1.14.14.1) | 0.80000 | Alprazolam
| 0.86492 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 427 | N | N | N | N | Adenosine
| AMPD1: adenosine monophosphate deaminase 1 (EC:3.5.4.6) | 0.75000 | Adenosine phosphate
| 0.010460 | ADCY1: adenylate cyclase 1 (brain) (EC:4.6.1.1) |
| 428 | N | N | N | N | Ponalrestat
| AKR1A1: aldo-keto reductase family 1, member A1 (aldehyde reductase) (EC:1.1.1.2) | 0.41176 | Tolrestat
| 0.49917 | AKR1B1: aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) |
| 429 | N | N | N | N | Methyclothiazide
| ATP4A: ATPase, H+/K+ exchanging, alpha polypeptide (EC:3.6.3.10) | 0.22222 | Omeprazole
| 0.65015 | ATP1A1 |
| 430 | N | N | N | N | Phytonadione
| PROC: protein C (inactivator of coagulation factors Va and VIIIa) (EC:3.4.21.69) | 0.35294 | Menadione
| 0.012858 | GGCX: gamma-glutamyl carboxylase (EC:4.1.1.90) |
| 431 | N | N | N | N | Deracoxib
 | CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.76667 | Celecoxib
| 0.022367 | PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) |
| 432 | N | N | N | N | Trichlormethiazide
| ATP4A: ATPase, H+/K+ exchanging, alpha polypeptide (EC:3.6.3.10) | 0.18919 | Omeprazole
| 0.65015 | ATP1A1 |
| 433 | N | N | N | N | Gemcitabine
| ACAA1: acetyl-CoA acyltransferase 1 (EC:2.3.1.16) | 0.59091 | Idoxuridine
| 0.025440 | CMPK1: cytidine monophosphate (UMP-CMP) kinase 1, cytosolic (EC:2.7.4.14) |
| 434 | N | N | N | N | Fludarabine phosphate
| APRT: adenine phosphoribosyltransferase (EC:2.4.2.7) | 0.88000 | Adenosine phosphate
| 0.015270 | RRM1: ribonucleotide reductase M1 (EC:1.17.4.1) |
| 435 | N | N | N | N | Metyrosine
| TAT: tyrosine aminotransferase (EC:2.6.1.5) | 0.62500 | Phenylalanine
| 0.015953 | TH: tyrosine hydroxylase (EC:1.14.16.2) |
| 436 | N | N | N | N | Liarozole hydrochloride
| CYP21A2: cytochrome P450, family 21, subfamily A, polypeptide 2 (EC:1.14.99.10) | 0.36364 | Alprazolam
| 0.25504 | CYP17A1: cytochrome P450, family 17, subfamily A, polypeptide 1 (EC:1.14.99.9) |
| 437 | N | N | N | N | Docebenone
| ALOX15B: arachidonate 15-lipoxygenase, type B (EC:1.13.11.33) | 0.17500 | Phenylbutazone
| 0.38637 | ALOX5: arachidonate 5-lipoxygenase (EC:1.13.11.34) |
| 438 | N | N | N | N | Adenosine
| APRT: adenine phosphoribosyltransferase (EC:2.4.2.7) | 0.75000 | Adenosine phosphate
| 0.016234 | ADCY1: adenylate cyclase 1 (brain) (EC:4.6.1.1) |
| 439 | N | N | Y | N | Simvastatin
| CYP3A5: cytochrome P450, family 3, subfamily A, polypeptide 5 (EC:1.14.14.1) | 0.17021 | Nifedipine
| 0.86492 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 440 | N | N | N | N | Fondaparinux sodium
| F7: coagulation factor VII (serum prothrombin conversion accelerator) (EC:3.4.21.21) | 0.047619 | Aminocaproic acid
| 0.36412 | F10: coagulation factor X (EC:3.4.21.6) |
| 441 | N | N | N | N | Fluconazole
| CYP2E1: cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) | 0.40625 | Liarozole hydrochloride
| 0.60720 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 442 | N | N | N | N | Hydroflumethiazide
| ATP4A: ATPase, H+/K+ exchanging, alpha polypeptide (EC:3.6.3.10) | 0.18919 | Omeprazole
| 0.65015 | ATP1A1 |
| 443 | N | N | N | N | Razaxaban hydrochloride
| F7: coagulation factor VII (serum prothrombin conversion accelerator) (EC:3.4.21.21) | 0.13043 | Menadione
| 0.36412 | F10: coagulation factor X (EC:3.4.21.6) |
| 444 | N | N | N | N | Milrinone
| CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.36000 | Fadrozole hydrochloride
| 0.029363 | PDE6G: phosphodiesterase 6G, cGMP-specific, rod, gamma (EC:3.1.4.35) |
| 445 | Y | N | N | N | Zopolrestat
| AKR1A1: aldo-keto reductase family 1, member A1 (aldehyde reductase) (EC:1.1.1.2) | 0.39474 | Tolrestat
| 0.49917 | AKR1B1: aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) |
| 446 | N | N | N | N | Acetaminophen
| FECH: ferrochelatase (EC:4.99.1.1) | 0.063830 | Deferoxamine
| 0.028826 | DIO1: deiodinase, iodothyronine, type I (EC:1.97.1.10) |
| 447 | N | Y | Y | N | Acetaminophen
| CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.38095 | Tolbutamide
| 0.13322 | CYP2E1: cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) |
| 448 | N | N | Y | N | Nicotine
| CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.36364 | Fadrozole hydrochloride
| 0.52877 | CYP2A13: cytochrome P450, family 2, subfamily A, polypeptide 13 (EC:1.14.14.1) |
| 449 | N | N | N | N | Adenosine
| ACSS2: acyl-CoA synthetase short-chain family member 2 (EC:6.2.1.1) | 0.75000 | Adenosine phosphate
| 0.011538 | ADCY1: adenylate cyclase 1 (brain) (EC:4.6.1.1) |
| 450 | N | N | N | N | Phenylbutazone
| CYP8B1: cytochrome P450, family 8, subfamily B, polypeptide 1 (EC:1.14.13.95) | 0.40625 | Trimipramine
| 0.38253 | PTGIS: prostaglandin I2 (prostacyclin) synthase (EC:5.3.99.4) |
| 451 | N | N | N | N | Pentostatin
 | PNP: purine nucleoside phosphorylase (EC:2.4.2.1) | 0.52000 | Inosine
| 0.022051 | ADA: adenosine deaminase (EC:3.5.4.4) |
| 452 | N | N | Y | N | Astemizole
| CYP3A7: cytochrome P450, family 3, subfamily A, polypeptide 7 (EC:1.14.14.1) | 0.42000 | Fadrozole hydrochloride hydrate
| 0.89469 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 453 | N | N | N | N | Isoflurophate
| ENPP3: ectonucleotide pyrophosphatase/phosphodiesterase 3 (EC:3.1.4.1 3.6.1.9) | 0.13636 | Caffeine
| 0.53259 | ENPP1: ectonucleotide pyrophosphatase/phosphodiesterase 1 (EC:3.1.4.1 3.6.1.9) |
| 454 | N | N | N | N | Bisoprolol
| CYP1A2: cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) | 0.33333 | Phenacetin
| 0.24342 | CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) |
| 455 | N | N | N | N | Oxiconazole nitrate
| ACAA1: acetyl-CoA acyltransferase 1 (EC:2.3.1.16) | 0.21053 | Acyclovir
| 0.015455 | ABO: ABO blood group (transferase A, alpha 1-3-N-acetylgalactosaminyltransferase; transferase B, alpha 1-3-galactosyltransferase) (EC:2.4.1.37 2.4.1.40) |
| 456 | N | N | N | N | Zenarestat
| AKR1A1: aldo-keto reductase family 1, member A1 (aldehyde reductase) (EC:1.1.1.2) | 0.38889 | Tolrestat
| 0.49917 | AKR1B1: aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) |
| 457 | N | N | N | N | Diethylstilbestrol
| PTGS2: prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) | 0.45161 | Mofezolac
| 0.043421 | LPO: lactoperoxidase (EC:1.11.1.7) |
| 458 | N | N | N | N | Ketoprofen
| IKBKB: inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta (EC:2.7.11.10) | 0.46667 | Sulindac
| 0.021136 | LALBA |
| 459 | N | N | N | N | Adenosine
| ACSS1: acyl-CoA synthetase short-chain family member 1 (EC:6.2.1.1) | 0.75000 | Adenosine phosphate
| 0.0093557 | ADCY1: adenylate cyclase 1 (brain) (EC:4.6.1.1) |
| 460 | N | N | N | N | Metoclopramide
 | BCHE: butyrylcholinesterase (EC:3.1.1.8) | 0.55172 | Dibucaine
| 0.011263 | TRIM32: tripartite motif containing 32 |
| 461 | N | N | N | N | Floxuridine
| CMPK1: cytidine monophosphate (UMP-CMP) kinase 1, cytosolic (EC:2.7.4.14) | 0.59091 | Gemcitabine
| 0.028713 | TYMS: thymidylate synthetase (EC:2.1.1.45) |
| 462 | N | N | N | N | Nicotine
| CYP2S1: cytochrome P450, family 2, subfamily S, polypeptide 1 (EC:1.14.14.1) | 0.36364 | Fadrozole hydrochloride
| 0.49333 | CYP2A13: cytochrome P450, family 2, subfamily A, polypeptide 13 (EC:1.14.14.1) |
| 463 | N | N | N | N | Niacin
| PRDX5: peroxiredoxin 5 (EC:1.11.1.15) | 0.80000 | Benzoic acid
| 0.029637 | QPRT: quinolinate phosphoribosyltransferase (EC:2.4.2.19) |
| 464 | N | N | N | N | Dyphylline
| ACAA1: acetyl-CoA acyltransferase 1 (EC:2.3.1.16) | 0.44000 | Ganciclovir
| 0.029970 | PDE6G: phosphodiesterase 6G, cGMP-specific, rod, gamma (EC:3.1.4.35) |
| 465 | N | N | N | N | Chlorzoxazone
| CYP1B1: cytochrome P450, family 1, subfamily B, polypeptide 1 (EC:1.14.14.1) | 0.32000 | Alprazolam
| 0.35910 | CYP1A1: cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) |
| 466 | N | N | N | N | Eflornithine hydrochloride
 | ATP5D | 0.26316 | Enflurane
| 0.026235 | ODC1: ornithine decarboxylase 1 (EC:4.1.1.17) |
| 467 | N | N | N | N | Terlakiren
 | ACE: angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 (EC:3.4.15.1) | 0.40678 | Fosinopril sodium
 | 0.0094680 | REN: renin (EC:3.4.23.15) |
| 468 | N | N | Y | N | Zaleplon
 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.42857 | Metyrapone
| 0.013301 | ACOX1: acyl-CoA oxidase 1, palmitoyl (EC:1.3.3.6) |
| 469 | N | N | N | N | Fludarabine phosphate
| PYGL: phosphorylase, glycogen, liver (EC:2.4.1.1) | 0.88000 | Adenosine phosphate
| 0.013442 | RRM1: ribonucleotide reductase M1 (EC:1.17.4.1) |
| 470 | N | N | N | N | Eflornithine hydrochloride
| ATP2C1: ATPase, Ca++ transporting, type 2C, member 1 (EC:3.6.3.8) | 0.26316 | Enflurane
| 0.013503 | ODC1: ornithine decarboxylase 1 (EC:4.1.1.17) |
| 471 | N | N | N | N | Fludarabine phosphate
| PYGM: phosphorylase, glycogen, muscle (EC:2.4.1.1) | 0.88000 | Adenosine phosphate
| 0.011936 | RRM1: ribonucleotide reductase M1 (EC:1.17.4.1) |
| 472 | N | N | N | N | Chlorzoxazone
| CYP2F1: cytochrome P450, family 2, subfamily F, polypeptide 1 (EC:1.14.14.1) | 0.32000 | Alprazolam
| 0.52025 | CYP2A7: cytochrome P450, family 2, subfamily A, polypeptide 7 (EC:1.14.14.1) |
| 473 | N | N | N | N | Gemcitabine
| POLA1: polymerase (DNA directed), alpha 1, catalytic subunit (EC:2.7.7.7) | 0.40000 | Fludarabine phosphate
| 0.017727 | CMPK1: cytidine monophosphate (UMP-CMP) kinase 1, cytosolic (EC:2.7.4.14) |
| 474 | N | N | N | N | Floxuridine
| DCK: deoxycytidine kinase (EC:2.7.1.74) | 0.59091 | Gemcitabine
| 0.020964 | TYMS: thymidylate synthetase (EC:2.1.1.45) |
| 475 | N | N | N | N | Biotin
| BCKDK: branched chain ketoacid dehydrogenase kinase (EC:2.7.11.4) | 0.19048 | Isoleucine
| 0.021419 | PCCB |
| 476 | N | N | N | N | Fludarabine phosphate
| PYGB: phosphorylase, glycogen; brain (EC:2.4.1.1) | 0.88000 | Adenosine phosphate
| 0.011907 | RRM1: ribonucleotide reductase M1 (EC:1.17.4.1) |
| 477 | N | N | N | N | Flavin adenine dinucleotide
| FMO3: flavin containing monooxygenase 3 (EC:1.14.13.8 1.14.13.148) | 0.14706 | Sulindac
| 0.57558 | FMO1 |
| 478 | N | N | Y | N | Haloperidol
| CYP3A5: cytochrome P450, family 3, subfamily A, polypeptide 5 (EC:1.14.14.1) | 0.37500 | Fadrozole hydrochloride
| 0.86492 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 479 | N | N | N | N | Loratadine
| CYP3A5: cytochrome P450, family 3, subfamily A, polypeptide 5 (EC:1.14.14.1) | 0.36111 | Alprazolam
| 0.86492 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 480 | N | N | Y | N | Miconazole nitrate
| CYP2E1: cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) | 0.48571 | Liarozole hydrochloride
| 0.60720 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 481 | N | N | N | N | Fidarestat
| AKR1A1: aldo-keto reductase family 1, member A1 (aldehyde reductase) (EC:1.1.1.2) | 0.24324 | Haloperidol
| 0.49917 | AKR1B1: aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) |
| 482 | N | N | N | N | Benzthiazide
| CA13: carbonic anhydrase XIII (EC:4.2.1.1) | 0.59259 | Chlorothiazide
 | 0.63871 | CA1: carbonic anhydrase I (EC:4.2.1.1) |
| 483 | N | N | N | N | Threonine
| MCCC1: methylcrotonoyl-CoA carboxylase 1 (alpha) (EC:6.4.1.4) | 0.14286 | Biotin
| 0.33639 | PCCA |
| 484 | N | N | N | N | Gemcitabine
| POLB | 0.75000 | Cytarabine
| 0.026443 | DCK |
| 485 | N | N | N | N | Phytonadione
| F2: coagulation factor II (thrombin) (EC:3.4.21.5) | 0.35294 | Menadione
| 0.010540 | GGCX: gamma-glutamyl carboxylase (EC:4.1.1.90) |
| 486 | N | N | Y | N | Nicotine
| CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.39130 | Mirtazapine
| 0.14011 | CYP2A7: cytochrome P450, family 2, subfamily A, polypeptide 7 (EC:1.14.14.1) |
| 487 | N | N | Y | N | Carbamazepine
| CYP3A5: cytochrome P450, family 3, subfamily A, polypeptide 5 (EC:1.14.14.1) | 0.48148 | Trimipramine
| 0.86492 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 488 | N | N | N | N | Cytarabine
| CMPK1: cytidine monophosphate (UMP-CMP) kinase 1, cytosolic (EC:2.7.4.14) | 0.75000 | Gemcitabine
| 0.026359 | POLB |
| 489 | N | N | N | N | Cilastatin sodium
 | ACE: angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 (EC:3.4.15.1) | 0.34884 | Zofenoprilat arginine
| 0.015368 | DPEP1: dipeptidase 1 (renal) (EC:3.4.13.19) |
| 490 | N | N | N | N | Diethylstilbestrol
| CYC1: cytochrome c-1 | 0.035088 | Deferoxamine
| 0.034093 | PRDX5: peroxiredoxin 5 (EC:1.11.1.15) |
| 491 | N | N | N | N | Acetaminophen
| PIK3CG: phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma (EC:2.7.11.1 2.7.1.153) | 0.063830 | Deferoxamine
| 0.015683 | PRDX4: peroxiredoxin 4 (EC:1.11.1.15) |
| 492 | N | N | N | N | Orotic acid
| ACACA: acetyl-CoA carboxylase alpha (EC:6.4.1.2 6.3.4.14) | 0.58333 | Uracil
| 0.0089401 | DHODH: dihydroorotate dehydrogenase (quinone) (EC:1.3.5.2) |
| 493 | Y | N | Y | N | Omeprazole
| CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.72414 | Pantoprazole
| 0.017103 | ATP4A: ATPase, H+/K+ exchanging, alpha polypeptide (EC:3.6.3.10) |
| 494 | N | N | Y | N | Cytarabine
| DCK | 0.75000 | Gemcitabine
| 0.026443 | POLB |
| 495 | N | N | Y | N | Methotrexate
| GGH: gamma-glutamyl hydrolase (conjugase, folylpolygammaglutamyl hydrolase) (EC:3.4.19.9) | 0.80556 | Folic acid
| 0.039110 | DHFR: dihydrofolate reductase (EC:1.5.1.3) |
| 496 | N | N | N | N | Trilostane
 | PLA2G4A: phospholipase A2, group IVA (cytosolic, calcium-dependent) (EC:3.1.1.5 3.1.1.4) | 0.40000 | Medrysone
 | 0.013333 | HSD3B1: hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 (EC:1.1.1.145 5.3.3.1) |
| 497 | N | N | Y | N | Pemetrexed disodium
| DHFR: dihydrofolate reductase (EC:1.5.1.3) | 0.63415 | Methotrexate sodium
| 0.028456 | TYMS: thymidylate synthetase (EC:2.1.1.45) |
| 498 | N | N | N | N | Chlorzoxazone
| CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.32000 | Alprazolam
| 0.59436 | CYP2E1: cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) |
| 499 | N | N | N | N | Salicylic acid
| NAT2: N-acetyltransferase 2 (arylamine N-acetyltransferase) (EC:2.3.1.5) | 0.31034 | Sulfasalazine
| 0.022765 | ALOX15B: arachidonate 15-lipoxygenase, type B (EC:1.13.11.33) |
| 500 | N | N | Y | N | Acetaminophen
| CYP2C8: cytochrome P450, family 2, subfamily C, polypeptide 8 (EC:1.14.14.1) | 0.38095 | Tolbutamide
| 0.58269 | CYP2E1: cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) |
| 501 | N | Y | N | N | Aminocaproic acid
| F2: coagulation factor II (thrombin) (EC:3.4.21.5) | 0.13953 | Napsagatran
 | 0.19139 | F10: coagulation factor X (EC:3.4.21.6) |
| 502 | N | N | N | N | Maprotiline
| F2: coagulation factor II (thrombin) (EC:3.4.21.5) | 0.55556 | Chlorpromazine
| 0.015077 | RRM2B: ribonucleotide reductase M2 B (TP53 inducible) (EC:1.17.4.1) |
| 503 | N | N | Y | N | Diethylstilbestrol
| CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.43750 | Haloperidol
| 0.025357 | GPX7: glutathione peroxidase 7 (EC:1.11.1.9) |
| 504 | N | N | Y | N | Triazolam
| CYP3A5: cytochrome P450, family 3, subfamily A, polypeptide 5 (EC:1.14.14.1) | 0.87500 | Alprazolam
| 0.86492 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 505 | N | N | N | N | Lopinavir
| REN: renin (EC:3.4.23.15) | 0.40941 | Enalkiren
 | 0.020542 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 506 | N | N | Y | N | Perphenazine
| CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.61290 | Clozapine
| 0.35919 | CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) |
| 507 | N | N | N | N | Bentiromide
| ELANE: elastase, neutrophil expressed (EC:3.4.21.37) | 0.42857 | Sivelestat
| 0.24292 | CTRC: chymotrypsin C (caldecrin) (EC:3.4.21.2) |
| 508 | N | N | N | N | Imatinib mesylate
| PRKAA1: protein kinase, AMP-activated, alpha 1 catalytic subunit (EC:2.7.11.1 2.7.11.26 2.7.11.27 2.7.11.31) | 0.12069 | Adenosine phosphate
| 0.10391 | MAP2K2: mitogen-activated protein kinase kinase 2 (EC:2.7.12.2) |
| 509 | N | N | N | N | Topiramate
| ATP1A1 | 0.16667 | Digoxin
| 0.013190 | CA2: carbonic anhydrase II (EC:4.2.1.1) |
| 510 | N | N | Y | N | Gefitinib
 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.50000 | Cisapride
| 0.025570 | ERBB3: v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) (EC:2.7.10.1) |
| 511 | N | N | N | N | Pentoxifylline
| CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) | 0.61905 | Caffeine
| 0.031325 | PDE6G: phosphodiesterase 6G, cGMP-specific, rod, gamma (EC:3.1.4.35) |
| 512 | N | N | N | N | Pentoxifylline
| CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.61905 | Caffeine
| 0.029363 | PDE6G: phosphodiesterase 6G, cGMP-specific, rod, gamma (EC:3.1.4.35) |
| 513 | N | N | N | N | Ravuconazole (prop.INN)
 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.51429 | Letrozole
| 0.12233 | CYP51A1: cytochrome P450, family 51, subfamily A, polypeptide 1 (EC:1.14.13.70) |
| 514 | N | N | N | N | Bentiromide
| CELA3B: chymotrypsin-like elastase family, member 3B (EC:3.4.21.70) | 0.11429 | Aminocaproic acid
| 0.54182 | CTRC: chymotrypsin C (caldecrin) (EC:3.4.21.2) |
| 515 | N | N | N | N | Alvocidib hydrochloride
| CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) | 0.44444 | Clozapine
| 0.032780 | CDK5: cyclin-dependent kinase 5 (EC:2.7.11.22) |
| 516 | N | N | Y | N | Diazepam
| CYP3A7: cytochrome P450, family 3, subfamily A, polypeptide 7 (EC:1.14.14.1) | 0.68000 | Alprazolam
| 0.89469 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 517 | N | N | N | N | Ethinamate
| CA13: carbonic anhydrase XIII (EC:4.2.1.1) | 0.10000 | Sezolamide hydrochloride
| 0.63871 | CA1: carbonic anhydrase I (EC:4.2.1.1) |
| 518 | N | N | N | N | Diethylstilbestrol
| CYP1A2: cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) | 0.40000 | Letrozole
| 0.036838 | GPX7: glutathione peroxidase 7 (EC:1.11.1.9) |
| 519 | N | N | N | N | Perphenazine
| CYP3A7: cytochrome P450, family 3, subfamily A, polypeptide 7 (EC:1.14.14.1) | 0.36111 | Alprazolam
| 0.89469 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 520 | N | N | N | N | Quilostigmine
| CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.50000 | Clozapine
| 0.011904 | ACHE: acetylcholinesterase (EC:3.1.1.7) |
| 521 | N | N | Y | N | Cisapride
| CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.37500 | Clozapine
| 0.35919 | CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) |
| 522 | N | N | Y | N | Methotrexate
| FPGS: folylpolyglutamate synthase (EC:6.3.2.17) | 0.80556 | Folic acid
| 0.019512 | DHFR: dihydrofolate reductase (EC:1.5.1.3) |
| 523 | N | N | N | N | Diethylstilbestrol
| FECH: ferrochelatase (EC:4.99.1.1) | 0.035088 | Deferoxamine
| 0.043148 | GPX7: glutathione peroxidase 7 (EC:1.11.1.9) |
| 524 | N | N | N | N | Felbamate
| CYP2C18: cytochrome P450, family 2, subfamily C, polypeptide 18 (EC:1.14.14.1) | 0.35484 | Nifedipine
| 0.85870 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 525 | N | N | N | N | Aminocaproic acid
| ENPP1: ectonucleotide pyrophosphatase/phosphodiesterase 1 (EC:3.1.4.1 3.6.1.9) | 0.16000 | Pentoxifylline
| 0.026382 | KLK1: kallikrein 1 (EC:3.4.21.35) |
| 526 | N | N | N | N | Diethylstilbestrol
| PIK3CG: phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma (EC:2.7.11.1 2.7.1.153) | 0.035088 | Deferoxamine
| 0.022324 | GPX1: glutathione peroxidase 1 (EC:1.11.1.9) |
| 527 | N | N | N | N | Ketorolac tromethamine
 | ACE: angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 (EC:3.4.15.1) | 0.42500 | Ceronapril
 | 0.013176 | PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) |
| 528 | N | N | N | N | Profenamine hydrochloride
| CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.60714 | Trimipramine
| 0.012623 | BCHE: butyrylcholinesterase (EC:3.1.1.8) |
| 529 | N | N | N | N | Celecoxib
| CYP2C18: cytochrome P450, family 2, subfamily C, polypeptide 18 (EC:1.14.14.1) | 0.41176 | Letrozole
| 0.85922 | CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 530 | N | N | N | N | Adenosine
| PYGB: phosphorylase, glycogen; brain (EC:2.4.1.1) | 0.75000 | Adenosine phosphate
| 0.010330 | ADCY1: adenylate cyclase 1 (brain) (EC:4.6.1.1) |
| 531 | N | N | N | N | Clozapine
| CYP3A7: cytochrome P450, family 3, subfamily A, polypeptide 7 (EC:1.14.14.1) | 0.45161 | Alprazolam
| 0.89469 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 532 | N | N | N | N | Rosiglitazone maleate
 | CYP2C18: cytochrome P450, family 2, subfamily C, polypeptide 18 (EC:1.14.14.1) | 0.31579 | Aminoglutethimide
| 0.79843 | CYP2C8: cytochrome P450, family 2, subfamily C, polypeptide 8 (EC:1.14.14.1) |
| 533 | N | N | N | N | Adenosine
| PYGM | 0.75000 | Adenosine phosphate
| 0.010046 | ADCY1: adenylate cyclase 1 (brain) (EC:4.6.1.1) |
| 534 | N | N | N | N | Adenosine
| PYGL: phosphorylase, glycogen, liver (EC:2.4.1.1) | 0.75000 | Adenosine phosphate
| 0.0085241 | ADCY1: adenylate cyclase 1 (brain) (EC:4.6.1.1) |
| 535 | Y | N | Y | N | Zileuton
| PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) | 0.47826 | Tiaprofenic acid
 | 0.012760 | ALOX5: arachidonate 5-lipoxygenase (EC:1.13.11.34) |
| 536 | N | Y | N | N | Tranexamic acid
 | PLAT: plasminogen activator, tissue (EC:3.4.21.68) | 0.33333 | Aminocaproic acid
| 0.30726 | PLAU: plasminogen activator, urokinase (EC:3.4.21.73) |
| 537 | N | N | N | N | Loratadine
| CYP1A2: cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) | 0.56250 | Clozapine
| 0.11769 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 538 | N | N | N | N | Pyrimethamine
 | CYP1A2: cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) | 0.40000 | Chlorzoxazone
| 0.025376 | DHFR: dihydrofolate reductase (EC:1.5.1.3) |
| 539 | N | Y | N | N | Phenytoin
| CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) | 0.46154 | Diphenhydramine
| 0.35919 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 540 | N | N | Y | N | Cisapride
| CYP3A5: cytochrome P450, family 3, subfamily A, polypeptide 5 (EC:1.14.14.1) | 0.35000 | Trimipramine
| 0.86492 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 541 | N | N | N | N | Phenacetin
| PRDX5: peroxiredoxin 5 (EC:1.11.1.15) | 0.71429 | Acetaminophen
| 0.018605 | CYP1A1: cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) |
| 542 | N | N | N | N | Bosutinib
 | CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) | 0.51111 | Cisapride
| 0.022964 | ERBB3: v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) (EC:2.7.10.1) |
| 543 | N | N | N | N | Adenosine phosphate
| PNP: purine nucleoside phosphorylase (EC:2.4.2.1) | 0.61538 | Inosine
| 0.031670 | APRT: adenine phosphoribosyltransferase (EC:2.4.2.7) |
| 544 | N | N | N | N | Flurbiprofen axetil
 | ACHE: acetylcholinesterase (EC:3.1.1.7) | 0.41379 | Neostigmine bromide
| 0.014743 | PTGS2: prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) |
| 545 | N | N | N | N | Eletriptan hydrobromide
| CYP3A5: cytochrome P450, family 3, subfamily A, polypeptide 5 (EC:1.14.14.1) | 0.38889 | Alprazolam
| 0.86492 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 546 | N | N | N | N | Rosiglitazone maleate
| CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.32500 | Diazepam
| 0.14990 | CYP2C8: cytochrome P450, family 2, subfamily C, polypeptide 8 (EC:1.14.14.1) |
| 547 | N | N | N | N | Mirtazapine
| CYP3A5: cytochrome P450, family 3, subfamily A, polypeptide 5 (EC:1.14.14.1) | 0.44828 | Trimipramine
| 0.86492 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 548 | N | N | N | N | Diphenhydramine
| PTGS2: prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) | 0.55556 | Phenylbutazone
| 0.015261 | CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) |
| 549 | N | N | N | N | Sivelestat sodium
 | PRTN3: proteinase 3 (EC:3.4.21.76) | 0.073171 | Aminocaproic acid
| 0.50758 | ELANE: elastase, neutrophil expressed (EC:3.4.21.37) |
| 550 | N | N | N | N | Phentermine
| TH: tyrosine hydroxylase (EC:1.14.16.2) | 0.56250 | Metyrosine
| 0.014975 | MAOB |
| 551 | N | N | N | N | Phytonadione
| VKORC1: vitamin K epoxide reductase complex, subunit 1 (EC:1.1.4.1) | 0.35294 | Menadione
| 0.025117 | GGCX: gamma-glutamyl carboxylase (EC:4.1.1.90) |
| 552 | N | N | Y | N | Donepezil hydrochloride
| CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) | 0.48780 | Cisapride
| 0.017115 | BCHE: butyrylcholinesterase (EC:3.1.1.8) |
| 553 | N | N | N | N | Nilutamide
| NQO1: NAD(P)H dehydrogenase, quinone 1 (EC:1.6.5.2) | 0.15000 | Mitomycin
| 0.018752 | POR: P450 (cytochrome) oxidoreductase (EC:1.6.2.4) |
| 554 | N | N | N | N | Rosiglitazone maleate
| AKR1B1: aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) | 0.37500 | Risarestat
| 0.019157 | CYP2C8: cytochrome P450, family 2, subfamily C, polypeptide 8 (EC:1.14.14.1) |
| 555 | Y | N | Y | N | Chlorzoxazone
| CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.34783 | Diazepam
| 0.14011 | CYP2A7: cytochrome P450, family 2, subfamily A, polypeptide 7 (EC:1.14.14.1) |
| 556 | N | N | N | N | Trimipramine
| F2: coagulation factor II (thrombin) (EC:3.4.21.5) | 0.75000 | Promethazine
| 0.021363 | CYP4A22 |
| 557 | N | N | Y | N | Terfenadine
| CYP3A5: cytochrome P450, family 3, subfamily A, polypeptide 5 (EC:1.14.14.1) | 0.42500 | Trimipramine
| 0.86492 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 558 | N | N | N | N | Chlorzoxazone
| CYP2B6: cytochrome P450, family 2, subfamily B, polypeptide 6 (EC:1.14.14.1) | 0.32000 | Alprazolam
| 0.54684 | CYP2A7: cytochrome P450, family 2, subfamily A, polypeptide 7 (EC:1.14.14.1) |
| 559 | N | N | N | N | Floxuridine
| DPYD: dihydropyrimidine dehydrogenase (EC:1.3.1.2) | 0.44444 | Fluorouracil
| 0.015267 | TYMS: thymidylate synthetase (EC:2.1.1.45) |
| 560 | N | N | N | N | Acetaminophen
| CYP2J2: cytochrome P450, family 2, subfamily J, polypeptide 2 (EC:1.14.14.1) | 0.38095 | Tolbutamide
| 0.38880 | CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) |
| 561 | N | N | N | N | Tilmacoxib
 | CA1: carbonic anhydrase I (EC:4.2.1.1) | 0.39286 | Ethoxzolamide
| 0.022842 | PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) |
| 562 | N | N | N | N | Acetaminophen
| RRM2: ribonucleotide reductase M2 (EC:1.17.4.1) | 0.063830 | Deferoxamine
| 0.030384 | PRDX1: peroxiredoxin 1 (EC:1.11.1.15) |
| 563 | N | N | N | N | Salicylic acid
| ACAT1: acetyl-CoA acetyltransferase 1 (EC:2.3.1.9) | 0.31034 | Sulfasalazine
| 0.018560 | LTA4H |
| 564 | N | N | N | N | Oxcarbazepine
| CYP2C18: cytochrome P450, family 2, subfamily C, polypeptide 18 (EC:1.14.14.1) | 0.51852 | Trimipramine
| 0.85870 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 565 | N | N | Y | N | Simvastatin
| CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) | 0.17778 | Bisoprolol
| 0.13075 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 566 | N | N | N | N | Zileuton
| LTA4H | 0.40000 | Ketoprofen
| 0.013786 | ALOX5: arachidonate 5-lipoxygenase (EC:1.13.11.34) |
| 567 | N | N | Y | N | Fludarabine phosphate
| DCK | 0.40000 | Gemcitabine
| 0.019062 | RRM1: ribonucleotide reductase M1 (EC:1.17.4.1) |
| 568 | N | N | N | N | Ribavirin
| ENPP2: ectonucleotide pyrophosphatase/phosphodiesterase 2 (EC:3.1.4.39) | 0.19355 | Pentoxifylline
| 0.43240 | ENPP1: ectonucleotide pyrophosphatase/phosphodiesterase 1 (EC:3.1.4.1 3.6.1.9) |
| 569 | N | N | N | N | Verapamil
| CYP3A43: cytochrome P450, family 3, subfamily A, polypeptide 43 (EC:1.14.14.1) | 0.37500 | Trimipramine
| 0.78013 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 570 | N | N | N | N | Benzoic acid
| EPX: eosinophil peroxidase (EC:1.11.1.7) | 0.72727 | Salicylic acid
| 0.018360 | PRDX5: peroxiredoxin 5 (EC:1.11.1.15) |
| 571 | N | N | Y | N | Mesalamine
| IKBKB: inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta (EC:2.7.11.10) | 0.75000 | Salicylic acid
| 0.018130 | TPMT: thiopurine S-methyltransferase (EC:2.1.1.67) |
| 572 | N | Y | N | N | Deferoxamine
| GPX4: glutathione peroxidase 4 (EC:1.11.1.12) | 0.035088 | Diethylstilbestrol
| 0.046704 | PRDX5: peroxiredoxin 5 (EC:1.11.1.15) |
| 573 | N | N | N | N | Citric acid, anhydrous
| AKR1A1: aldo-keto reductase family 1, member A1 (aldehyde reductase) (EC:1.1.1.2) | 0.12121 | Tolrestat
| 0.49917 | AKR1B1: aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) |
| 574 | N | N | N | N | Fludarabine phosphate
| CMPK1: cytidine monophosphate (UMP-CMP) kinase 1, cytosolic (EC:2.7.4.14) | 0.40000 | Gemcitabine
| 0.017727 | POLA1: polymerase (DNA directed), alpha 1, catalytic subunit (EC:2.7.7.7) |
| 575 | N | N | N | N | Risarestat
| AKR1A1: aldo-keto reductase family 1, member A1 (aldehyde reductase) (EC:1.1.1.2) | 0.21053 | Tolrestat
| 0.49917 | AKR1B1: aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) |
| 576 | N | N | Y | N | Gefitinib
| CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) | 0.50000 | Cisapride
| 0.022964 | ERBB3: v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) (EC:2.7.10.1) |
| 577 | N | Y | N | N | Deferoxamine
| GPX7: glutathione peroxidase 7 (EC:1.11.1.9) | 0.035088 | Diethylstilbestrol
| 0.043148 | FECH: ferrochelatase (EC:4.99.1.1) |
| 578 | N | N | N | N | Diazoxide
| CA13: carbonic anhydrase XIII (EC:4.2.1.1) | 0.47619 | Chlorothiazide
| 0.63871 | CA1: carbonic anhydrase I (EC:4.2.1.1) |
| 579 | N | N | N | N | Atazanavir sulfate
 | REN: renin (EC:3.4.23.15) | 0.44706 | Ditekiren
 | 0.021371 | UGT1A10: UDP glucuronosyltransferase 1 family, polypeptide A10 (EC:2.4.1.17) |
| 580 | N | N | N | N | Fasudil hydrochloride
 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.41935 | Clozapine
| 0.027294 | MAPK12: mitogen-activated protein kinase 12 (EC:2.7.11.24) |
| 581 | N | N | N | N | Histidine
 | TH: tyrosine hydroxylase (EC:1.14.16.2) | 0.64286 | Phenylalanine
| 0.016662 | HARS: histidyl-tRNA synthetase (EC:6.1.1.21) |
| 582 | N | N | N | N | Vesnarinone
| CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.48571 | Clozapine
| 0.029363 | PDE6G: phosphodiesterase 6G, cGMP-specific, rod, gamma (EC:3.1.4.35) |
| 583 | N | N | Y | N | Nicotine
| CYP1A1: cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) | 0.36364 | Fadrozole hydrochloride
| 0.27003 | CYP2A13: cytochrome P450, family 2, subfamily A, polypeptide 13 (EC:1.14.14.1) |
| 584 | N | N | N | N | Clozapine
| CYP2A7: cytochrome P450, family 2, subfamily A, polypeptide 7 (EC:1.14.14.1) | 0.45161 | Alprazolam
| 0.51016 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 585 | N | N | N | N | Melphalan
 | TH: tyrosine hydroxylase (EC:1.14.16.2) | 0.55000 | Phenylalanine
| 0.020343 | AGXT: alanine-glyoxylate aminotransferase (EC:2.6.1.44 2.6.1.51) |
| 586 | N | N | N | N | Pantoprazole
| CYP3A7: cytochrome P450, family 3, subfamily A, polypeptide 7 (EC:1.14.14.1) | 0.35484 | Methoxsalen
| 0.89469 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 587 | N | N | N | N | Sivelestat
| PRTN3: proteinase 3 (EC:3.4.21.76) | 0.11429 | Aminocaproic acid
| 0.50758 | ELANE: elastase, neutrophil expressed (EC:3.4.21.37) |
| 588 | N | N | N | N | Sodium salicylate
 | ALOX5: arachidonate 5-lipoxygenase (EC:1.13.11.34) | 0.75000 | Salicylic acid
| 0.012760 | PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) |
| 589 | N | N | N | N | Cytarabine
| ADCY1: adenylate cyclase 1 (brain) (EC:4.6.1.1) | 0.63636 | Adenosine
| 0.015111 | POLB |
| 590 | N | N | N | N | Orlistat
| MGLL: monoglyceride lipase (EC:3.1.1.23) | 0.20000 | Capecitabine
| 0.040662 | LIPA: lipase A, lysosomal acid, cholesterol esterase (EC:3.1.1.13) |
| 591 | N | N | N | N | Sivelestat
| ACE: angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 (EC:3.4.15.1) | 0.51219 | Quinapril
 | 0.011822 | ELANE: elastase, neutrophil expressed (EC:3.4.21.37) |
| 592 | N | N | N | N | Liarozole fumarate
| CYP4A11: cytochrome P450, family 4, subfamily A, polypeptide 11 (EC:1.14.15.3) | 0.18421 | Alprazolam
| 0.50873 | CYP4B1: cytochrome P450, family 4, subfamily B, polypeptide 1 (EC:1.14.14.1) |
| 593 | N | N | N | N | Docebenone
| ALOX15: arachidonate 15-lipoxygenase (EC:1.13.11.33) | 0.17500 | Phenylbutazone
| 0.38087 | ALOX5: arachidonate 5-lipoxygenase (EC:1.13.11.34) |
| 594 | N | N | Y | N | Rosiglitazone maleate
| CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.32500 | Diazepam
| 0.81101 | CYP2C8: cytochrome P450, family 2, subfamily C, polypeptide 8 (EC:1.14.14.1) |
| 595 | N | N | N | N | Benzoic acid
| LPO: lactoperoxidase (EC:1.11.1.7) | 0.72727 | Salicylic acid
| 0.019876 | PRDX5: peroxiredoxin 5 (EC:1.11.1.15) |
| 596 | N | N | Y | N | Ketoprofen
| CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.56522 | Metyrapone
| 0.022367 | PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) |
| 597 | N | N | N | N | Aminocaproic acid
| KARS: lysyl-tRNA synthetase (EC:6.1.1.6) | 0.72727 | Lysine
 | 0.027477 | KLK8: kallikrein-related peptidase 8 (EC:3.4.21.118) |
| 598 | N | N | N | N | Cytarabine
| ADK: adenosine kinase (EC:2.7.1.20) | 0.61905 | Ribavirin
| 0.023733 | POLB |
| 599 | N | N | N | N | Fluorometholone
| CYP19A1: cytochrome P450, family 19, subfamily A, polypeptide 1 (EC:1.14.14.1) | 0.48485 | Testolactone
| 0.014633 | PLA2G4A: phospholipase A2, group IVA (cytosolic, calcium-dependent) (EC:3.1.1.5 3.1.1.4) |
| 600 | N | N | N | N | Mesoridazine
| F2: coagulation factor II (thrombin) (EC:3.4.21.5) | 0.56667 | Chlorpromazine
| 0.014876 | CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) |
| 601 | N | N | N | N | Liarozole hydrochloride
| CYP4A11: cytochrome P450, family 4, subfamily A, polypeptide 11 (EC:1.14.15.3) | 0.36364 | Alprazolam
| 0.50873 | CYP4B1: cytochrome P450, family 4, subfamily B, polypeptide 1 (EC:1.14.14.1) |
| 602 | N | N | N | N | Citric acid, anhydrous
| PDE11A: phosphodiesterase 11A (EC:3.1.4.35 3.1.4.17) | 0.28261 | Sildenafil citrate
 | 0.32019 | PDE5A: phosphodiesterase 5A, cGMP-specific (EC:3.1.4.35) |
| 603 | N | N | N | N | Biotin
| TARS: threonyl-tRNA synthetase (EC:6.1.1.3) | 0.14286 | Threonine
| 0.014573 | HLCS: holocarboxylase synthetase (biotin-(proprionyl-CoA-carboxylase (ATP-hydrolysing)) ligase) (EC:6.3.4.10 6.3.4.11 6.3.4.15 6.3.4.9) |
| 604 | N | N | N | N | Naproxen
| PTGIS: prostaglandin I2 (prostacyclin) synthase (EC:5.3.99.4) | 0.41667 | Metyrapone
| 0.018722 | PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) |
| 605 | N | N | N | N | Physostigmine salicylate
| ACE: angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 (EC:3.4.15.1) | 0.44186 | Benazepril hydrochloride
 | 0.011580 | ACHE: acetylcholinesterase (EC:3.1.1.7) |
| 606 | N | N | N | N | Levetiracetam
| ACE: angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 (EC:3.4.15.1) | 0.36842 | Captopril
 | 0.013775 | CA1: carbonic anhydrase I (EC:4.2.1.1) |
| 607 | N | N | N | N | Inosine
| ADK: adenosine kinase (EC:2.7.1.20) | 0.61538 | Adenosine phosphate
| 0.020909 | PNP: purine nucleoside phosphorylase (EC:2.4.2.1) |
| 608 | N | N | N | N | Pentostatin
| ACAA1: acetyl-CoA acyltransferase 1 (EC:2.3.1.16) | 0.44000 | Idoxuridine
| 0.018897 | ADA |
| 609 | N | N | Y | N | Omeprazole
| CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.72414 | Pantoprazole
| 0.015547 | ATP4A: ATPase, H+/K+ exchanging, alpha polypeptide (EC:3.6.3.10) |
| 610 | N | N | N | N | Cyclothiazide
| CA13: carbonic anhydrase XIII (EC:4.2.1.1) | 0.64000 | Hydrochlorothiazide
| 0.63871 | CA1: carbonic anhydrase I (EC:4.2.1.1) |
| 611 | N | N | N | N | Minalrestat
| AKR1C1: aldo-keto reductase family 1, member C1 (EC:1.3.1.20 1.1.1.149 1.1.1.112) | 0.38461 | Haloperidol
| 0.49596 | AKR1B1: aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) |
| 612 | N | N | N | N | Gabapentin
 | BCKDK: branched chain ketoacid dehydrogenase kinase (EC:2.7.11.4) | 0.25000 | Valine
| 0.020644 | PSAT1: phosphoserine aminotransferase 1 (EC:2.6.1.52) |
| 613 | N | N | N | N | Celgosivir hydrochloride
| ACHE: acetylcholinesterase (EC:3.1.1.7) | 0.33333 | Capecitabine
| 0.012269 | GAA: glucosidase, alpha; acid (EC:3.2.1.20) |
| 614 | N | N | N | N | Verapamil
| CA4: carbonic anhydrase IV (EC:4.2.1.1) | 0.22917 | Benzthiazide
| 0.19740 | CA1: carbonic anhydrase I (EC:4.2.1.1) |
| 615 | N | N | N | N | Ciclopirox olamine
| LTA4H | 0.22500 | Ketotifen fumarate
| 0.019303 | PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) |
| 616 | N | N | N | N | Clofibrate
| LIPG: lipase, endothelial (EC:3.1.1.3) | 0.32258 | Capecitabine
| 0.45390 | LPL: lipoprotein lipase (EC:3.1.1.34) |
| 617 | N | N | Y | N | Phenylbutazone
| CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.50000 | Phenytoin
| 0.061448 | PTGIS: prostaglandin I2 (prostacyclin) synthase (EC:5.3.99.4) |
| 618 | N | N | N | N | Orlistat
| PAFAH2: platelet-activating factor acetylhydrolase 2, 40kDa (EC:3.1.1.47) | 0.20000 | Capecitabine
| 0.025315 | LIPA: lipase A, lysosomal acid, cholesterol esterase (EC:3.1.1.13) |
| 619 | N | N | N | N | Promethazine
| LOXL3: lysyl oxidase-like 3 | 0.64000 | Chlorpromazine
| 0.012999 | F2: coagulation factor II (thrombin) (EC:3.4.21.5) |
| 620 | N | N | N | N | Ketotifen fumarate
| PDE9A: phosphodiesterase 9A (EC:3.1.4.35) | 0.37209 | Vesnarinone
| 0.16421 | PDE7A: phosphodiesterase 7A (EC:3.1.4.17) |
| 621 | N | N | N | N | Promethazine
| LOXL4: lysyl oxidase-like 4 | 0.64000 | Chlorpromazine
| 0.012761 | F2: coagulation factor II (thrombin) (EC:3.4.21.5) |
| 622 | N | N | N | N | Napsagatran
| ACE: angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 (EC:3.4.15.1) | 0.37037 | Delapril hydrochloride
 | 0.010996 | F2: coagulation factor II (thrombin) (EC:3.4.21.5) |
| 623 | N | N | N | N | Acetohexamide
| AKR1C1: aldo-keto reductase family 1, member C1 (EC:1.3.1.20 1.1.1.149 1.1.1.112) | 0.33333 | Haloperidol
| 0.023746 | DCXR: dicarbonyl/L-xylulose reductase (EC:1.1.1.10) |
| 624 | N | N | Y | N | Astemizole
| CYP3A5: cytochrome P450, family 3, subfamily A, polypeptide 5 (EC:1.14.14.1) | 0.42000 | Fadrozole hydrochloride hydrate
| 0.86492 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 625 | N | N | N | N | Oxiconazole nitrate
| AKR1B1: aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) | 0.43590 | Zenarestat
| 0.024614 | ABO: ABO blood group (transferase A, alpha 1-3-N-acetylgalactosaminyltransferase; transferase B, alpha 1-3-galactosyltransferase) (EC:2.4.1.37 2.4.1.40) |
| 626 | N | N | N | N | Gabapentin
| PLG: plasminogen (EC:3.4.21.7) | 0.64286 | Tranexamic acid
| 0.017223 | PSAT1: phosphoserine aminotransferase 1 (EC:2.6.1.52) |
| 627 | N | N | N | N | Bosutinib
| CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.51111 | Cisapride
| 0.025570 | ERBB3: v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) (EC:2.7.10.1) |
| 628 | N | N | N | N | Promethazine
| LOXL2: lysyl oxidase-like 2 (EC:1.4.3.-) | 0.64000 | Chlorpromazine
| 0.011638 | F2: coagulation factor II (thrombin) (EC:3.4.21.5) |
| 629 | N | N | N | N | Orlistat
| TYMP: thymidine phosphorylase (EC:2.4.2.4) | 0.20000 | Capecitabine
| 0.020500 | PNPLA3: patatin-like phospholipase domain containing 3 (EC:3.1.1.3) |
| 630 | N | N | N | N | Amlexanox
 | DHFR: dihydrofolate reductase (EC:1.5.1.3) | 0.43333 | Trimethoprim
 | 0.023456 | EXTL2: exostoses (multiple)-like 2 (EC:2.4.1.223) |
| 631 | N | N | N | Y | Orlistat
| PLA2G12A: phospholipase A2, group XIIA (EC:3.1.1.4) | 0.20000 | Capecitabine
| 0.037930 | PNLIPRP2: pancreatic lipase-related protein 2 (EC:3.1.1.3 3.1.1.26) |
| 632 | N | N | N | N | Allopurinol
 | ACAA1: acetyl-CoA acyltransferase 1 (EC:2.3.1.16) | 0.30000 | Acyclovir
| 0.010657 | XDH: xanthine dehydrogenase (EC:1.17.1.4 1.17.3.2) |
| 633 | N | N | N | N | Orlistat
| PLA2G6: phospholipase A2, group VI (cytosolic, calcium-independent) (EC:3.1.1.4) | 0.20000 | Capecitabine
| 0.020117 | PNPLA3: patatin-like phospholipase domain containing 3 (EC:3.1.1.3) |
| 634 | N | N | N | N | Terfenadine
| CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.42500 | Trimipramine
| 0.35919 | CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) |
| 635 | N | N | N | N | Citric acid, anhydrous
| PDE9A: phosphodiesterase 9A (EC:3.1.4.35) | 0.28261 | Sildenafil citrate
| 0.10579 | PDE5A: phosphodiesterase 5A, cGMP-specific (EC:3.1.4.35) |
| 636 | N | N | N | N | Orlistat
| LIPE: lipase, hormone-sensitive (EC:3.1.1.79) | 0.20000 | Capecitabine
| 0.017504 | CEL: carboxyl ester lipase (bile salt-stimulated lipase) (EC:3.1.1.13 3.1.1.3) |
| 637 | N | N | N | N | Floxuridine
| PNP: purine nucleoside phosphorylase (EC:2.4.2.1) | 0.56522 | Cladribine
| 0.035471 | TYMS: thymidylate synthetase (EC:2.1.1.45) |
| 638 | N | N | N | N | Sirolimus
 | PLA2G4A: phospholipase A2, group IVA (cytosolic, calcium-dependent) (EC:3.1.1.5 3.1.1.4) | 0.35454 | Flunisolide
 | 0.026005 | FKBP1A: FK506 binding protein 1A, 12kDa (EC:5.2.1.8) |
| 639 | N | N | N | N | Adenosine
| RRM1: ribonucleotide reductase M1 (EC:1.17.4.1) | 0.65385 | Fludarabine phosphate
| 0.0097663 | ADCY1: adenylate cyclase 1 (brain) (EC:4.6.1.1) |
| 640 | N | N | N | N | Acetohexamide
| AKR1B10: aldo-keto reductase family 1, member B10 (aldose reductase) (EC:1.1.1.2) | 0.33333 | Haloperidol
| 0.022981 | DCXR: dicarbonyl/L-xylulose reductase (EC:1.1.1.10) |
| 641 | N | N | N | N | Benzthiazide
| CA3: carbonic anhydrase III, muscle specific (EC:4.2.1.1) | 0.59259 | Chlorothiazide
| 0.60142 | CA2: carbonic anhydrase II (EC:4.2.1.1) |
| 642 | N | N | N | N | Hydroflumethiazide
| CA13: carbonic anhydrase XIII (EC:4.2.1.1) | 0.76191 | Hydrochlorothiazide
| 0.63871 | CA1: carbonic anhydrase I (EC:4.2.1.1) |
| 643 | N | N | N | N | Topotecan hydrochloride
 | TOP2B: topoisomerase (DNA) II beta 180kDa (EC:5.99.1.3) | 0.33962 | Daunorubicin hydrochloride
 | 0.016108 | TOP1: topoisomerase (DNA) I (EC:5.99.1.2) |
| 644 | N | N | N | N | Orlistat
| AOAH: acyloxyacyl hydrolase (neutrophil) (EC:3.1.1.77) | 0.20000 | Capecitabine
| 0.020476 | LIPA: lipase A, lysosomal acid, cholesterol esterase (EC:3.1.1.13) |
| 645 | N | N | Y | N | Diazepam
| CYP3A5: cytochrome P450, family 3, subfamily A, polypeptide 5 (EC:1.14.14.1) | 0.68000 | Alprazolam
| 0.86492 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 646 | N | N | N | N | Indomethacin
| PTGIS: prostaglandin I2 (prostacyclin) synthase (EC:5.3.99.4) | 0.42424 | Alprazolam
| 0.018722 | PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) |
| 647 | N | N | N | N | Haloperidol
| CYP3A43 | 0.37500 | Fadrozole hydrochloride
| 0.78013 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 648 | N | N | N | N | Threonine
| MCCC2: methylcrotonoyl-CoA carboxylase 2 (beta) (EC:6.4.1.4) | 0.14286 | Biotin
| 0.22230 | PCCB |
| 649 | N | N | Y | N | Methoxyflurane
| CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.66667 | Halothane
| 0.59436 | CYP2E1: cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) |
| 650 | N | N | N | N | Ibuprofen
| CYP2E1: cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) | 0.36842 | Acetaminophen
| 0.59436 | CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 651 | N | N | N | N | Mirtazapine
| CYP2E1: cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) | 0.44828 | Trimipramine
| 0.35638 | CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) |
| 652 | N | N | N | N | Orlistat
| BPHL: biphenyl hydrolase-like (serine hydrolase) | 0.20000 | Capecitabine
| 0.028812 | LIPA: lipase A, lysosomal acid, cholesterol esterase (EC:3.1.1.13) |
| 653 | N | N | N | N | Valine
| CASP1: caspase 1, apoptosis-related cysteine peptidase (EC:3.4.22.36) | 0.70000 | Penicillamine
| 0.022277 | PCCB |
| 654 | N | N | N | N | Salicylamide
 | BST1: bone marrow stromal cell antigen 1 (EC:3.2.2.5) | 0.58333 | Niacinamide
 | 0.019403 | PTGS2: prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) |
| 655 | N | N | Y | N | Etoricoxib
| CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.56250 | Celecoxib
| 0.022367 | PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) |
| 656 | N | N | Y | N | Diphenhydramine
| CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.51852 | Trimipramine
| 0.35919 | CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) |
| 657 | N | N | N | N | Topotecan hydrochloride
| TOP2A: topoisomerase (DNA) II alpha 170kDa (EC:5.99.1.3) | 0.33962 | Daunorubicin hydrochloride
| 0.015780 | TOP1: topoisomerase (DNA) I (EC:5.99.1.2) |
| 658 | N | N | N | N | Astemizole
| CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.46154 | Clozapine
| 0.35919 | CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) |
| 659 | N | N | N | N | Efegatran sulfate
| REN: renin (EC:3.4.23.15) | 0.37705 | Zankiren hydrochloride
 | 0.015677 | F2: coagulation factor II (thrombin) (EC:3.4.21.5) |
| 660 | N | N | Y | N | Donepezil hydrochloride
| CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.48780 | Cisapride
| 0.012623 | BCHE: butyrylcholinesterase (EC:3.1.1.8) |
| 661 | N | N | N | N | Gabapentin
| PLAU: plasminogen activator, urokinase (EC:3.4.21.73) | 0.64286 | Tranexamic acid
| 0.022165 | BCAT2: branched chain amino-acid transaminase 2, mitochondrial (EC:2.6.1.42) |
| 662 | N | N | N | N | Ibuprofen
| CYP2C18: cytochrome P450, family 2, subfamily C, polypeptide 18 (EC:1.14.14.1) | 0.32000 | Tolbutamide
| 0.85922 | CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 663 | N | N | N | N | Carbamazepine
| CA1: carbonic anhydrase I (EC:4.2.1.1) | 0.29412 | Benzthiazide
| 0.022337 | CYP2C8: cytochrome P450, family 2, subfamily C, polypeptide 8 (EC:1.14.14.1) |
| 664 | N | N | Y | N | Promethazine
| CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) | 0.75000 | Trimipramine
| 0.014876 | F2: coagulation factor II (thrombin) (EC:3.4.21.5) |
| 665 | N | N | N | N | Olanzapine
| TRIM32: tripartite motif containing 32 | 0.60714 | Clozapine
| 0.014311 | CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) |
| 666 | N | N | Y | N | Mirtazapine
| CYP2C8: cytochrome P450, family 2, subfamily C, polypeptide 8 (EC:1.14.14.1) | 0.44828 | Trimipramine
| 0.37298 | CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) |
| 667 | N | N | N | N | Itopride hydrochloride
| CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.51282 | Cisapride
| 0.012623 | BCHE: butyrylcholinesterase (EC:3.1.1.8) |
| 668 | N | N | N | N | Chlorzoxazone
| CYP2C8: cytochrome P450, family 2, subfamily C, polypeptide 8 (EC:1.14.14.1) | 0.32000 | Alprazolam
| 0.58269 | CYP2E1: cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) |
| 669 | N | N | Y | N | Fluvastatin sodium
 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.39474 | Trimipramine
| 0.014302 | HMGCR: 3-hydroxy-3-methylglutaryl-CoA reductase (EC:1.1.1.34) |
| 670 | N | N | N | N | Epalrestat
| ACE: angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 (EC:3.4.15.1) | 0.38461 | Temocapril hydrochloride
 | 0.014328 | AKR1B1: aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) |
| 671 | N | N | N | N | Diethylstilbestrol
| RRM2: ribonucleotide reductase M2 (EC:1.17.4.1) | 0.035088 | Deferoxamine
| 0.032800 | GPX2: glutathione peroxidase 2 (gastrointestinal) (EC:1.11.1.9) |
| 672 | N | N | N | N | Propylthiouracil
| SULT1A2: sulfotransferase family, cytosolic, 1A, phenol-preferring, member 2 (EC:2.8.2.1) | 0.22222 | Acetaminophen
| 0.023458 | DIO3: deiodinase, iodothyronine, type III (EC:1.97.1.11) |
| 673 | N | N | N | N | Ribavirin
| PNP: purine nucleoside phosphorylase (EC:2.4.2.1) | 0.56522 | Inosine
| 0.020909 | ADK: adenosine kinase (EC:2.7.1.20) |
| 674 | N | N | N | N | Adenosine
| ACAA1: acetyl-CoA acyltransferase 1 (EC:2.3.1.16) | 0.44000 | Idoxuridine
| 0.013020 | ADCY1: adenylate cyclase 1 (brain) (EC:4.6.1.1) |
| 675 | N | N | N | N | Orlistat
| H6PD: hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase) (EC:1.1.1.47 3.1.1.31) | 0.20000 | Capecitabine
| 0.017406 | LIPC: lipase, hepatic (EC:3.1.1.3) |
| 676 | N | N | N | N | Phenacetin
| CYP1B1: cytochrome P450, family 1, subfamily B, polypeptide 1 (EC:1.14.14.1) | 0.47619 | Tolbutamide
| 0.35910 | CYP1A1: cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) |
| 677 | N | N | N | N | Ketoprofen
| CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.56522 | Metyrapone
| 0.024874 | LALBA |
| 678 | N | N | Y | N | Cisapride
| CYP2C8: cytochrome P450, family 2, subfamily C, polypeptide 8 (EC:1.14.14.1) | 0.35417 | Verapamil
| 0.37298 | CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) |
| 679 | N | N | N | N | Gulutamine
| PCCA | 0.46154 | Isoleucine
| 0.099854 | ACACA: acetyl-CoA carboxylase alpha (EC:6.4.1.2 6.3.4.14) |
| 680 | N | N | Y | N | Diethylstilbestrol
| CYP2E1: cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) | 0.40000 | Letrozole
| 0.034476 | GPX2: glutathione peroxidase 2 (gastrointestinal) (EC:1.11.1.9) |
| 681 | N | N | Y | N | Rofecoxib
 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.50000 | Diazepam
| 0.014789 | PTGS2: prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) |
| 682 | N | N | Y | N | Eletriptan hydrobromide
| CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.41667 | Clozapine
| 0.14153 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 683 | N | N | N | N | Ethoxzolamide
| ATP1A1 | 0.38461 | Methyclothiazide
| 0.013918 | CA1: carbonic anhydrase I (EC:4.2.1.1) |
| 684 | N | N | N | N | Diethylstilbestrol
| CYP1A1: cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) | 0.40000 | Letrozole
| 0.029947 | PRDX1: peroxiredoxin 1 (EC:1.11.1.15) |
| 685 | N | N | N | N | Orlistat
| CLC: Charcot-Leyden crystal protein (EC:3.1.1.5) | 0.20000 | Capecitabine
| 0.026761 | PNLIPRP2: pancreatic lipase-related protein 2 (EC:3.1.1.3 3.1.1.26) |
| 686 | N | N | N | N | Trichlormethiazide
| CA13: carbonic anhydrase XIII (EC:4.2.1.1) | 0.76191 | Hydrochlorothiazide
| 0.63871 | CA1: carbonic anhydrase I (EC:4.2.1.1) |
| 687 | N | N | N | N | Milrinone
| CYP1A2: cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) | 0.36000 | Fadrozole hydrochloride
| 0.028814 | PDE6H: phosphodiesterase 6H, cGMP-specific, cone, gamma (EC:3.1.4.35) |
| 688 | N | N | N | Y | Orlistat
| PLA2G3: phospholipase A2, group III (EC:3.1.1.4) | 0.20000 | Capecitabine
| 0.018132 | PNPLA3: patatin-like phospholipase domain containing 3 (EC:3.1.1.3) |
| 689 | N | N | N | N | Acetohexamide
| ACE: angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 (EC:3.4.15.1) | 0.38889 | Alacepril
| 0.012963 | DCXR: dicarbonyl/L-xylulose reductase (EC:1.1.1.10) |
| 690 | N | N | N | N | Fenoprofen
 | LALBA | 0.85000 | Ketoprofen
| 0.024348 | PTGS2: prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) |
| 691 | N | N | N | N | Fadrozole hydrochloride
| CYP4A11: cytochrome P450, family 4, subfamily A, polypeptide 11 (EC:1.14.15.3) | 0.33333 | Alprazolam
| 0.50873 | CYP4B1: cytochrome P450, family 4, subfamily B, polypeptide 1 (EC:1.14.14.1) |
| 692 | N | N | N | N | Mirtazapine
| CYP2A7: cytochrome P450, family 2, subfamily A, polypeptide 7 (EC:1.14.14.1) | 0.44828 | Trimipramine
| 0.32161 | CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) |
| 693 | Y | N | N | N | Zileuton
| PTGS2: prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) | 0.47826 | Tiaprofenic acid
| 0.011221 | ALOX5: arachidonate 5-lipoxygenase (EC:1.13.11.34) |
| 694 | N | N | N | N | Nadide
| FDXR: ferredoxin reductase (EC:1.18.1.2) | 0.49266 | Flavin adenine dinucleotide
| 0.031424 | NMNAT3: nicotinamide nucleotide adenylyltransferase 3 (EC:2.7.7.1 2.7.7.18) |
| 695 | Y | N | Y | N | Tacrolimus
| FKBP1A: FK506 binding protein 1A, 12kDa (EC:5.2.1.8) | 0.49096 | Sirolimus
| 0.055658 | PPIB: peptidylprolyl isomerase B (cyclophilin B) (EC:5.2.1.8) |
| 696 | N | N | N | N | Acetaminophen
| CYP2F1: cytochrome P450, family 2, subfamily F, polypeptide 1 (EC:1.14.14.1) | 0.38095 | Tolbutamide
| 0.50585 | CYP2E1: cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) |
| 697 | N | N | Y | N | Gulutamine
| ABAT: 4-aminobutyrate aminotransferase (EC:2.6.1.19 2.6.1.22) | 0.58333 | Vigabatrin
 | 0.012100 | GLUD1: glutamate dehydrogenase 1 (EC:1.4.1.3) |
| 698 | N | N | N | N | Midazolam
| CYP3A43 | 0.80000 | Alprazolam
| 0.78013 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 699 | N | N | N | N | Uracil
| GLUD1: glutamate dehydrogenase 1 (EC:1.4.1.3) | 0.083333 | Nadide
| 0.014853 | DPYD: dihydropyrimidine dehydrogenase (EC:1.3.1.2) |
| 700 | N | N | N | N | Methoxyflurane
| CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.66667 | Halothane
| 0.60720 | CYP2E1: cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) |
| 701 | N | N | N | N | Mofegiline hydrochloride
 | AKR1B1: aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) | 0.32258 | Haloperidol
| 0.021730 | MAOA: monoamine oxidase A (EC:1.4.3.4) |
| 702 | N | N | N | N | Simvastatin
| CYP3A43 | 0.17021 | Nifedipine
| 0.78013 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 703 | N | N | N | N | Methyclothiazide
| CA13: carbonic anhydrase XIII (EC:4.2.1.1) | 0.68182 | Hydrochlorothiazide
| 0.63871 | CA1: carbonic anhydrase I (EC:4.2.1.1) |
| 704 | N | N | N | N | Chlorzoxazone
| CYP2C18: cytochrome P450, family 2, subfamily C, polypeptide 18 (EC:1.14.14.1) | 0.32000 | Alprazolam
| 0.59738 | CYP2E1: cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) |
| 705 | N | N | N | N | Citric acid, anhydrous
| AKR1C1: aldo-keto reductase family 1, member C1 (EC:1.3.1.20 1.1.1.149 1.1.1.112) | 0.083333 | Haloperidol
| 0.49596 | AKR1B1: aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) |
| 706 | N | N | N | N | Tartaric acid
 | PCCB | 0.50000 | Threonine
| 0.023110 | ACP1: acid phosphatase 1, soluble (EC:3.1.3.2 3.1.3.48) |
| 707 | N | N | N | N | Isoflurophate
| CEL: carboxyl ester lipase (bile salt-stimulated lipase) (EC:3.1.1.13 3.1.1.3) | 0.12195 | Orlistat
| 0.20493 | BCHE: butyrylcholinesterase (EC:3.1.1.8) |
| 708 | N | N | N | N | Chlorzoxazone
| CYP2J2: cytochrome P450, family 2, subfamily J, polypeptide 2 (EC:1.14.14.1) | 0.32000 | Alprazolam
| 0.38822 | CYP2A7: cytochrome P450, family 2, subfamily A, polypeptide 7 (EC:1.14.14.1) |
| 709 | N | N | N | N | Benzoic acid
| MPO | 0.72727 | Salicylic acid
| 0.019867 | PRDX5: peroxiredoxin 5 (EC:1.11.1.15) |
| 710 | N | N | N | N | Isoflurophate
| ENPP2: ectonucleotide pyrophosphatase/phosphodiesterase 2 (EC:3.1.4.39) | 0.13636 | Caffeine
| 0.43240 | ENPP1: ectonucleotide pyrophosphatase/phosphodiesterase 1 (EC:3.1.4.1 3.6.1.9) |
| 711 | N | N | N | N | Deracoxib
| CA1: carbonic anhydrase I (EC:4.2.1.1) | 0.45946 | Bendroflumethiazide
| 0.022842 | PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) |
| 712 | N | N | N | N | Tipifarnib
 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.48077 | Liarozole hydrochloride
| 0.019603 | FNTA: farnesyltransferase, CAAX box, alpha (EC:2.5.1.59 2.5.1.58) |
| 713 | N | N | N | N | Ximelagatran
| REN: renin (EC:3.4.23.15) | 0.45283 | Terlakiren
| 0.015677 | F2: coagulation factor II (thrombin) (EC:3.4.21.5) |
| 714 | N | N | N | N | Orlistat
| PGLS: 6-phosphogluconolactonase (EC:3.1.1.31) | 0.20000 | Capecitabine
| 0.024573 | PNPLA3: patatin-like phospholipase domain containing 3 (EC:3.1.1.3) |
| 715 | N | N | N | N | Fondaparinux sodium
| PROC: protein C (inactivator of coagulation factors Va and VIIIa) (EC:3.4.21.69) | 0.0088500 | Menadione
| 0.32454 | F10: coagulation factor X (EC:3.4.21.6) |
| 716 | N | N | N | N | Ravuconazole (prop.INN)
| CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.51429 | Fluconazole
| 0.076563 | CYP51A1: cytochrome P450, family 51, subfamily A, polypeptide 1 (EC:1.14.13.70) |
| 717 | N | N | N | N | Sodium salicylate
| MPO | 0.75000 | Salicylic acid
| 0.039978 | PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) |
| 718 | N | N | N | N | Cladribine
| TYMS: thymidylate synthetase (EC:2.1.1.45) | 0.56522 | Floxuridine
| 0.035471 | PNP: purine nucleoside phosphorylase (EC:2.4.2.1) |
| 719 | N | N | N | N | Oxcarbazepine
| ACE: angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 (EC:3.4.15.1) | 0.41176 | Benazeprilat
 | 0.010985 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 720 | N | N | N | N | Glimepiride
| REN: renin (EC:3.4.23.15) | 0.40000 | Terlakiren
| 0.016019 | CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 721 | N | N | N | N | Fumaric acid
 | GLUD1: glutamate dehydrogenase 1 (EC:1.4.1.3) | 0.50000 | Gulutamine
| 0.012401 | ME2: malic enzyme 2, NAD(+)-dependent, mitochondrial (EC:1.1.1.38) |
| 722 | N | N | N | N | Proline
 | ACE: angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 (EC:3.4.15.1) | 0.46667 | Captopril
| 0.013158 | PRODH: proline dehydrogenase (oxidase) 1 (EC:1.5.99.8) |
| 723 | N | N | N | N | Pantoprazole
| CYP3A5: cytochrome P450, family 3, subfamily A, polypeptide 5 (EC:1.14.14.1) | 0.35484 | Methoxsalen
| 0.86492 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 724 | N | N | N | N | Aminoglutethimide
| AKR1B1: aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) | 0.44444 | Risarestat
| 0.029508 | CYP4F2: cytochrome P450, family 4, subfamily F, polypeptide 2 (EC:1.14.13.30) |
| 725 | N | N | N | N | Nicotine
| CYP2C18: cytochrome P450, family 2, subfamily C, polypeptide 18 (EC:1.14.14.1) | 0.36364 | Fadrozole hydrochloride
| 0.51608 | CYP2A13: cytochrome P450, family 2, subfamily A, polypeptide 13 (EC:1.14.14.1) |
| 726 | N | N | N | N | Glimepiride
| F2: coagulation factor II (thrombin) (EC:3.4.21.5) | 0.44681 | Ximelagatran
| 0.014521 | CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 727 | N | N | N | N | Isoleucine
| MCCC1: methylcrotonoyl-CoA carboxylase 1 (alpha) (EC:6.4.1.4) | 0.19048 | Biotin
| 0.33639 | PCCA |
| 728 | N | N | N | N | Ergocalciferol
| HMGCR: 3-hydroxy-3-methylglutaryl-CoA reductase (EC:1.1.1.34) | 0.32558 | Dalvastatin
 | 0.011624 | CYP27B1: cytochrome P450, family 27, subfamily B, polypeptide 1 (EC:1.14.13.13) |
| 729 | N | N | N | N | Razaxaban hydrochloride
| PROC: protein C (inactivator of coagulation factors Va and VIIIa) (EC:3.4.21.69) | 0.13043 | Menadione
| 0.32454 | F10: coagulation factor X (EC:3.4.21.6) |
| 730 | N | N | N | N | Rivastigmine tartrate
| ACE: angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 (EC:3.4.15.1) | 0.36956 | Enalapril maleate
 | 0.011580 | ACHE: acetylcholinesterase (EC:3.1.1.7) |
| 731 | N | N | Y | N | Leflunomide
 | CYP1A2: cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) | 0.45454 | Phenacetin
| 0.018763 | DHODH: dihydroorotate dehydrogenase (quinone) (EC:1.3.5.2) |
| 732 | N | N | N | N | Etazolate hydrochloride
 | ACHE: acetylcholinesterase (EC:3.1.1.7) | 0.39286 | Neostigmine bromide
| 0.034003 | PDE6G: phosphodiesterase 6G, cGMP-specific, rod, gamma (EC:3.1.4.35) |
| 733 | N | N | N | N | Tranexamic acid
| ABAT: 4-aminobutyrate aminotransferase (EC:2.6.1.19 2.6.1.22) | 0.64286 | Gabapentin
| 0.015746 | PLAU: plasminogen activator, urokinase (EC:3.4.21.73) |
| 734 | N | N | N | N | Fludarabine phosphate
| TYMS: thymidylate synthetase (EC:2.1.1.45) | 0.40000 | Gemcitabine
| 0.013909 | RRM1: ribonucleotide reductase M1 (EC:1.17.4.1) |
| 735 | N | N | N | N | Phenylbutazone
| CYP7A1: cytochrome P450, family 7, subfamily A, polypeptide 1 (EC:1.14.13.17) | 0.40625 | Trimipramine
| 0.26998 | PTGIS: prostaglandin I2 (prostacyclin) synthase (EC:5.3.99.4) |
| 736 | N | N | N | N | Biotin
| BCAT1: branched chain amino-acid transaminase 1, cytosolic (EC:2.6.1.42) | 0.27273 | Gabapentin
| 0.020930 | PCCA |
| 737 | N | N | N | N | Racemethionine
| BCKDK: branched chain ketoacid dehydrogenase kinase (EC:2.7.11.4) | 0.63636 | Isoleucine
| 0.023184 | MSRA: methionine sulfoxide reductase A (EC:1.8.4.11) |
| 738 | N | N | N | N | Ravuconazole (prop.INN)
| CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.51429 | Fluconazole
| 0.060377 | CYP51A1: cytochrome P450, family 51, subfamily A, polypeptide 1 (EC:1.14.13.70) |
| 739 | N | N | N | N | Ditekiren
| HMGCR: 3-hydroxy-3-methylglutaryl-CoA reductase (EC:1.1.1.34) | 0.26584 | Atorvastatin calcium
 | 0.012824 | REN: renin (EC:3.4.23.15) |
| 740 | N | N | N | N | Imatinib mesylate
| IKBKE: inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilon (EC:2.7.11.10) | 0.34615 | Sulfasalazine
| 0.088066 | MAP2K1: mitogen-activated protein kinase kinase 1 (EC:2.7.12.2) |
| 741 | N | N | N | N | Valine
| MCCC1: methylcrotonoyl-CoA carboxylase 1 (alpha) (EC:6.4.1.4) | 0.14286 | Biotin
| 0.33639 | PCCA |
| 742 | N | N | N | N | Phytonadione
| F9: coagulation factor IX (EC:3.4.21.22) | 0.35294 | Menadione
| 0.012080 | GGCX: gamma-glutamyl carboxylase (EC:4.1.1.90) |
| 743 | N | N | Y | N | Atazanavir sulfate
| CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.45714 | Lopinavir
| 0.020804 | UGT2A3: UDP glucuronosyltransferase 2 family, polypeptide A3 (EC:2.4.1.17) |
| 744 | N | N | N | N | Citric acid, anhydrous
| CPE: carboxypeptidase E (EC:3.4.17.10) | 0.50000 | Edetic acid
 | 0.034356 | CPB1: carboxypeptidase B1 (tissue) (EC:3.4.17.2) |
| 745 | N | N | Y | N | Nadide
| ALDH9A1: aldehyde dehydrogenase 9 family, member A1 (EC:1.2.1.3 1.2.1.19 1.2.1.47) | 0.034483 | Disulfiram
| 0.36495 | ALDH2: aldehyde dehydrogenase 2 family (mitochondrial) (EC:1.2.1.3) |
| 746 | N | N | N | N | Phytonadione
| F7: coagulation factor VII (serum prothrombin conversion accelerator) (EC:3.4.21.21) | 0.35294 | Menadione
| 0.011633 | GGCX: gamma-glutamyl carboxylase (EC:4.1.1.90) |
| 747 | N | N | N | N | Salicylamide
| ALOX5: arachidonate 5-lipoxygenase (EC:1.13.11.34) | 0.53846 | Salicylic acid
| 0.012760 | PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) |
| 748 | N | N | Y | N | Methotrexate sodium
| GGH: gamma-glutamyl hydrolase (conjugase, folylpolygammaglutamyl hydrolase) (EC:3.4.19.9) | 0.73684 | Folic acid
| 0.039110 | DHFR: dihydrofolate reductase (EC:1.5.1.3) |
| 749 | N | N | N | N | Phenytoin
| CYP2E1: cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) | 0.38461 | Metyrapone
| 0.60720 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 750 | N | N | N | N | Cytarabine
| PNP: purine nucleoside phosphorylase (EC:2.4.2.1) | 0.56522 | Inosine
| 0.025612 | POLB |
| 751 | N | N | N | N | Bentiromide
| ACE: angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 (EC:3.4.15.1) | 0.39535 | Quinaprilat
 | 0.016518 | CTRC: chymotrypsin C (caldecrin) (EC:3.4.21.2) |
| 752 | N | N | N | N | Gulutamine
| ME2: malic enzyme 2, NAD(+)-dependent, mitochondrial (EC:1.1.1.38) | 0.50000 | Fumaric acid
| 0.012401 | GLUD1: glutamate dehydrogenase 1 (EC:1.4.1.3) |
| 753 | N | N | N | N | Natamycin
 | PLA2G4A: phospholipase A2, group IVA (cytosolic, calcium-dependent) (EC:3.1.1.5 3.1.1.4) | 0.28659 | Flunisolide
| 0.014912 | ABO: ABO blood group (transferase A, alpha 1-3-N-acetylgalactosaminyltransferase; transferase B, alpha 1-3-galactosyltransferase) (EC:2.4.1.37 2.4.1.40) |
| 754 | N | N | N | N | Tartaric acid
| PCCA | 0.50000 | Threonine
| 0.019995 | ACP1: acid phosphatase 1, soluble (EC:3.1.3.2 3.1.3.48) |
| 755 | N | N | N | N | Vesnarinone
| CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) | 0.51282 | Aripiprazole
| 0.031325 | PDE6G: phosphodiesterase 6G, cGMP-specific, rod, gamma (EC:3.1.4.35) |
| 756 | N | N | N | N | Amlexanox
| AKR1B1: aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) | 0.43750 | Ponalrestat
| 0.019822 | EXTL2: exostoses (multiple)-like 2 (EC:2.4.1.223) |
| 757 | N | N | N | N | Clofibrate
| LIPC: lipase, hepatic (EC:3.1.1.3) | 0.32258 | Capecitabine
| 0.41326 | LPL: lipoprotein lipase (EC:3.1.1.34) |
| 758 | N | N | N | N | Palmitic acid
| CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.26667 | Deferoxamine
| 0.79849 | CYP2C8: cytochrome P450, family 2, subfamily C, polypeptide 8 (EC:1.14.14.1) |
| 759 | N | N | N | N | Clozapine
| CYP3A5: cytochrome P450, family 3, subfamily A, polypeptide 5 (EC:1.14.14.1) | 0.45161 | Alprazolam
| 0.86492 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 760 | N | N | N | N | Itopride hydrochloride
| F2: coagulation factor II (thrombin) (EC:3.4.21.5) | 0.48571 | Dibucaine
| 0.015532 | BCHE: butyrylcholinesterase (EC:3.1.1.8) |
| 761 | N | N | Y | N | Diazepam
| CYP1A2: cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) | 0.68000 | Alprazolam
| 0.21271 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 762 | N | N | N | N | Dalvastatin
| ACHE: acetylcholinesterase (EC:3.1.1.7) | 0.35135 | Galantamine hydrobromide
| 0.012045 | HMGCR: 3-hydroxy-3-methylglutaryl-CoA reductase (EC:1.1.1.34) |
| 763 | N | N | N | N | Metyrosine
| ALOX5: arachidonate 5-lipoxygenase (EC:1.13.11.34) | 0.61111 | Ibuprofen
| 0.016413 | TH: tyrosine hydroxylase (EC:1.14.16.2) |
| 764 | N | Y | Y | N | Mesalamine
| MPO | 0.75000 | Salicylic acid
| 0.039978 | PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) |
| 765 | N | N | N | N | Penicillamine
| VARS2: valyl-tRNA synthetase 2, mitochondrial (EC:6.1.1.9) | 0.70000 | Valine
| 0.012934 | CASP1: caspase 1, apoptosis-related cysteine peptidase (EC:3.4.22.36) |
| 766 | N | N | N | N | Methotrexate
| ACE: angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 (EC:3.4.15.1) | 0.43182 | Quinaprilat
| 0.019584 | DHFR: dihydrofolate reductase (EC:1.5.1.3) |
| 767 | N | N | N | N | Omeprazole
| DHFR: dihydrofolate reductase (EC:1.5.1.3) | 0.45714 | Trimetrexate
 | 0.015653 | ATP4A: ATPase, H+/K+ exchanging, alpha polypeptide (EC:3.6.3.10) |
| 768 | N | N | Y | N | Carbamazepine
| CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.48148 | Trimipramine
| 0.79849 | CYP2C8: cytochrome P450, family 2, subfamily C, polypeptide 8 (EC:1.14.14.1) |
| 769 | N | Y | N | N | Bendroflumethiazide
| CA13: carbonic anhydrase XIII (EC:4.2.1.1) | 0.51724 | Hydrochlorothiazide
| 0.63871 | CA1: carbonic anhydrase I (EC:4.2.1.1) |
| 770 | N | N | N | N | Tilmacoxib
| CA2: carbonic anhydrase II (EC:4.2.1.1) | 0.38710 | Methyclothiazide
| 0.018944 | PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) |
| 771 | N | N | N | N | Natamycin
| ACAA1: acetyl-CoA acyltransferase 1 (EC:2.3.1.16) | 0.10345 | Idoxuridine
| 0.015455 | ABO: ABO blood group (transferase A, alpha 1-3-N-acetylgalactosaminyltransferase; transferase B, alpha 1-3-galactosyltransferase) (EC:2.4.1.37 2.4.1.40) |
| 772 | N | N | N | N | Perphenazine
| CYP3A5: cytochrome P450, family 3, subfamily A, polypeptide 5 (EC:1.14.14.1) | 0.36111 | Alprazolam
| 0.86492 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 773 | N | N | N | N | Niacinamide
| QPRT: quinolinate phosphoribosyltransferase (EC:2.4.2.19) | 0.50000 | Niacin
| 0.024869 | BST1: bone marrow stromal cell antigen 1 (EC:3.2.2.5) |
| 774 | N | N | N | N | Medrysone
| CYP19A1: cytochrome P450, family 19, subfamily A, polypeptide 1 (EC:1.14.14.1) | 0.46875 | Testolactone
| 0.014633 | PLA2G4A: phospholipase A2, group IVA (cytosolic, calcium-dependent) (EC:3.1.1.5 3.1.1.4) |
| 775 | N | N | N | N | Nepicastat hydrochloride
 | AKR1B1: aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) | 0.36111 | Lidorestat
| 0.025245 | DBH: dopamine beta-hydroxylase (dopamine beta-monooxygenase) (EC:1.14.17.1) |
| 776 | N | N | N | N | Bisoprolol
| HMGCR: 3-hydroxy-3-methylglutaryl-CoA reductase (EC:1.1.1.34) | 0.46154 | Cerivastatin sodium
 | 0.011980 | CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) |
| 777 | N | N | N | N | Phenacetin
| SULT1A2: sulfotransferase family, cytosolic, 1A, phenol-preferring, member 2 (EC:2.8.2.1) | 0.71429 | Acetaminophen
| 0.021243 | CYP1A1: cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) |
| 778 | N | N | N | N | Alvocidib hydrochloride
| MAPK3: mitogen-activated protein kinase 3 (EC:2.7.11.24) | 0.31579 | Fasudil hydrochloride
| 0.30392 | CDK2: cyclin-dependent kinase 2 (EC:2.7.11.22) |
| 779 | N | N | N | N | Minalrestat
| CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.41176 | Diazepam
| 0.020573 | AKR1B1: aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) |
| 780 | N | N | N | N | Citric acid, anhydrous
| IDE: insulin-degrading enzyme (EC:3.4.24.56) | 0.50000 | Edetic acid
| 0.020381 | MIF: macrophage migration inhibitory factor (glycosylation-inhibiting factor) (EC:5.3.3.12 5.3.2.1) |
| 781 | N | N | N | N | Floxuridine
| TK2: thymidine kinase 2, mitochondrial (EC:2.7.1.21) | 0.44444 | Fluorouracil
| 0.025147 | TYMS: thymidylate synthetase (EC:2.1.1.45) |
| 782 | N | N | N | N | Deferoxamine
| WARS: tryptophanyl-tRNA synthetase (EC:6.1.1.2) | 0.041667 | Propylthiouracil
| 0.027023 | PRDX1: peroxiredoxin 1 (EC:1.11.1.15) |
| 783 | N | N | N | N | Mycophenolate mofetil
 | ACHE: acetylcholinesterase (EC:3.1.1.7) | 0.33333 | Donepezil hydrochloride
| 0.015455 | IMPDH1: IMP (inosine 5'-monophosphate) dehydrogenase 1 (EC:1.1.1.205) |
| 784 | N | N | N | N | Zileuton
| CA1: carbonic anhydrase I (EC:4.2.1.1) | 0.39130 | Ethoxzolamide
| 0.020347 | ALOX5: arachidonate 5-lipoxygenase (EC:1.13.11.34) |
| 785 | N | N | N | N | Salicylic acid
| PRDX3: peroxiredoxin 3 (EC:1.11.1.15) | 0.31250 | Acetaminophen
| 0.022175 | IKBKB: inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta (EC:2.7.11.10) |
| 786 | N | N | N | N | Menadione
| PRSS2: protease, serine, 2 (trypsin 2) (EC:3.4.21.4) | 0.043478 | Isoflurophate
| 0.26545 | F9: coagulation factor IX (EC:3.4.21.22) |
| 787 | N | N | N | N | Nicotine
| CYP2J2: cytochrome P450, family 2, subfamily J, polypeptide 2 (EC:1.14.14.1) | 0.36364 | Fadrozole hydrochloride
| 0.39990 | CYP2A13: cytochrome P450, family 2, subfamily A, polypeptide 13 (EC:1.14.14.1) |
| 788 | N | N | N | N | Threonine
| PC: pyruvate carboxylase (EC:6.4.1.1) | 0.14286 | Biotin
| 0.21172 | PCCA |
| 789 | N | N | N | N | Nalidixic acid
 | ACAA1: acetyl-CoA acyltransferase 1 (EC:2.3.1.16) | 0.37500 | Acyclovir
| 0.013773 | TOP2B: topoisomerase (DNA) II beta 180kDa (EC:5.99.1.3) |
| 790 | N | N | N | N | Penicillamine
| ALDH6A1: aldehyde dehydrogenase 6 family, member A1 (EC:1.2.1.27 1.2.1.18) | 0.70000 | Valine
| 0.017036 | CASP1: caspase 1, apoptosis-related cysteine peptidase (EC:3.4.22.36) |
| 791 | N | N | N | N | Diazepam
| CYP2E1: cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) | 0.68000 | Alprazolam
| 0.60720 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 792 | N | Y | N | N | Deferoxamine
| GPX2: glutathione peroxidase 2 (gastrointestinal) (EC:1.11.1.9) | 0.035088 | Diethylstilbestrol
| 0.035543 | DIO1: deiodinase, iodothyronine, type I (EC:1.97.1.10) |
| 793 | N | N | N | N | Zaleplon
| CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.42857 | Metyrapone
| 0.012339 | ACOX1: acyl-CoA oxidase 1, palmitoyl (EC:1.3.3.6) |
| 794 | N | N | N | N | Phenacetin
| DIO1: deiodinase, iodothyronine, type I (EC:1.97.1.10) | 0.71429 | Acetaminophen
| 0.023799 | CYP1A1: cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) |
| 795 | N | N | N | N | Phenacetin
| DIO2: deiodinase, iodothyronine, type II (EC:1.97.1.10) | 0.71429 | Acetaminophen
| 0.024453 | CYP1A1: cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) |
| 796 | N | N | N | N | Niacinamide
| NNMT | 0.50000 | Niacin
| 0.024112 | BST1: bone marrow stromal cell antigen 1 (EC:3.2.2.5) |
| 797 | N | N | N | N | Flavin adenine dinucleotide
| ADCY1: adenylate cyclase 1 (brain) (EC:4.6.1.1) | 0.49266 | Nadide
| 0.019744 | ACADS: acyl-CoA dehydrogenase, C-2 to C-3 short chain (EC:1.3.8.1) |
| 798 | N | N | N | N | Valacyclovir hydrochloride
| DHFR: dihydrofolate reductase (EC:1.5.1.3) | 0.32353 | Trimethoprim
| 0.024139 | ACAA1: acetyl-CoA acyltransferase 1 (EC:2.3.1.16) |
| 799 | N | N | N | N | Icopezil maleate
| ACE: angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 (EC:3.4.15.1) | 0.44444 | Benazeprilat
| 0.011580 | ACHE: acetylcholinesterase (EC:3.1.1.7) |
| 800 | N | N | N | N | Acetohexamide
| CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.53846 | Tolbutamide
| 0.017405 | DCXR: dicarbonyl/L-xylulose reductase (EC:1.1.1.10) |
| 801 | N | N | N | N | Ethinamate
| CA3: carbonic anhydrase III, muscle specific (EC:4.2.1.1) | 0.10000 | Sezolamide hydrochloride
| 0.60142 | CA2: carbonic anhydrase II (EC:4.2.1.1) |
| 802 | N | N | Y | N | Rosiglitazone maleate
| CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.31579 | Aminoglutethimide
| 0.79849 | CYP2C8: cytochrome P450, family 2, subfamily C, polypeptide 8 (EC:1.14.14.1) |
| 803 | N | N | N | N | Gulutamine
| PCCB | 0.46154 | Isoleucine
| 0.038514 | ACACA: acetyl-CoA carboxylase alpha (EC:6.4.1.2 6.3.4.14) |
| 804 | N | N | N | N | Citric acid, anhydrous
| MME: membrane metallo-endopeptidase (EC:3.4.24.11) | 0.50000 | Edetic acid
| 0.023860 | MIF: macrophage migration inhibitory factor (glycosylation-inhibiting factor) (EC:5.3.3.12 5.3.2.1) |
| 805 | N | N | N | N | Loratadine
| CYP3A43 | 0.36111 | Alprazolam
| 0.78013 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 806 | N | N | N | N | Cilomilast
 | ACE: angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 (EC:3.4.15.1) | 0.36585 | Cilazapril
 | 0.016550 | PDE6H: phosphodiesterase 6H, cGMP-specific, cone, gamma (EC:3.1.4.35) |
| 807 | N | N | N | N | Fluorouracil
| ACAA1: acetyl-CoA acyltransferase 1 (EC:2.3.1.16) | 0.44444 | Idoxuridine
| 0.023384 | DPYD: dihydropyrimidine dehydrogenase (EC:1.3.1.2) |
| 808 | N | N | N | N | Demecarium bromide
| CEL: carboxyl ester lipase (bile salt-stimulated lipase) (EC:3.1.1.13 3.1.1.3) | 0.26230 | Orlistat
| 0.20493 | BCHE: butyrylcholinesterase (EC:3.1.1.8) |
| 809 | N | N | N | N | Metoclopramide
| ACHE: acetylcholinesterase (EC:3.1.1.7) | 0.42424 | Itopride hydrochloride
| 0.013404 | TRIM32: tripartite motif containing 32 |
| 810 | N | N | N | N | Eletriptan hydrobromide
| CA1: carbonic anhydrase I (EC:4.2.1.1) | 0.41026 | Bendroflumethiazide
| 0.019360 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 811 | N | N | N | N | Sodium salicylate
| IKBKB: inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta (EC:2.7.11.10) | 0.75000 | Salicylic acid
| 0.012624 | PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) |
| 812 | N | N | N | N | Salicylic acid
| PRDX4: peroxiredoxin 4 (EC:1.11.1.15) | 0.31250 | Acetaminophen
| 0.026876 | IKBKB: inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta (EC:2.7.11.10) |
| 813 | N | N | N | N | Capecitabine
| CMPK1: cytidine monophosphate (UMP-CMP) kinase 1, cytosolic (EC:2.7.4.14) | 0.43333 | Gemcitabine
| 0.052896 | PLA2G10: phospholipase A2, group X (EC:3.1.1.4) |
| 814 | N | N | N | N | Carbamazepine
| CYP3A43 | 0.48148 | Trimipramine
| 0.78013 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 815 | N | N | N | N | Salicylic acid
| TPMT | 0.75000 | Mesalamine
| 0.023321 | ALOX15B: arachidonate 15-lipoxygenase, type B (EC:1.13.11.33) |
| 816 | N | Y | N | N | Deferoxamine
| GPX1: glutathione peroxidase 1 (EC:1.11.1.9) | 0.035088 | Diethylstilbestrol
| 0.039142 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 817 | N | N | N | N | Phenytoin
| LALBA | 0.50000 | Phenylbutazone
| 0.024483 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 818 | N | N | N | N | Sulfinpyrazone
| PTGIS: prostaglandin I2 (prostacyclin) synthase (EC:5.3.99.4) | 0.67742 | Phenylbutazone
| 0.017473 | PTGS2: prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) |
| 819 | N | N | N | N | Benazeprilat
| AKR1B1: aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) | 0.43243 | Ponalrestat
| 0.014328 | ACE: angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 (EC:3.4.15.1) |
| 820 | N | N | N | N | Phenylalanine
| PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) | 0.57143 | Salicylic acid
| 0.018618 | FARS2: phenylalanyl-tRNA synthetase 2, mitochondrial (EC:6.1.1.20) |
| 821 | N | N | N | N | Deferoxamine
| REN: renin (EC:3.4.23.15) | 0.21875 | Aliskiren
 | 0.025435 | PRDX1: peroxiredoxin 1 (EC:1.11.1.15) |
| 822 | N | N | N | N | Topiramate
| PLA2G4A: phospholipase A2, group IVA (cytosolic, calcium-dependent) (EC:3.1.1.5 3.1.1.4) | 0.26190 | Flurandrenolide
 | 0.018276 | CA2: carbonic anhydrase II (EC:4.2.1.1) |
| 823 | N | N | N | N | Tranexamic acid
| F12: coagulation factor XII (Hageman factor) (EC:3.4.21.38) | 0.33333 | Aminocaproic acid
| 0.24070 | PLAU: plasminogen activator, urokinase (EC:3.4.21.73) |
| 824 | N | N | N | N | Phenacetin
| PRDX1: peroxiredoxin 1 (EC:1.11.1.15) | 0.71429 | Acetaminophen
| 0.029947 | CYP1A1: cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) |
| 825 | N | N | Y | N | Methotrexate sodium
| FPGS | 0.73684 | Folic acid
| 0.019512 | DHFR: dihydrofolate reductase (EC:1.5.1.3) |
| 826 | N | Y | N | N | Deferoxamine
| GPX3: glutathione peroxidase 3 (plasma) (EC:1.11.1.9) | 0.035088 | Diethylstilbestrol
| 0.038088 | PRDX1: peroxiredoxin 1 (EC:1.11.1.15) |
| 827 | N | N | N | N | Testolactone
| HMGCR: 3-hydroxy-3-methylglutaryl-CoA reductase (EC:1.1.1.34) | 0.37838 | Lovastatin
| 0.013159 | CYP19A1: cytochrome P450, family 19, subfamily A, polypeptide 1 (EC:1.14.14.1) |
| 828 | N | N | N | N | Milrinone
| CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) | 0.36000 | Fadrozole hydrochloride
| 0.031325 | PDE6G: phosphodiesterase 6G, cGMP-specific, rod, gamma (EC:3.1.4.35) |
| 829 | N | N | N | N | Diphenhydramine
| F2: coagulation factor II (thrombin) (EC:3.4.21.5) | 0.56000 | Promethazine
| 0.014876 | CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) |
| 830 | N | N | N | N | Uracil
| WARS: tryptophanyl-tRNA synthetase (EC:6.1.1.2) | 0.46154 | Propylthiouracil
| 0.012027 | DPYD: dihydropyrimidine dehydrogenase (EC:1.3.1.2) |
| 831 | N | N | N | N | Orlistat
| AADAC: arylacetamide deacetylase (EC:3.1.1.3) | 0.20000 | Capecitabine
| 0.040389 | CEL: carboxyl ester lipase (bile salt-stimulated lipase) (EC:3.1.1.13 3.1.1.3) |
| 832 | N | N | N | N | Docebenone
| LTA4H | 0.17500 | Phenylbutazone
| 0.013786 | ALOX5: arachidonate 5-lipoxygenase (EC:1.13.11.34) |
| 833 | N | N | N | N | Digoxin
| PLA2G4A: phospholipase A2, group IVA (cytosolic, calcium-dependent) (EC:3.1.1.5 3.1.1.4) | 0.31848 | Flunisolide
| 0.011338 | ATP1A1 |
| 834 | N | N | N | N | Diazoxide
| CA3: carbonic anhydrase III, muscle specific (EC:4.2.1.1) | 0.47619 | Chlorothiazide
| 0.60142 | CA2: carbonic anhydrase II (EC:4.2.1.1) |
| 835 | N | N | N | N | Phenacetin
| DIO3: deiodinase, iodothyronine, type III (EC:1.97.1.11) | 0.71429 | Acetaminophen
| 0.020169 | CYP1A2: cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) |
| 836 | N | N | N | N | Sodium salicylate
| EPX: eosinophil peroxidase (EC:1.11.1.7) | 0.75000 | Salicylic acid
| 0.037469 | PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) |
| 837 | N | N | N | N | Felbamate
| ACE: angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 (EC:3.4.15.1) | 0.32258 | Pentopril
 | 0.010985 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 838 | N | N | Y | N | Cladribine
| POLA1: polymerase (DNA directed), alpha 1, catalytic subunit (EC:2.7.7.7) | 0.65385 | Fludarabine phosphate
| 0.014682 | PNP: purine nucleoside phosphorylase (EC:2.4.2.1) |
| 839 | N | N | N | N | Sulfinpyrazone
| LALBA | 0.67742 | Phenylbutazone
| 0.024348 | PTGS2: prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) |
| 840 | N | N | N | N | Tranexamic acid
| BCAT1: branched chain amino-acid transaminase 1, cytosolic (EC:2.6.1.42) | 0.64286 | Gabapentin
| 0.018257 | PLAU: plasminogen activator, urokinase (EC:3.4.21.73) |
| 841 | N | N | N | N | Orlistat
| ESD: esterase D (EC:3.1.2.12 3.1.1.56) | 0.20000 | Capecitabine
| 0.042052 | PNLIP: pancreatic lipase (EC:3.1.1.3) |
| 842 | N | N | Y | N | Ibuprofen
| CYP2C8: cytochrome P450, family 2, subfamily C, polypeptide 8 (EC:1.14.14.1) | 0.32000 | Tolbutamide
| 0.79849 | CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 843 | N | N | N | N | Amphotericin B
 | ACAA1: acetyl-CoA acyltransferase 1 (EC:2.3.1.16) | 0.078947 | Idoxuridine
| 0.015455 | ABO: ABO blood group (transferase A, alpha 1-3-N-acetylgalactosaminyltransferase; transferase B, alpha 1-3-galactosyltransferase) (EC:2.4.1.37 2.4.1.40) |
| 844 | N | N | N | N | Mesalamine
| LPO: lactoperoxidase (EC:1.11.1.7) | 0.75000 | Salicylic acid
| 0.046083 | PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) |
| 845 | N | N | N | N | Methoxsalen
| HSD11B1: hydroxysteroid (11-beta) dehydrogenase 1 (EC:1.1.1.146) | 0.32000 | Metyrapone
| 0.027887 | CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 846 | N | N | N | N | Metyrapone
| DHRS4: dehydrogenase/reductase (SDR family) member 4 (EC:1.1.1.184) | 0.20000 | Menadione
| 0.22812 | DCXR: dicarbonyl/L-xylulose reductase (EC:1.1.1.10) |
| 847 | N | N | N | N | Floxuridine
| UMPS: uridine monophosphate synthetase (EC:2.4.2.10 4.1.1.23) | 0.44444 | Fluorouracil
| 0.017797 | TYMS: thymidylate synthetase (EC:2.1.1.45) |
| 848 | N | N | N | N | Phenacetin
| PRDX3: peroxiredoxin 3 (EC:1.11.1.15) | 0.71429 | Acetaminophen
| 0.025920 | CYP1A2: cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) |
| 849 | N | N | N | N | Adenosine phosphate
| NT5C2: 5'-nucleotidase, cytosolic II (EC:3.1.3.5) | 0.48148 | Ribavirin
| 0.027486 | APRT: adenine phosphoribosyltransferase (EC:2.4.2.7) |
| 850 | N | N | N | N | Tilmacoxib
| CA4: carbonic anhydrase IV (EC:4.2.1.1) | 0.38710 | Methyclothiazide
| 0.018312 | PTGS2: prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) |
| 851 | N | N | N | N | Dibucaine
| TRIM32: tripartite motif containing 32 | 0.55172 | Metoclopramide
| 0.012824 | F2: coagulation factor II (thrombin) (EC:3.4.21.5) |
| 852 | N | N | N | N | Peramivir
 | ACE: angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 (EC:3.4.15.1) | 0.36842 | Perindopril
 | 0.013549 | NEU2: sialidase 2 (cytosolic sialidase) (EC:3.2.1.18) |
| 853 | N | N | N | N | Irinotecan hydrochloride
 | TOP2B: topoisomerase (DNA) II beta 180kDa (EC:5.99.1.3) | 0.29578 | Pirarubicin
 | 0.016108 | TOP1: topoisomerase (DNA) I (EC:5.99.1.2) |
| 854 | N | N | Y | N | Nicotine
| CYP2C8: cytochrome P450, family 2, subfamily C, polypeptide 8 (EC:1.14.14.1) | 0.36364 | Fadrozole hydrochloride
| 0.51420 | CYP2A13: cytochrome P450, family 2, subfamily A, polypeptide 13 (EC:1.14.14.1) |
| 855 | N | N | N | N | Dichlorphenamide
 | DHFR: dihydrofolate reductase (EC:1.5.1.3) | 0.30769 | Proguanil hydrochloride
 | 0.037935 | CA7: carbonic anhydrase VII (EC:4.2.1.1) |
| 856 | N | N | N | N | Diazoxide
| CYP1A2: cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) | 0.47059 | Chlorzoxazone
| 0.023687 | CA4: carbonic anhydrase IV (EC:4.2.1.1) |
| 857 | N | N | N | N | Methoxyflurane
| CYP2A7: cytochrome P450, family 2, subfamily A, polypeptide 7 (EC:1.14.14.1) | 0.66667 | Halothane
| 0.46889 | CYP2E1: cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) |
| 858 | N | N | N | N | Chlorzoxazone
| CYP2S1 | 0.32000 | Alprazolam
| 0.47181 | CYP2A7: cytochrome P450, family 2, subfamily A, polypeptide 7 (EC:1.14.14.1) |
| 859 | N | N | N | N | Rasagiline mesylate
 | CA1: carbonic anhydrase I (EC:4.2.1.1) | 0.39130 | Zonisamide
 | 0.021288 | MAOB |
| 860 | N | N | N | N | Floxuridine
| TK1: thymidine kinase 1, soluble (EC:2.7.1.21) | 0.44444 | Fluorouracil
| 0.020371 | TYMS: thymidylate synthetase (EC:2.1.1.45) |
| 861 | N | N | N | N | Methimazole
| PRDX5: peroxiredoxin 5 (EC:1.11.1.15) | 0.23077 | Benzoic acid
| 0.036495 | DIO2: deiodinase, iodothyronine, type II (EC:1.97.1.10) |
| 862 | N | N | N | N | Phenacetin
| PRDX4: peroxiredoxin 4 (EC:1.11.1.15) | 0.71429 | Acetaminophen
| 0.022575 | CYP1A1: cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) |
| 863 | N | N | N | N | Nadide
| GCDH: glutaryl-CoA dehydrogenase (EC:1.3.8.6) | 0.49266 | Flavin adenine dinucleotide
| 0.026792 | HSD17B1: hydroxysteroid (17-beta) dehydrogenase 1 (EC:1.1.1.62) |
| 864 | N | N | Y | N | Naproxen
| CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.52381 | Ibuprofen
| 0.022367 | PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) |
| 865 | N | N | N | N | Orotic acid
| TYMS: thymidylate synthetase (EC:2.1.1.45) | 0.42857 | Fluorouracil
| 0.022878 | DHODH: dihydroorotate dehydrogenase (quinone) (EC:1.3.5.2) |
| 866 | N | N | N | N | Sodium salicylate
| LPO: lactoperoxidase (EC:1.11.1.7) | 0.75000 | Salicylic acid
| 0.046083 | PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) |
| 867 | N | N | N | N | Phenylalanine
| HARS: histidyl-tRNA synthetase (EC:6.1.1.21) | 0.64286 | Histidine
| 0.025739 | FARSA: phenylalanyl-tRNA synthetase, alpha subunit (EC:6.1.1.20) |
| 868 | N | N | N | N | Irinotecan hydrochloride
| TOP2A: topoisomerase (DNA) II alpha 170kDa (EC:5.99.1.3) | 0.29578 | Pirarubicin
| 0.015780 | TOP1: topoisomerase (DNA) I (EC:5.99.1.2) |
| 869 | N | N | N | N | Midazolam
| CYP1A2: cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) | 0.80000 | Alprazolam
| 0.11769 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 870 | N | N | N | N | Floxuridine
| UPP2: uridine phosphorylase 2 (EC:2.4.2.3) | 0.44444 | Fluorouracil
| 0.019017 | TYMS: thymidylate synthetase (EC:2.1.1.45) |
| 871 | N | N | N | N | Tipifarnib
| CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.48077 | Liarozole hydrochloride
| 0.022891 | FNTA: farnesyltransferase, CAAX box, alpha (EC:2.5.1.59 2.5.1.58) |
| 872 | Y | N | N | N | Pimobendan
 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.50000 | Diazepam
| 0.029363 | PDE6G: phosphodiesterase 6G, cGMP-specific, rod, gamma (EC:3.1.4.35) |
| 873 | N | N | N | N | Vigabatrin
| ACACA: acetyl-CoA carboxylase alpha (EC:6.4.1.2 6.3.4.14) | 0.58333 | Gulutamine
| 0.010208 | ABAT: 4-aminobutyrate aminotransferase (EC:2.6.1.19 2.6.1.22) |
| 874 | N | N | N | N | Mesalamine
| EPX: eosinophil peroxidase (EC:1.11.1.7) | 0.75000 | Salicylic acid
| 0.037469 | PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) |
| 875 | N | N | N | N | Promethazine
| CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.75000 | Trimipramine
| 0.012581 | F2: coagulation factor II (thrombin) (EC:3.4.21.5) |
| 876 | N | N | N | N | Libenzapril
 | AKR1B1: aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) | 0.37143 | Risarestat
| 0.014328 | ACE: angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 (EC:3.4.15.1) |
| 877 | N | N | N | N | Niacin
| BST1: bone marrow stromal cell antigen 1 (EC:3.2.2.5) | 0.50000 | Niacinamide
| 0.024869 | QPRT: quinolinate phosphoribosyltransferase (EC:2.4.2.19) |
| 878 | N | N | N | N | Sivelestat
| PTGS2: prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) | 0.51282 | Acemetacin
 | 0.016750 | ELANE: elastase, neutrophil expressed (EC:3.4.21.37) |
| 879 | N | N | N | N | Miconazole
| ABO: ABO blood group (transferase A, alpha 1-3-N-acetylgalactosaminyltransferase; transferase B, alpha 1-3-galactosyltransferase) (EC:2.4.1.37 2.4.1.40) | 0.77419 | Oxiconazole nitrate
| 0.020169 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 880 | N | N | N | N | Triazolam
| CYP3A43 | 0.87500 | Alprazolam
| 0.78013 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 881 | N | N | N | N | Phenylalanine
| HAL: histidine ammonia-lyase (EC:4.3.1.3) | 0.64286 | Histidine
| 0.018860 | FARS2: phenylalanyl-tRNA synthetase 2, mitochondrial (EC:6.1.1.20) |
| 882 | N | N | N | N | Leucovorin calcium
 | DHFR: dihydrofolate reductase (EC:1.5.1.3) | 0.56818 | Methotrexate sodium
| 0.028456 | TYMS: thymidylate synthetase (EC:2.1.1.45) |
| 883 | N | N | N | N | Vigabatrin
| GLUD1: glutamate dehydrogenase 1 (EC:1.4.1.3) | 0.58333 | Gulutamine
| 0.012100 | ABAT: 4-aminobutyrate aminotransferase (EC:2.6.1.19 2.6.1.22) |
| 884 | N | N | Y | N | Miconazole
| CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) | 0.54839 | Liarozole hydrochloride
| 0.35919 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 885 | N | N | N | N | Salicylic acid
| PRDX1: peroxiredoxin 1 (EC:1.11.1.15) | 0.31250 | Acetaminophen
| 0.027451 | IKBKB: inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta (EC:2.7.11.10) |
| 886 | N | N | N | N | Leucovorin calcium
| ACE: angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 (EC:3.4.15.1) | 0.37500 | Lisinopril
 | 0.011056 | TYMS: thymidylate synthetase (EC:2.1.1.45) |
| 887 | N | N | Y | N | Olanzapine
| CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.60714 | Clozapine
| 0.35919 | CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) |
| 888 | N | N | N | N | Tretinoin
| ALDH7A1: aldehyde dehydrogenase 7 family, member A1 (EC:1.2.1.3 1.2.1.8 1.2.1.31) | 0.15152 | Disulfiram
| 0.22151 | ALDH1A2: aldehyde dehydrogenase 1 family, member A2 (EC:1.2.1.36) |
| 889 | N | N | N | N | Acarbose
 | ATP1A1 | 0.36651 | Deslanoside
| 0.011908 | AMY2A: amylase, alpha 2A (pancreatic) (EC:3.2.1.1) |
| 890 | N | N | N | N | Floxuridine
| UPP1: uridine phosphorylase 1 (EC:2.4.2.3) | 0.44444 | Fluorouracil
| 0.017560 | TYMS: thymidylate synthetase (EC:2.1.1.45) |
| 891 | N | N | N | N | Terbinafine
 | ACHE: acetylcholinesterase (EC:3.1.1.7) | 0.37931 | Rivastigmine
| 0.013938 | SQLE: squalene epoxidase (EC:1.14.13.132) |
| 892 | N | N | N | N | Lovastatin
| PLA2G4A: phospholipase A2, group IVA (cytosolic, calcium-dependent) (EC:3.1.1.5 3.1.1.4) | 0.36170 | Fluocinonide
 | 0.0098159 | HMGCR: 3-hydroxy-3-methylglutaryl-CoA reductase (EC:1.1.1.34) |
| 893 | N | N | N | N | Indomethacin
| PDE7A: phosphodiesterase 7A (EC:3.1.4.17) | 0.38889 | Pimobendan
| 0.018778 | ALOX15: arachidonate 15-lipoxygenase (EC:1.13.11.33) |
| 894 | N | N | N | N | Pantoprazole
| CA1: carbonic anhydrase I (EC:4.2.1.1) | 0.37209 | Verapamil
| 0.021147 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 895 | N | N | N | N | Haloperidol
| HSD11B1: hydroxysteroid (11-beta) dehydrogenase 1 (EC:1.1.1.146) | 0.30303 | Metyrapone
| 0.10272 | DCXR: dicarbonyl/L-xylulose reductase (EC:1.1.1.10) |
| 896 | N | N | N | N | Midazolam
| CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.80000 | Alprazolam
| 0.14915 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 897 | N | N | N | N | Methoxyflurane
| CYP1A1: cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) | 0.66667 | Halothane
| 0.24083 | CYP2E1: cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) |
| 898 | N | N | N | N | Exatecan mesylate
 | TOP2B: topoisomerase (DNA) II beta 180kDa (EC:5.99.1.3) | 0.30000 | Daunorubicin hydrochloride
| 0.016108 | TOP1: topoisomerase (DNA) I (EC:5.99.1.2) |
| 899 | N | N | N | N | Celgosivir hydrochloride
| HMGCR: 3-hydroxy-3-methylglutaryl-CoA reductase (EC:1.1.1.34) | 0.37143 | Lovastatin
| 0.012311 | GAA: glucosidase, alpha; acid (EC:3.2.1.20) |
| 900 | N | N | N | N | Olanzapine
| CYP2E1: cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) | 0.37500 | Alprazolam
| 0.35638 | CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) |
| 901 | N | N | N | N | Methoxsalen
| HSD11B2: hydroxysteroid (11-beta) dehydrogenase 2 (EC:1.1.1.146) | 0.32000 | Metyrapone
| 0.029233 | CH25H: cholesterol 25-hydroxylase (EC:1.14.99.38) |
| 902 | N | N | N | N | Phenacetin
| EPX: eosinophil peroxidase (EC:1.11.1.7) | 0.71429 | Acetaminophen
| 0.014592 | CYP1A2: cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) |
| 903 | N | N | N | N | Nadide
| DAO: D-amino-acid oxidase (EC:1.4.3.3) | 0.49266 | Flavin adenine dinucleotide
| 0.031685 | GAPDH: glyceraldehyde-3-phosphate dehydrogenase (EC:1.2.1.12) |
| 904 | N | N | N | N | Cyclothiazide
| CA3: carbonic anhydrase III, muscle specific (EC:4.2.1.1) | 0.64000 | Hydrochlorothiazide
| 0.60142 | CA2: carbonic anhydrase II (EC:4.2.1.1) |
| 905 | N | N | N | N | Nadide
| XDH: xanthine dehydrogenase (EC:1.17.1.4 1.17.3.2) | 0.49266 | Flavin adenine dinucleotide
| 0.020050 | HSD17B1: hydroxysteroid (17-beta) dehydrogenase 1 (EC:1.1.1.62) |
| 906 | N | N | N | N | Benzoic acid
| PRDX1: peroxiredoxin 1 (EC:1.11.1.15) | 0.33333 | Acetaminophen
| 0.095456 | PRDX5: peroxiredoxin 5 (EC:1.11.1.15) |
| 907 | N | N | N | N | Orotic acid
| ACAA1: acetyl-CoA acyltransferase 1 (EC:2.3.1.16) | 0.27273 | Idoxuridine
| 0.021396 | DHODH: dihydroorotate dehydrogenase (quinone) (EC:1.3.5.2) |
| 908 | N | N | N | N | Esomeprazole magnesium
| HMGCR: 3-hydroxy-3-methylglutaryl-CoA reductase (EC:1.1.1.34) | 0.35227 | Rosuvastatin calcium
 | 0.0093394 | ATP4A: ATPase, H+/K+ exchanging, alpha polypeptide (EC:3.6.3.10) |
| 909 | N | N | N | N | Exatecan mesylate
| TOP2A: topoisomerase (DNA) II alpha 170kDa (EC:5.99.1.3) | 0.30000 | Daunorubicin hydrochloride
| 0.015780 | TOP1: topoisomerase (DNA) I (EC:5.99.1.2) |
| 910 | N | N | N | N | Acetohexamide
| AKR1A1: aldo-keto reductase family 1, member A1 (aldehyde reductase) (EC:1.1.1.2) | 0.33333 | Haloperidol
| 0.022436 | DCXR: dicarbonyl/L-xylulose reductase (EC:1.1.1.10) |
| 911 | N | N | N | N | Raltitrexed
| AKR1B1: aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) | 0.40000 | Ponalrestat
| 0.021810 | TYMS: thymidylate synthetase (EC:2.1.1.45) |
| 912 | N | N | Y | N | Verapamil
| CYP2C18: cytochrome P450, family 2, subfamily C, polypeptide 18 (EC:1.14.14.1) | 0.37500 | Trimipramine
| 0.79843 | CYP2C8: cytochrome P450, family 2, subfamily C, polypeptide 8 (EC:1.14.14.1) |
| 913 | N | N | N | N | Pranoprofen
 | CYP1A2: cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) | 0.50000 | Mirtazapine
| 0.013912 | PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) |
| 914 | N | N | N | N | Phenylalanine
| HDC: histidine decarboxylase (EC:4.1.1.22) | 0.64286 | Histidine
| 0.017394 | FARS2: phenylalanyl-tRNA synthetase 2, mitochondrial (EC:6.1.1.20) |
| 915 | N | N | N | N | Salicylamide
| MPO | 0.53846 | Salicylic acid
| 0.039978 | PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) |
| 916 | N | N | N | N | Selegiline hydrochloride
 | ACHE: acetylcholinesterase (EC:3.1.1.7) | 0.47368 | Edrophonium chloride
| 0.013318 | MAOA: monoamine oxidase A (EC:1.4.3.4) |
| 917 | N | N | N | N | Flavin adenine dinucleotide
| BLVRB: biliverdin reductase B (flavin reductase (NADPH)) (EC:1.3.1.24 1.5.1.30) | 0.48148 | Riboflavin
| 0.040923 | DAO: D-amino-acid oxidase (EC:1.4.3.3) |
| 918 | N | N | N | N | Fluorouracil
| DCK | 0.22727 | Gemcitabine
| 0.23118 | TK2: thymidine kinase 2, mitochondrial (EC:2.7.1.21) |
| 919 | N | N | N | N | Profenamine hydrochloride
| ACE: angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 (EC:3.4.15.1) | 0.44737 | Benazepril hydrochloride
| 0.013064 | BCHE: butyrylcholinesterase (EC:3.1.1.8) |
| 920 | N | N | N | N | Phenacetin
| MPO | 0.71429 | Acetaminophen
| 0.021732 | CYP1A1: cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) |
| 921 | N | N | Y | N | Celecoxib
| CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.42105 | Eletriptan hydrobromide
| 0.14915 | CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 922 | N | N | N | N | Perphenazine
| TRIM32: tripartite motif containing 32 | 0.61290 | Clozapine
| 0.014311 | CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) |
| 923 | N | N | N | N | Phenacetin
| LPO: lactoperoxidase (EC:1.11.1.7) | 0.71429 | Acetaminophen
| 0.013853 | CYP1A2: cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) |
| 924 | N | N | N | N | Orlistat
| PAFAH1B3: platelet-activating factor acetylhydrolase 1b, catalytic subunit 3 (29kDa) (EC:3.1.1.47) | 0.20000 | Capecitabine
| 0.025172 | LIPA: lipase A, lysosomal acid, cholesterol esterase (EC:3.1.1.13) |
| 925 | N | N | N | N | Tacrine hydrochloride
| CA1: carbonic anhydrase I (EC:4.2.1.1) | 0.36364 | Diazoxide
| 0.018213 | ACHE: acetylcholinesterase (EC:3.1.1.7) |
| 926 | N | N | N | N | Flavin adenine dinucleotide
| RFK: riboflavin kinase (EC:2.7.1.26) | 0.48148 | Riboflavin
| 0.036571 | NQO1: NAD(P)H dehydrogenase, quinone 1 (EC:1.6.5.2) |
| 927 | N | N | N | N | Anastrozole
| CYP4A11: cytochrome P450, family 4, subfamily A, polypeptide 11 (EC:1.14.15.3) | 0.34483 | Metyrapone
| 0.50873 | CYP4B1: cytochrome P450, family 4, subfamily B, polypeptide 1 (EC:1.14.14.1) |
| 928 | N | N | N | N | Sulfasalazine
| MPO | 0.33333 | Diethylstilbestrol
| 0.016875 | NAT2: N-acetyltransferase 2 (arylamine N-acetyltransferase) (EC:2.3.1.5) |
| 929 | N | N | N | N | Mycophenolate mofetil
| NT5C2: 5'-nucleotidase, cytosolic II (EC:3.1.3.5) | 0.24390 | Pentoxifylline
| 0.014870 | IMPDH1: IMP (inosine 5'-monophosphate) dehydrogenase 1 (EC:1.1.1.205) |
| 930 | N | N | N | N | Benzoic acid
| PRDX3: peroxiredoxin 3 (EC:1.11.1.15) | 0.33333 | Acetaminophen
| 0.091240 | PRDX5: peroxiredoxin 5 (EC:1.11.1.15) |
| 931 | N | N | N | N | Capecitabine
| DCK | 0.43333 | Gemcitabine
| 0.034332 | PLA2G2D: phospholipase A2, group IID (EC:3.1.1.4) |
| 932 | N | N | N | N | Riboflavin
| DPYD: dihydropyrimidine dehydrogenase (EC:1.3.1.2) | 0.48148 | Flavin adenine dinucleotide
| 0.019245 | RFK: riboflavin kinase (EC:2.7.1.26) |
| 933 | N | N | N | N | Cholecalciferol
| HMGCR: 3-hydroxy-3-methylglutaryl-CoA reductase (EC:1.1.1.34) | 0.32558 | Lovastatin
| 0.014868 | CYP27A1: cytochrome P450, family 27, subfamily A, polypeptide 1 (EC:1.14.13.15) |
| 934 | N | N | N | N | Moclobemide
| DCXR: dicarbonyl/L-xylulose reductase (EC:1.1.1.10) | 0.57143 | Haloperidol
| 0.027805 | MAOA: monoamine oxidase A (EC:1.4.3.4) |
| 935 | N | N | N | N | Capecitabine
| ZMPSTE24: zinc metallopeptidase STE24 (EC:3.4.24.84) | 0.32258 | Clofibrate
| 0.026416 | PLA2G10: phospholipase A2, group X (EC:3.1.1.4) |
| 936 | N | N | N | N | Orlistat
| PAFAH1B2: platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (30kDa) (EC:3.1.1.47) | 0.20000 | Capecitabine
| 0.024619 | PNLIP: pancreatic lipase (EC:3.1.1.3) |
| 937 | N | N | N | N | Lopinavir
| CYP4A11: cytochrome P450, family 4, subfamily A, polypeptide 11 (EC:1.14.15.3) | 0.33333 | Trimipramine
| 0.50873 | CYP4B1: cytochrome P450, family 4, subfamily B, polypeptide 1 (EC:1.14.14.1) |
| 938 | N | N | N | N | Edetic acid
| AKR1B1: aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) | 0.50000 | Citric acid, anhydrous
| 0.019000 | CPE |
| 939 | N | N | N | N | Gabapentin
| ACADSB: acyl-CoA dehydrogenase, short/branched chain (EC:1.3.8.5) | 0.23529 | Isoleucine
| 0.045302 | ACOX1: acyl-CoA oxidase 1, palmitoyl (EC:1.3.3.6) |
| 940 | N | N | N | N | Choline salicylate
 | CRAT: carnitine O-acetyltransferase (EC:2.3.1.7) | 0.47368 | Levocarnitine
 | 0.016847 | PTGS2: prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) |
| 941 | N | N | N | N | Nadide
| ACADS: acyl-CoA dehydrogenase, C-2 to C-3 short chain (EC:1.3.8.1) | 0.49266 | Flavin adenine dinucleotide
| 0.036975 | HSD17B10: hydroxysteroid (17-beta) dehydrogenase 10 (EC:1.1.1.35 1.1.1.178) |
| 942 | N | N | N | N | Glimepiride
| CYP2C8: cytochrome P450, family 2, subfamily C, polypeptide 8 (EC:1.14.14.1) | 0.40541 | Tolbutamide
| 0.79849 | CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 943 | N | N | N | N | Razaxaban hydrochloride
| F2: coagulation factor II (thrombin) (EC:3.4.21.5) | 0.33333 | Chlorpromazine
| 0.19139 | F10: coagulation factor X (EC:3.4.21.6) |
| 944 | N | N | N | N | Uracil
| TPO: thyroid peroxidase (EC:1.11.1.8) | 0.46154 | Propylthiouracil
| 0.010795 | DPYD: dihydropyrimidine dehydrogenase (EC:1.3.1.2) |
| 945 | N | N | N | N | Isoleucine
| CASP1: caspase 1, apoptosis-related cysteine peptidase (EC:3.4.22.36) | 0.63636 | Penicillamine
| 0.029208 | ACADSB: acyl-CoA dehydrogenase, short/branched chain (EC:1.3.8.5) |
| 946 | N | N | N | N | Azelaic acid
 | ACACA: acetyl-CoA carboxylase alpha (EC:6.4.1.2 6.3.4.14) | 0.53333 | Gulutamine
| 0.013144 | SRD5A2: steroid-5-alpha-reductase, alpha polypeptide 2 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 2) (EC:1.3.1.30) |
| 947 | N | N | N | N | Mitomycin
| PLA2G4A: phospholipase A2, group IVA (cytosolic, calcium-dependent) (EC:3.1.1.5 3.1.1.4) | 0.28261 | Fluocinonide
| 0.016808 | NQO1: NAD(P)H dehydrogenase, quinone 1 (EC:1.6.5.2) |
| 948 | N | N | N | N | Fadrozole hydrochloride hydrate
| CYP4A11: cytochrome P450, family 4, subfamily A, polypeptide 11 (EC:1.14.15.3) | 0.31111 | Alprazolam
| 0.50873 | CYP4B1: cytochrome P450, family 4, subfamily B, polypeptide 1 (EC:1.14.14.1) |
| 949 | N | N | N | N | Penicillamine
| ACAD8: acyl-CoA dehydrogenase family, member 8 | 0.70000 | Valine
| 0.018780 | CASP1: caspase 1, apoptosis-related cysteine peptidase (EC:3.4.22.36) |
| 950 | N | N | N | N | Benzoic acid
| PRDX4: peroxiredoxin 4 (EC:1.11.1.15) | 0.33333 | Acetaminophen
| 0.088898 | PRDX5: peroxiredoxin 5 (EC:1.11.1.15) |
| 951 | N | N | N | N | Moclobemide
| CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.57143 | Haloperidol
| 0.015930 | MAOA: monoamine oxidase A (EC:1.4.3.4) |
| 952 | N | N | N | N | Choline salicylate
| CROT: carnitine O-octanoyltransferase (EC:2.3.1.137) | 0.47368 | Levocarnitine
| 0.015552 | PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) |
| 953 | N | N | Y | N | Fluvastatin sodium
| CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) | 0.39474 | Trimipramine
| 0.011980 | HMGCR: 3-hydroxy-3-methylglutaryl-CoA reductase (EC:1.1.1.34) |
| 954 | N | N | N | N | Sivelestat
| PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) | 0.51282 | Acemetacin
| 0.014492 | ELANE: elastase, neutrophil expressed (EC:3.4.21.37) |
| 955 | N | N | N | N | Nadide
| IVD: isovaleryl-CoA dehydrogenase (EC:1.3.8.4) | 0.49266 | Flavin adenine dinucleotide
| 0.031928 | ADH7: alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide (EC:1.1.1.1) |
| 956 | N | N | N | N | Adenosine phosphate
| IMPDH1: IMP (inosine 5'-monophosphate) dehydrogenase 1 (EC:1.1.1.205) | 0.48148 | Ribavirin
| 0.021964 | APRT: adenine phosphoribosyltransferase (EC:2.4.2.7) |
| 957 | N | N | N | N | Imatinib mesylate
| CHUK: conserved helix-loop-helix ubiquitous kinase (EC:2.7.11.10) | 0.34615 | Sulfasalazine
| 0.074714 | MAP2K1: mitogen-activated protein kinase kinase 1 (EC:2.7.12.2) |
| 958 | N | N | Y | N | Ketotifen fumarate
| PDE4B: phosphodiesterase 4B, cAMP-specific (EC:3.1.4.17) | 0.37209 | Vesnarinone
| 0.21860 | PDE7A: phosphodiesterase 7A (EC:3.1.4.17) |
| 959 | N | N | N | N | Tolrestat
| ACHE: acetylcholinesterase (EC:3.1.1.7) | 0.34210 | Itopride hydrochloride
| 0.020508 | AKR1B1: aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) |
| 960 | N | N | N | N | Propylthiouracil
| CYP1A2: cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) | 0.27273 | Aminoglutethimide
| 0.023342 | DIO1: deiodinase, iodothyronine, type I (EC:1.97.1.10) |
| 961 | N | N | N | N | Choline salicylate
| CPT2: carnitine palmitoyltransferase 2 (EC:2.3.1.21) | 0.47368 | Levocarnitine
| 0.020146 | PTGS2: prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) |
| 962 | N | N | N | N | Tipifarnib
| CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.48077 | Liarozole hydrochloride
| 0.017771 | FNTA: farnesyltransferase, CAAX box, alpha (EC:2.5.1.59 2.5.1.58) |
| 963 | N | N | N | N | Hydroflumethiazide
| CA3: carbonic anhydrase III, muscle specific (EC:4.2.1.1) | 0.76191 | Hydrochlorothiazide
| 0.60142 | CA2: carbonic anhydrase II (EC:4.2.1.1) |
| 964 | N | N | N | N | Alrestatin sodium
| AKR1C1: aldo-keto reductase family 1, member C1 (EC:1.3.1.20 1.1.1.149 1.1.1.112) | 0.24324 | Haloperidol
| 0.49596 | AKR1B1: aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) |
| 965 | N | N | N | N | Pentoxifylline
| IMPDH1: IMP (inosine 5'-monophosphate) dehydrogenase 1 (EC:1.1.1.205) | 0.24390 | Mycophenolate mofetil
| 0.025934 | PDE6G: phosphodiesterase 6G, cGMP-specific, rod, gamma (EC:3.1.4.35) |
| 966 | N | N | N | N | Choline salicylate
| CPT1A: carnitine palmitoyltransferase 1A (liver) (EC:2.3.1.21) | 0.47368 | Levocarnitine
| 0.016417 | PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) |
| 967 | N | N | N | N | Iproniazid
 | CYP1A2: cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) | 0.52941 | Phenacetin
| 0.021749 | MAOB |
| 968 | N | N | N | N | Sumatriptan
 | MUSK: muscle, skeletal, receptor tyrosine kinase (EC:2.7.10.1) | 0.33333 | Metoclopramide
| 0.011076 | TRIM32: tripartite motif containing 32 |
| 969 | N | N | N | N | Ketotifen fumarate
| PDE5A: phosphodiesterase 5A, cGMP-specific (EC:3.1.4.35) | 0.37209 | Vesnarinone
| 0.11302 | PDE7B: phosphodiesterase 7B (EC:3.1.4.17) |
| 970 | N | N | N | N | Triazolam
| AKR1B1: aldo-keto reductase family 1, member B1 (aldose reductase) (EC:1.1.1.21) | 0.44118 | Zenarestat
| 0.020573 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 971 | N | N | Y | N | Chlorpromazine
| BCHE: butyrylcholinesterase (EC:3.1.1.8) | 0.69231 | Profenamine hydrochloride
| 0.018983 | MAOA: monoamine oxidase A (EC:1.4.3.4) |
| 972 | N | N | N | N | Raltitrexed
| DHFR: dihydrofolate reductase (EC:1.5.1.3) | 0.66667 | Methotrexate
| 0.028456 | TYMS: thymidylate synthetase (EC:2.1.1.45) |
| 973 | N | N | N | N | Calcitriol
| HMGCR: 3-hydroxy-3-methylglutaryl-CoA reductase (EC:1.1.1.34) | 0.33333 | Simvastatin
| 0.011624 | CYP27B1: cytochrome P450, family 27, subfamily B, polypeptide 1 (EC:1.14.13.13) |
| 974 | N | N | Y | N | Diphenhydramine
| PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) | 0.55556 | Phenylbutazone
| 0.014918 | CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) |
| 975 | N | N | N | N | Eletriptan hydrobromide
| CYP3A43 | 0.38889 | Alprazolam
| 0.78013 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 976 | N | N | Y | N | Omeprazole
| CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | 0.72414 | Pantoprazole
| 0.014487 | ATP4A: ATPase, H+/K+ exchanging, alpha polypeptide (EC:3.6.3.10) |
| 977 | N | N | N | N | Racemethionine
| BCAT1: branched chain amino-acid transaminase 1, cytosolic (EC:2.6.1.42) | 0.63636 | Isoleucine
| 0.020803 | MSRA: methionine sulfoxide reductase A (EC:1.8.4.11) |
| 978 | N | N | N | N | Diazoxide
| CYP1A1: cytochrome P450, family 1, subfamily A, polypeptide 1 (EC:1.14.14.1) | 0.47059 | Chlorzoxazone
| 0.022252 | CA4: carbonic anhydrase IV (EC:4.2.1.1) |
| 979 | N | Y | N | N | Deferoxamine
| GPX5 | 0.035088 | Diethylstilbestrol
| 0.035631 | PRDX5: peroxiredoxin 5 (EC:1.11.1.15) |
| 980 | N | N | N | N | Alvocidib hydrochloride
| CYP1A2: cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) | 0.44444 | Clozapine
| 0.024135 | CDK1: cyclin-dependent kinase 1 (EC:2.7.11.23 2.7.11.22) |
| 981 | N | N | N | N | Ketotifen fumarate
| PDE1A: phosphodiesterase 1A, calmodulin-dependent (EC:3.1.4.17) | 0.37209 | Vesnarinone
| 0.17938 | PDE7B: phosphodiesterase 7B (EC:3.1.4.17) |
| 982 | N | N | N | N | Oseltamivir phosphate
 | ACHE: acetylcholinesterase (EC:3.1.1.7) | 0.23810 | Capecitabine
| 0.021118 | NEU4: sialidase 4 (EC:3.2.1.18) |
| 983 | N | N | N | N | Tretinoin
| HMGCR: 3-hydroxy-3-methylglutaryl-CoA reductase (EC:1.1.1.34) | 0.28205 | Dalvastatin
| 0.011195 | ALDH1A2: aldehyde dehydrogenase 1 family, member A2 (EC:1.2.1.36) |
| 984 | N | N | N | N | Liarozole hydrochloride
| CYP4F2: cytochrome P450, family 4, subfamily F, polypeptide 2 (EC:1.14.13.30) | 0.36364 | Alprazolam
| 0.41197 | CYP4B1: cytochrome P450, family 4, subfamily B, polypeptide 1 (EC:1.14.14.1) |
| 985 | N | N | N | N | Benzoic acid
| ALOX5: arachidonate 5-lipoxygenase (EC:1.13.11.34) | 0.72727 | Salicylic acid
| 0.017690 | PRDX5: peroxiredoxin 5 (EC:1.11.1.15) |
| 986 | N | N | N | N | Trifluridine
| ABO: ABO blood group (transferase A, alpha 1-3-N-acetylgalactosaminyltransferase; transferase B, alpha 1-3-galactosyltransferase) (EC:2.4.1.37 2.4.1.40) | 0.24138 | Acyclovir
| 0.015455 | ACAA1: acetyl-CoA acyltransferase 1 (EC:2.3.1.16) |
| 987 | N | N | N | N | Dyphylline
| CYP2D6: cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) | 0.68421 | Caffeine
| 0.031325 | PDE6G: phosphodiesterase 6G, cGMP-specific, rod, gamma (EC:3.1.4.35) |
| 988 | N | N | N | N | Ganciclovir
| PNP: purine nucleoside phosphorylase (EC:2.4.2.1) | 0.48000 | Inosine
| 0.021956 | ACAA1: acetyl-CoA acyltransferase 1 (EC:2.3.1.16) |
| 989 | N | N | N | N | Menadione
| PRSS3: protease, serine, 3 (EC:3.4.21.4) | 0.043478 | Isoflurophate
| 0.24890 | F9: coagulation factor IX (EC:3.4.21.22) |
| 990 | N | N | N | N | Carbamazepine
| AADAC: arylacetamide deacetylase (EC:3.1.1.3) | 0.24390 | Verapamil
| 0.021091 | CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) |
| 991 | N | N | N | N | Sulfasalazine
| EPX: eosinophil peroxidase (EC:1.11.1.7) | 0.33333 | Diethylstilbestrol
| 0.017870 | NAT2: N-acetyltransferase 2 (arylamine N-acetyltransferase) (EC:2.3.1.5) |
| 992 | N | N | N | N | Amphotericin B
| ATP1A1 | 0.37147 | Digoxin
| 0.011877 | ABO: ABO blood group (transferase A, alpha 1-3-N-acetylgalactosaminyltransferase; transferase B, alpha 1-3-galactosyltransferase) (EC:2.4.1.37 2.4.1.40) |
| 993 | N | N | N | N | Felbamate
| DHFR: dihydrofolate reductase (EC:1.5.1.3) | 0.30769 | Pyrimethamine
| 0.025546 | CYP2C19: cytochrome P450, family 2, subfamily C, polypeptide 19 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 994 | N | N | N | N | Ribavirin
| POLB | 0.61905 | Cytarabine
| 0.023733 | ADK: adenosine kinase (EC:2.7.1.20) |
| 995 | N | N | N | N | Pranoprofen
| CYP3A4: cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | 0.50000 | Mirtazapine
| 0.014789 | PTGS2: prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) |
| 996 | N | N | N | N | Aspirin
 | ALOX5: arachidonate 5-lipoxygenase (EC:1.13.11.34) | 0.64286 | Salicylic acid
| 0.012760 | PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) |
| 997 | N | N | Y | N | Pantoprazole
| CYP1A2: cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) | 0.35484 | Methoxsalen
| 0.22792 | CYP2C9: cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) |
| 998 | N | N | N | N | Diflunisal
 | IKBKB: inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta (EC:2.7.11.10) | 0.48276 | Sulindac
| 0.012624 | PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) |
| 999 | N | N | N | N | Idoxuridine
| PNP: purine nucleoside phosphorylase (EC:2.4.2.1) | 0.56522 | Cladribine
| 0.021956 | ACAA1: acetyl-CoA acyltransferase 1 (EC:2.3.1.16) |
| 1000 | N | N | N | N | Capecitabine
| ACAA1: acetyl-CoA acyltransferase 1 (EC:2.3.1.16) | 0.44828 | Idoxuridine
| 0.028488 | PLA2G2A: phospholipase A2, group IIA (platelets, synovial fluid) (EC:3.1.1.4) |